Heme oxygenase-1 in cardiovascular diseases by Lakkisto, Päivi
 
 
Department of Clinical Chemistry 
Department of Medicine 

























To be presented, with the permission of the Medical Faculty of the University of 
Helsinki, for public examination in Lecture hall 2 of Biomedicum Helsinki, 
Haartmaninkatu 8, on December 17th, 2010, at 12 noon. 
  
 





Professor Kari Pulkki, MD, PhD 
Department of Clinical Chemistry 




Docent Ilkka Tikkanen, MD, PhD 
Department of Medicine 







Professor Terho Lehtimäki, MD, PhD 
Department of Clinical Chemistry 




Docent Pasi Tavi, MSc, PhD 
A.I. Virtanen Institute 







Docent Anna-Liisa Levonen, MD, PhD 
A.I. Virtanen Institute 












ISBN 978-952-92-8272-2 (paperback) 
ISBN 978-952-10-6718-1 (PDF) 
http://ethesis.helsinki.fi 
 
















































TABLE OF CONTENTS 
4  
TABLE OF CONTENTS 
 
ABBREVIATIONS ....................................................................................................................6 
LIST OF ORIGINAL PUBLICATIONS.......................................................................................8 
ABSTRACT..............................................................................................................................9 
1 INTRODUCTION..................................................................................................................11 
2 REVIEW OF THE LITERATURE..........................................................................................12 
2.1 Heme oxygenase (HO).................................................................................................12 
2.2 Induction and regulation of HO-1................................................................................13 
2.2.1 HO-1-inducing factors..............................................................................................13 
2.2.2 Regulation of HO-1 expression................................................................................14 
2.3 Protective role of HO-1 and its reaction products......................................................17 
2.3.1 Antioxidant effect.....................................................................................................17 
2.3.2 Antiapoptotic effect..................................................................................................18 
2.3.3 Anti-inflammatory effect...........................................................................................18 
2.3.4 Antiproliferative effect..............................................................................................19 
2.3.5 Vasoactive effects ...................................................................................................19 
2.3.6 Anticoagulative effect ..............................................................................................20 
2.3.7 Proangiogenic effect................................................................................................20 
2.3.8 Loss of protection in HO-1 deficiency.......................................................................21 
2.4 HO-1 and its reaction products in cardiovascular diseases......................................22 
2.4.1 HO-1 in myocardial infarction and heart failure.........................................................22 
2.4.2 HO-1 in atherosclerosis and vascular injury .............................................................25 
2.4.3 HO-1 in hypertension...............................................................................................26 
3 AIMS OF THE STUDY.........................................................................................................28 
4 MATERIALS AND METHODS .............................................................................................29 
4.1 Animals ........................................................................................................................29 
4.2 Experimental myocardial infarction............................................................................29 
4.2.1 Experimental protocol 1: HO-1 expression in postinfarction hearts (I).......................29 
4.2.2 Experimental protocol 2: Effects of pre-emptive HO-1 induction and CO donor 
pretreatment on recovery of myocardial infarction (II, III)...................................................29 
4.3 Isolated rat heart preparation (IV) ...............................................................................31 
4.4 Real-time quantitative RT-PCR (I–IV) ..........................................................................32 
4.5 Histology and infarct size (II, III)..................................................................................33 
4.6 Immunohistochemical analyses (I–IV) ........................................................................33 
4.7 Western blotting and ELISA (I–IV)...............................................................................35 
4.8 Measurement of cyclic GMP (IV) .................................................................................35 
4.9 Statistical analyses: experimental studies (I–IV)........................................................35 
4.10 Clinical study (V)........................................................................................................36 
4.10.1 Patients and study design......................................................................................36 
4.10.2 Blood samples and data collection.........................................................................36 
4.10.3 HO-1 genotyping ...................................................................................................38 
4.10.4 HO-1 plasma concentration ...................................................................................39 
4.10.5 Statistical analyses: clinical study ..........................................................................39 
4.11 Ethical aspects...........................................................................................................40 
5 RESULTS............................................................................................................................41 
5.1 HO-1 expression is induced in infarcted rat hearts in vivo (I–III)...............................41 
5.2 HO-1 and CO protect the heart (II–IV) .........................................................................43 
5.2.1 Infarct size (II, III).....................................................................................................43 
TABLE OF CONTENTS 
5  
5.2.2 HO-1 and CO inhibit cardiomyocyte apoptosis (III)...................................................43 
5.2.3 HO-1 and CO modulate cardiomyocyte DNA repair (III) ...........................................43 
5.2.4 HO-1 improves postischemic cardiac function (IV) ...................................................45 
5.3 HO-1 and CO promote neovascularization and myocardial regeneration in infarcted 
rat hearts (II).......................................................................................................................46 
5.3.1 Differential effects of HO-1 and CO on capillary and vascular density ......................46 
5.3.2 CO activates c-kit+ stem/progenitor cells and promotes differentiation of c-kit+ cells 
into vascular smooth muscle cells and cardiomyocytes ....................................................47 
5.3.3 HO-1 and CO modulate expression of angiogenic factors ........................................48 
5.4 HO-1 and CO modulate proliferation of cardiac cells in infarcted rat hearts in vivo 
(II, III) ..................................................................................................................................48 
5.4.1 Proliferation of cells in the infarcted rat hearts (III)....................................................48 
5.4.2 Proliferation of cardiomyocytes in the infarcted rat hearts (II, III) ..............................48 
5.4.3 Proliferation of fibroblasts in the infarcted rat hearts (III)...........................................50 
5.5 Effects of HO-1 and CO on fibrosis and expression of extracellular matrix 
components in infarcted rat hearts (III) ............................................................................50 
5.5.1 Interstitial and perivascular fibrosis and cardiomyocyte cross-sectional area............50 
5.5.2 Expression of extracellular matrix components ........................................................52 
5.5.3 Expression of CTGF, TGF- 1, and ANP ..................................................................52 
5.6 Clinical study ...............................................................................................................53 
5.6.1 HO-1 polymorphisms...............................................................................................53 
5.6.2 HO-1 plasma concentrations ...................................................................................54 
5.6.3 Association of HO-1 polymorphisms with HO-1 plasma concentrations, disease 
severity, and mortality ......................................................................................................55 
5.6.4 Association of HO-1 plasma concentrations with disease severity and mortality.......56 
6 DISCUSSION.......................................................................................................................58 
6.1 HO-1 expression in infarcted rat hearts (I–III).............................................................58 
6.2 Protection against postischemic dysfunction and ventricular fibrillation by HO-1 in 
ischemic/reperfused rat hearts (IV) ..................................................................................59 
6.3 The myriad effects of HO-1 and CO on the recovery from rat myocardial infarction 
(II, III) ..................................................................................................................................62 
6.3.1 Neovascularization and myocardial regeneration (II)................................................62 
6.3.2 Expression of angiogenic factors .............................................................................63 
6.3.3 Proliferation and survival of cardiomyocytes ............................................................65 
6.3.4 Cardiac fibrosis and extracellular matrix components (III) ........................................66 
6.3.5 Infarct size (II, III).....................................................................................................68 
6.3.6 Limitations of the myocardial infarction studies (II, III) ..............................................68 
6.3.7 Therapeutic potential of HO-1 and CO in myocardial infarction ................................68 
6.4 Role of HO-1 in critically ill patients – focus on patients with cardiac disease ........69 
6.5 Future prospects .........................................................................................................71 
7 CONCLUSIONS ..................................................................................................................73 
8 ACKNOWLEDGEMENTS....................................................................................................74 







AF Aortic flow 
ANOVA One way analysis of variance 
ANP Atrial natriuretic peptide 
APACHE II Acute Physiology and Chronic Health Evaluation II score 
AUC Area under curve 
CF Coronary flow 
cGMP Guanosine 3’5’-cyclic monophosphate, cyclic GMP 
CO Carbon monoxide 
COHb Carboxyhemoglobin 
Coll1a1  Prococollagen type I alpha 1 
Coll3a1 Prococollagen type III alpha 1 
CoPPIX Cobalt protoporphyrin IX 
CORM Carbon monoxide-releasing molecule  
CRP C-reactive protein 
CSC Cardiac stem cell 
CTGF Connective tissue growth factor 
cTnI Cardiac troponin I 
Cx43 Connexin 43 
DAPI 4´6-diamino-2-phenylindole 
+/- dp/dt Positive and negative first derivative of left ventricular pressure 
ELISA Enzyme-linked immunosorbent assay 
ERK Extracellular-regulated kinase 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
H3P Phosphorylated histone H3 
HIF-1              Hypoxia-inducible factor 1 alpha 
HO Heme oxygenase 
HR Heart rate 
ICD-10 International Classification of Diseases 10th edition 
ICU Intensive care unit 
IL Interleukin 
IQR Interquartile range 
I/R                  Ischemia/reperfusion 
LAD Left anterior descending coronary artery 
LD Linkage disequilibrium 
LVDP Left ventricular developed pressure 
LVEDP Left ventricular end-diastolic pressure 
MAPK Mitogen-activated protein kinase 
MC Methylene chloride 
ABBREVIATIONS 
7  
MHC Cardiac myosin heavy chain 
MI Myocardial infarction 
MOD Multiple organ dysfunction 
MSC Mesenchymal stem cell 
NO Nitric oxide 
Nrf2 Nuclear factor-erythroid 2-related factor 2 
PAI-1 Plasminogen activator inhibitor type 1 
PCNA Proliferating cell nuclear antigen 
PDGF Platelet-derived growth factor 
ROC Receiver-operating characteristic 
ROS Reactive oxygen species 
RT-PCR  Reverse transcription-polymerase chain reaction 
SAPS II Simplified Acute Physiology Score II 
SDF-1   Stromal cell-derived factor 1 alpha 
SEM Standard error of mean 
sGC Soluble guanylate cyclase 
SMA Smooth muscle actin 
SMC Smooth muscle cell 
SNP Single-nucleotide polymorphism 
SOFA Sequential Organ Failure Assessment score 
Tbx18 T-box transcription factor Tbx18 
TGF- 1          Transforming growth factor beta1 
TNF-  Tumor necrosis factor  
TRITC Tetramethyl rhodamine isothiocyanate 
TUNEL Terminal transferase-mediated DNA nick-end labeling 
VEGF Vascular endothelial growth factor 
VF Ventricular fibrillation 
VSMC Vascular smooth muscle cell 
vWF von Willebrand factor 
ZnPP IX Zinc protoporphyrin IX 
 
 
                





LIST OF ORIGINAL PUBLICATIONS 
8 
LIST OF ORIGINAL PUBLICATIONS 
 
This  thesis  is  based  on  the  following  original  publications,  referred  to  in  the  text  by  Roman  
numerals (I-V). In addition, some unpublished data are presented.  
 
 
I Lakkisto P,  Palojoki  E,  Bäcklund T,  Saraste  A,  Tikkanen I,  Voipio-Pulkki  L-M,  Pulkki  K.  
Expression of Heme Oxygenase-1 in Response to Myocardial  Infarction in Rats.  J Mol Cell  
Cardiol 2002; 34: 1357-1365.  
 
II Lakkisto P, Kytö V, Forsten H, Siren J-M, Segersvärd H, Voipio-Pulkki L-M, Laine M, 
Pulkki K, Tikkanen I. Heme oxygenase-1 and carbon monoxide promote neovascularization 
after myocardial infarction by modulating the expression of HIF-1 , SDF-1  and VEGF-B. 
Eur J Pharmacol 2010; 635: 156-164. 
 
III Lakkisto P,  Siren  J-M,  Kytö  V,  Forsten  H,  Laine  M,  Pulkki  K,  Tikkanen  I.  Heme  
oxygenase-1 induction protects the heart and modulates cellular and extracellular 
remodeling after myocardial infarction in rats. Submitted. 
 
IV Lakkisto P, Csonka C, Fodor G, Bencsik P, Voipio-Pulkki L-M, Ferdinandy P, Pulkki K. The 
heme oxygenase inducer hemin protects against cardiac dysfunction and ventricular 
fibrillation in ischemic/ reperfused rat hearts:  role of Cx43. Scand J Clin Lab Invest 2009; 
69: 209-218. 
 
V Saukkonen K*, Lakkisto P*, Kaunisto M, Varpula M, Voipio-Pulkki L-M, Varpula T, Pettilä 
V, Pulkki K. Heme oxygenase-1 polymorphism and plasma concentrations in the critically ill 
patients. Shock 2010; published online April 6; doi: 10.1097/SHK.0b013e3181e14de9.           




The original publications have been reproduced with the permission of the copyright holders.   
 
The  publication  V  has  been  included  in  the  thesis  for  doctoral  degree  by  Katri  Saukkonen  at  


















Myocardial  infarction  (MI)  is  a  major  cause  of  morbidity  and  mortality.  MI  leads  to  left  
ventricular remodeling, which may eventually progress to heart failure. New strategies are 
needed for protecting the myocardium against ischemic injury and enhancing the recovery and 
repair of the infarcted heart. The present studies were undertaken to investigate the role of 
heme oxygenase-1 (HO-1) in protection and repair of infarcted and ischemic/reperfused hearts 
and to examine the potential mechanisms mediating the protective effects of HO-1 in these 
experimental rat models. In addition, the role of HO-1 polymorphisms and HO-1 plasma 
concentrations in critically ill patients and in the subgroup of cardiac patients was evaluated.  
 
A  total  of  334  adult  male  Wistar  rats  were  used  in  the  experimental  studies  (278 rats  in  I–III  
and 56 in IV). An experimental MI model was used to investigate the expression and localization 
of HO-1 in the infarcted hearts and to assess the effects of HO-1 induction and carbon monoxide 
(CO) donor pretreatment on recovery and regeneration of the infarcted hearts (I–III). Gene 
expression was measured by real-time RT-PCR and protein levels by Western blotting and 
ELISA. Immunohistochemical analysis was used to assess cardiac regeneration and ventricular 
remodeling in the infarcted rat hearts. Isolated rat heart preparations were used to investigate 
the  protective  effect  of  HO-1  against  ischemia/reperfusion  (I/R)-induced  cardiac  dysfunction  
and ventricular arrhythmias (IV). HO-1 plasma concentrations and HO-1 polymorphisms were 
assessed in 231 critically ill  intensive care unit (ICU) patients (154 men and 77 women, 17–87 
years of age), and the association of HO-1 polymorphisms and plasma levels with illness 
severity, organ dysfunction, ICU, and hospital mortalities was examined (V). Illness severity was 
determined by the Simplified Acute Physiology Score (SAPS) II and Acute Physiology and 
Chronic  Health  Evaluation  (APACHE)  II  score,  and  the  degree  of  organ  dysfunction  by  the  
Sequential Organ Failure Assessment (SOFA) score.  
 
In the experimental studies, HO-1 expression was induced in the infarcted rat hearts, especially 
in the infarct and infarct border areas (I–III). HO-1 protein was localized in the vascular walls, 
the cardiomyocytes of the infarct border area, and the monocytes/macrophages and fibroblasts 
of the infarct area. HO-1 induction and CO donor pretreatment had differential effects on the 
infarcted  rat  hearts.  They  both  promoted  neovascularization  in  the  infarcted  hearts,  but  CO  
activated  c-kit+  stem/progenitor  cells  via  hypoxia-inducible  factor  1  (HIF-1 , stromal cell-
derived factor 1  (SDF-1  and vascular endothelial  growth factor B (VEGF-B),  and promoted 
vasculogenesis and formation of new cardiomyocytes, whereas HO-1 promoted angiogenesis 
possibly via SDF-1 . In addition, HO-1 had many beneficial effects on cellular and extracellular 
remodeling in the infarcted hearts. It protected the heart in the early phase of infarct healing by 
increasing survival and proliferation of cardiomyocytes. The antiapoptotic effect of HO-1 
persisted  in  the  late  phases  of  infarct  healing.  In  addition,  HO-1  modulated  the  production  of  
extracellular matrix components and reduced perivascular fibrosis. Some of these beneficial 
effects of HO-1 were mediated by CO, e.g. the antiapoptotic effect. However, CO may also have 
adverse effects on the heart, since it increased the expression of extracellular matrix 
components. In isolated perfused rat hearts, HO-1 induction improved the recovery of 
postischemic cardiac function and abrogated reperfusion-induced ventricular fibrillation, 
possibly via connexin 43 (Cx43).  
 
In the clinical study (V), HO-1 plasma levels were increased in all critically ill patients, including 
cardiac  patients,  and  were  associated  with  the  degree  of  organ  dysfunction  (SOFA  score)  and  
disease severity (APACHE II and SAPS II scores). HO-1 plasma concentrations were also higher 
in ICU and hospital nonsurvivors than in survivors, and the maximum HO-1 concentration was 
an independent predictor of hospital mortality. Patients with the HO-1 -413T/GT(L)/+99C 
haplotype had lower HO-1 plasma concentrations and lower level of appearance of multiple 
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organ  dysfunction  (MOD)  (SOFA  score  >  6).  However,  HO-1 polymorphisms were not 
associated with ICU or hospital mortality. 
 
In  conclusion,  HO-1  in  the  experimental  models  played  an  important  role  in  the  recovery  and 
repair of infarcted hearts. HO-1 induction potentially may protect against I/R injury and cardiac 
dysfunction  in  isolated  rat  hearts.  Furthermore,  HO-1  induction  and  and  CO  donor  
pretreatment  enhanced  cardiac  regeneration  after  rat  MI,  and  HO-1  may  protect  against  
pathological left ventricular remodeling. In addition, HO-1 plasma levels were significantly 
increased in critically ill ICU patients and correlate with the degree of organ dysfunction, disease 
severity, and mortality, suggesting that HO-1 may be useful as a marker of disease severity and 













































Myocardial infarction (MI) and heart failure are major causes of morbidity and mortality 
worldwide. Treatment of MI involves early restoration of blood flow to limit infarct size and 
preserve cardiac function. MI is followed by left ventricular remodeling, which is characterized 
by inflammation and subsequent formation of the fibrous scar in the infarct area to replace the 
damaged myocardial tissue, and cardiomyocyte apoptosis, fibrosis, and hypertrophy of the 
noninfarcted myocardium. These structural changes may eventually lead to the development of 
heart failure, despite the established pharmacological treatment of the disease. To improve 
outcome of MI, new strategies for protecting the myocardium against ischemia/reperfusion 
(I/R) injury and for promoting the healing and repair of the infarcted heart are needed.  
 
The recent discovery of resident cardiac stem cells (CSCs) shows that the heart is a regenerating 
organ (Beltrami et al. 2003). However, the number of CSCs is relatively small. Therefore, 
activation  of  the  resident  CSCs  is  needed to  improve  cardiac  repair.  Angiogenic  cytokines  and 
growth factors secreted from the infarcted heart contribute to the activation of stem cells 
(Gnecchi et al. 2008, Srinivas et al. 2009), but the molecular mechanisms leading to the 
activation of CSCs are inadequately understood.  
 
Heme oxygenase-1 (HO-1) is a stress-responsive and cytoprotective enzyme that catalyzes the 
degradation of heme into the biologically active reaction products biliverdin, carbon monoxide 
(CO)  and  free  iron  (Tenhunen  1969,  Otterbein  2003).  HO-1  plays  a  key  role  in  maintaining  
cellular  homeostasis  (Otterbein  and Choi  2000,  Otterbein  et  al.  2003a).  The  cytoprotection  is  
mediated by the antiapoptotic, anti-inflammatory, antioxidative, antiproliferative, and 
vasodilatory properties of HO reaction products (Stocker et al. 1987, Thorup et al. 1999, Brouard 
et  al.  2000,  Otterbein  et  al.  2000,  Peyton  et  al.  2002).  Interestingly,  HO-1  is  also  known  to  
promote  angiogenesis  (Dulak  et  al.  2008).  Although  HO-1  has  been  acknowledged  as  a  
cardioprotective protein in various cardiovascular disease models (Idriss et al. 2008, Peterson et 
al. 2009), the cardioprotective mechanism of HO-1 is still uncompletely understood. In 
addition, the role of HO-1, especially in cardiac regeneration, is not known.  
 
HO-1 polymorphisms regulate the transcriptional activity of the HO-1 gene in humans (Hirai et 
al. 2003, Ono et al. 2004, Brydun et al. 2007). HO-1 polymorphisms have been associated with 
various clinical conditions, including the susceptibility to coronary artery disease and restenosis 
after  peripheral  angioplasty  (Kaneda  et  al.  2002,  Schillinger  et  al.  2004).  However,  the  
importance of HO-1 polymorphisms in these conditions is controversial, since larger studies in 
Caucasian patients have not confirmed the association of HO-1 polymorphisms with these 
conditions  (Tiroch  et  al.  2007,  Lublinghoff  et  al.  2009).  In  addition,  despite  the  increasing  
number of studies on HO-1 polymorphisms, the effect of these polymorphisms on HO-1 plasma 
levels  is  unknown.  Furthermore,  studies  investigating  HO-1  in  critically  ill  patients,  and  
especially in cardiac patients, are limited. 
 
The  present  study  aimed,  first,  at  evaluating  the  role  of  HO-1  as  a  cardioprotective  and  
prohealing enzyme in experimental rat models and at investigating the potential mechanisms 
mediating the beneficial effects of HO-1 in the heart. The second aim was to evaluate the role of 
HO-1 in critically ill patients by investigating the association of HO-1 polymorphisms and HO-1 
plasma concentrations with illness severity and mortality throughout the study population and 
in the subgroup of cardiac patients.  
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2 REVIEW OF THE LITERATURE 
 
2.1 Heme oxygenase (HO) 
 
HO catalyzes the first and rate-limiting step in the degradation of heme, as characterized by 
Tenhunen et  al.  (1968,  1969).  They  described  that  HO cleaves  heme at  the  -methene bridge, 
resulting in equimolar amounts of biliverdin-IX ,  CO  and  free  iron  (Fig.  1)  (Tenhunen  et  al.  
1969). Oxygen and nicotinamide adenine dinucleotide phosphate (NADPH) are required for the 
reaction and the central iron atom of heme is necessary for HO activity, because free porphyrin 
is not degraded by HO (Tenhunen et al. 1969). Subsequently, biliverdin-IX  is rapidly reduced 
to bilirubin-IX  by  biliverdin  reductase  (Tenhunen  et  al.  1970b)  and  iron  is  sequestered  in  
ferritin or transported out of the cells via an adenosine triphosphate (ATP)-dependent iron 

















Figure 1. Heme oxygenase (HO) reaction. HO catalyzes the degradation of heme to biliverdin, carbon 
monoxide (CO) and free iron (Fe). Biliverdin is reduced to bilirubin by biliverdin reductase (BVR). M = 
methyl, V = vinyl, P = propionic acid. 
 
Two isoforms of  HO have  been described.  HO-1  is  a  32-kDa inducible  isoform,  also  known as  
heat shock protein 32 (HSP-32), and HO-2 is a 36-kDa constitutively expressed isoform (Maines 
et al.  1986, Keyse and Tyrrell  1989).  A third isoform (HO-3) has been described in rats,  but it  
has since become evident that it is a pseudogene derived from the HO-2 transcript (McCoubrey 
et al. 1997, Hayashi et al. 2004). HO-1 and HO-2 are products of two genes (Cruse and Maines 
1988, Maines 1997). The HO-1 gene  is  localized  in  chromosome  22  and  the  HO-2 gene  in  
chromosome  16  (Kutty  et  al.  1994).  HO-1  and  HO-2  have  only  43%  homology  of  amino  acid  
sequences (Rotenberg and Maines 1990). However, they both have a highly conserved heme- 
catalytic  domain  and  a  similar  hydrophobic  region  at  the  carboxylterminus  to  anchor  the  
enzyme to the endoplasmic reticulum (Ishikawa et al. 1991, Rotenberg and Maines 1991). Both 
enzymes  are  catalytically  active,  and  the  HO  enzyme  activity  can  be  inhibited  using  synthetic  
metalloporphyrins of which zinc protoporphyrin-IX (ZnPPIX) and tin protoporphyrin-IX 
(SnPPIX) are most commonly used (Drummond and Kappas 1981, 1982). HO-1 is a ubiquitously 
expressed enzyme present at low levels in most organs. Under physiological conditions, high 
levels of HO-1 are found only in the spleen and other tissues/cells that degrade senescent 
erythrocytes, such as the reticuloendothelial cells of the liver and bone marrow (Tenhunen et al. 
1968, 1969). The tissue distribution of HO-2 differs from that of HO-1. High levels of HO-2 are 
found in the testes, brains, central nervous system, liver, kidneys, vasculature, and gut (Maines 
1997). 
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HOs are predominantly localized in the microsomal fraction, or smooth endoplasmic reticulum, 
of the cells as originally described by Tenhunen et al. (1969). However, HO-1 has recently been 
found in other subcellular compartments as well.  Kim et al.  (2004) found HO-1 in the plasma 
membrane caveolae of endothelial cells, together with biliverdin reductase, and suggested that 
compartmentalization of HO-1 in the caveolae may play a role in cellular protection by 
modulating  caveolae-mediated  signaling  cascades.  Two  years  later  Converso  et  al.  (2006)  
showed  that  a  fraction  of  HO-1  is  localized  in  the  liver  mitochondria,  again  together  with  
biliverdin reductase, and modulates mitochondrial heme metabolism and O2 uptake and 
production of reactive oxygen species (ROS). They suggested that mitochondrial localization 
may explain the protective effects of HO-1 under conditions characterized by increased 
mitochondrial ROS production, such as I/R, sepsis, and neurodegenerative disorders (Converso 
et al.  2006).  Lin and colleagues showed that exposure to hypoxia or hemin resulted in nuclear 
localization of a truncated form of HO-1 lacking the C-terminus of the protein (Lin et al. 2007). 
They also demonstrated that despite the decreased enzyme activity of this truncated nuclear 
HO-1, it was equally cytoprotective, presumably by activating transcription factors that are 
involved in the oxidative stress response, including activator protein 1 (AP-1) (Lin et al. 2007). 
In addition, Lin et al. (2008) showed that the ubiquitin-proteasome system mediates HO-1 




2.2 Induction and regulation of HO-1  
 
2.2.1 HO-1-inducing factors 
 
HO-1  expression  and  activity  are  highly  induced  by  numerous  factors.  The  induction  of  HO  
enzyme activity by its substrate heme was reported by Tenhunen et al.  (1970a) soon after they 
had  characterized  the  enzyme.  In  the  late  1980s,  Shibahara  et  al.  (1987)  showed  that  HO-1  
expression was increased by heat shock in rats and suggested that HO-1 is a heat shock protein. 
This was later confirmed by different groups, showing that the 32-kDa stress response protein, 
induced by numerous factors such as heavy metals and ultraviolet A (UVA) radiation, is  HO-1 
(Keyse and Tyrrell 1987, 1989, Taketani et al. 1989). However, although HO-1 is up-regulated in 
response to heat shock in rats (Taketani et al. 1988, Raju and Maines 1994), it is not induced by 
hyperthermia in humans (Yoshida et al. 1988, Shibahara et al. 1989, Taketani et al. 1989). 
 
An ever-growing number of HO-1-inducing stimuli has been characterized since these studies in 
the 1980s, and the role of HO-1 as a stress response protein has become evident (Otterbein and 
Choi  2000).  Some  of  the  HO-1-inducing  stimuli  are  listed  in  Table  1.  A  common  feature  for  
many  of  the  HO-1-inducing  factors  and  conditions  is  that  they  cause  oxidative  stress  by  
increasing  the  production  of  ROS  or  decreasing  intracellular  glutathione  levels  (Ryter  et  al.  
2006).  It  is  also  worth  noting  that  several  metalloporphyrins  (e.g.  ZnPPIX  and  SnPPIX)  can  
paradoxically induce HO-1 expression, although they also inhibit HO enzyme activity (Sardana 
and  Kappas  1987).  Due  to  the  high  inducibility  of  HO-1  along  with  its  cytoprotective  effects,  
Otterbein  and  colleagues  (2003a)  have  suggested  that  HO-1  may  function  as  a  ‘therapeutic  
funnel’  mediating  the  beneficial  effects  of  other  molecules,  such  as  interleukin  (IL)-10,  
prostaglandin J2 and HSPs (Lee and Chau 2002, Redaelli et al. 2002, Lee et al. 2003, Otterbein 
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Table 1. Inducers of HO-1 expression or enzyme activity. 
 
Stimulus Reference 
Heme Alam et al. 1989 
Heavy metals (cadmium, cobalt) Caltabiano et al. 1986, Taketani et al. 1988, 1989 
Hypoxia Borger and Essig 1998, Panchenko et al. 2000 
Hyperoxia Lee et al. 2000 
Ischemia/reperfusion  Raju and Maines 1996 
Reactive oxygen species Keyse et al. 1990, Keyse and Emslie 1992, Ohlmann et al. 2003 
Shear stress Wagner et al. 1997, De Keulenaer et al. 1998 
Lipopolysaccharide  Rizzardini et al. 1994, Camhi et al. 1995 
Nitric oxide,  peroxynitrite Durante et al. 1997, Hartsfield et al. 1997, Foresti et al. 1999 
Cytokines (IL-1 , IL-10, IL-11, IL-6, 
TNF- , TGF- ) 
Fukuda and Sassa 1993, Terry et al. 1998, 1999, Lee and Chau 
2002, Ning et al. 2002 
Growth factors (VEGF, PDGF) Durante et al. 1999, Bussolati et al. 2004, Bussolati and Mason 2006 
Drugs (aspirin, statins) Grosser et al. 2003, 2004, Lee et al. 2004 
Prostaglandins Lee et al. 2003, Alvarez-Maqueda et al. 2004 
ACTH Pomeraniec et al. 2004 
Angiotensin II Ishizaka and Griendling 1997, Ishizaka et al. 2000 
Antioxidants (curcumin, caffeic acid, 
resveratrol) Motterlini et al. 2000b, Scapagnini et al. 2002, Chen et al. 2005 
 
Abbreviations: ACTH = adrenocorticotrophic hormone, HO-1 = heme oxygenase-1, IL = interleukin, 
PDGF = platelet-derived growth factor, TGF-  = transforming growth factor- , TNF-  = tumor necrosis 
factor , VEGF = vascular endothelial growth factor.  
 
2.2.2 Regulation of HO-1 expression 
 
The innumerable amount of HO-1 inducers points to the presence of several response elements 
in the promoter of the HO-1 gene and numerous interactions between the components of 
different signaling pathways. Induction of HO-1 by various factors involves activation of 
different protein phosphorylation cascades, including mitogen-activated protein kinases 
(MAPKs), tyrosine kinases, phosphatidylinositol 3-kinase (PI3K), and protein kinases A, C, and 
G (Ryter et al. 2006). MAPK cascades are activated by cellular stress and they also regulate cell 
proliferation and differentiation (Cobb 1999). The MAPK system is composed of three signaling 
pathways: the extracellular-regulated kinases (ERK pathway), the c-Jun N-terminal kinases 
(JNK  pathway),  and  the  p38  kinases  (p38  pathway).  The  MAPKs  are  major  mediators  of  the  
HO-1  stress  response  and  HO-1  inducers  may  activate  one  or  more  of  these  MAPK  pathways  
(Ryter  et  al.  2006,  Alam  and  Cook  2007).  However,  the  p38  pathway  is  the  major  MAPK  
cascade activating HO-1 in response to various stresses. Sodium arsenite activates all three 
MAPK pathways in hepatoma cells and induces HO-1 (Elbirt et al. 1998). Induction of HO-1 by 
nitric  oxide  (NO)  involves  both  the  p38  MAPK  and  ERK  pathways  in  HeLa  cells  (Chen  and  
Maines 2000), whereas hypoxia induces HO-1 in rat cardiomyocytes via the p38 MAPK pathway 
(Kacimi et al. 2000).   
 
The HO-1 gene contains three major regulatory regions (Fig. 2); a proximal promoter region at 
0.3 kb upstream from the transcription initiation site and two distal enhancer regions at 4 and 
10  kb  upstream from the  transcription  initiation  site  (Alam et  al.  1994,  1995,  Alam and Cook 
2007). The dominant regulatory element in the distal enhancers is the stress-responsive 
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element  (StRE),  which  is  similar  to  the  Maf  response  element  (MARE)  and  the  antioxidant  
response element (ARE), and contains the heme response element and the AP-1 binding site 
(Ryter et al. 2006). Several transcription factors bind to the StRE as hetero- or homodimers, 
including  AP-1  factors  (Jun  and  Fos),  Maf  proteins,  and  the  cap’n’collar/basic-leucine  zipper  
transcription  factors  Nrf2  (nuclear  factor-erythroid  2-related  factor  2)  and  Bach1  (Alam  and  
Den 1992, Alam et al. 1999, Sun et al. 2002, 2004). The AP-1 factors mediate the activation of 
the HO-1 gene in response to hyperoxia and lipopolysaccharide (LPS) (Camhi et al. 1995, Lee et 
al. 2000). However, the major transcriptional regulator of the HO-1 gene  is  the  ARE-binding  
transcription  factor  Nrf2  (Ryter  et  al.  2006).  Nrf2  is  a  positive  regulator  of  antioxidant,  
cytoprotective,  and  anti-inflammatory  genes  containing  the  ARE  sequence  (Motohashi  and  
Yamamoto  2004,  Levonen  et  al.  2007,  Jyrkkänen  et  al.  2008).  Both  Nrf2  and  Bach1  form  
heterodimers with small Maf proteins. Nrf2 increases HO-1 transcription, while Bach1 competes 
with Nrf2 and represses HO-1 transcription  (Alam  et  al.  1999,  Sun  et  al.  2002,  2004).  Heme  
binds with Bach1, inhibits its DNA-binding activity, and promotes its nuclear export, thus 
enhancing  HO-1  expression  (Sun  et  al.  2002,  Suzuki  et  al.  2004).  In  addition,  a  cytoplasmic  
Kelch-like ECH-associated protein 1 (Keap1) binds Nrf2 under basal conditions, prevents its 
translocation to the nucleus, and facilitates its degradation, thus reducing HO-1 expression (Itoh 
et  al.  1999,  2003).  When  cells  are  exposed  to  oxidative  stress,  Nrf2  dissociates  from  Keap1,  











Figure 2. Simplified scheme of the regulatory elements in the heme oxygenase-1 gene promoter. The 
arrow marks the transcription initiation site. StRE = stress-responsive element, C/EBP = CAAT/enhancer-
binding protein site, CdRE = cadmium-responsive element, HSE = heat shock element, AP-1 = activator 
protein-1, NF- B = nuclear factor- B, IL-6RE = interleukin-6-responsive element, STAT = signal 
transducer and activator of transcription.   
 
 
In  addition  to  StRE,  many  other  regulatory  elements  have  been found in  the  HO-1  promoter,  
including the cytidine-adenosine-adenosine-thymidine (CAAT)/enhancer-binding protein 
(C/EBP) site and the cadmium-responsive element (CdRE) (Ryter et al. 2006). Binding sites for 
nuclear factor- B (NF- B),  signal  transducer  and  activator  of  transcription  3  (Stat3)  and  
hypoxia-inducible factor 1  (HIF-1  have also been identified, as well as IL-6, heat shock and 
metalloporphyrin-responsive  elements  (Shibahara  et  al.  1989,  Lavrovsky  et  al.  1994,  Lee  et  al.  
1997,  Deramaudt  et  al.  1999,  Yang  et  al.  2001,  Ryter  et  al.  2006).  Although Nrf2  is  the  major  
regulator of the HO-1 gene, the presence of the above-mentioned and several other regulatory 
elements in the HO-1 promoter corroborate the role of HO-1 as a stress response protein.  
 
The transcriptional activity of the human HO-1 gene is also affected by the following HO-1 
promoter polymorphisms: the GTn repeat length polymorphism and -413A/T single-nucleotide 
polymorphism (SNP). The short GTn repeat length allele and -413A allele enhance 
transcriptional activity of the HO-1 gene compared with the long GTn and -413T alleles (Hirai et 
al.  2003, Ono et al.  2004, Brydun et al.  2007).  The HO-1 promoter polymorphisms may be of 
functional importance in clinical conditions, since they have been associated e.g. with 
susceptibility to coronary artery disease and restenosis after peripheral angioplasty in some 
studies  (Kaneda  et  al.  2002,  Schillinger  et  al.  2004).  However,  in  some studies  no  association  
was found between HO-1 polymorphisms and the disease studied (Tiroch et al. 2007, Turpeinen 
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et al. 2007). Table 2 summarizes the studies investigating HO-1 polymorphisms in different 
diseases. 
 
Table 2. Major studies investigating HO-1 polymorphisms in different diseases. 
 
Disease Polymorphism N Association     with disease Reference 
Cardiovascular disease     
CAD GTn, -413A/T 3219 No Lublinghoff et al. 2009 
CAD in diabetic patients GTn 986 Yes Chen et al. 2008 
Coronary atherosclerosis GTn 110 Yes Brydun et al. 2007 
CAD in type II diabetic patients GTn 796 Yes Chen et al. 2002 
CAD in patients with risk factors GTn 577 Yes Kaneda et al. 2002 
CAD GTn 649 No Endler et al. 2004 
CAD -413A/T 2569 Yes Ono et al. 2004 
Cardiovascular adverse effects in 
peripheral artery disease patients GTn 472 Yes Dick et al. 2005 
Hypertension in women -413A/T 1998 Yes Ono et al. 2003 
Restenosis after coronary stenting GTn 1807 No Tiroch et al. 2007 
Restenosis after coronary stenting GTn, +99G/C 199 GTn Yes     +99G/C No Gulesserian et al. 2005 
Restenosis after coronary stenting GTn 323 Yes Chen et al. 2004 
Restenosis after balloon angioplasty GTn 381 Yes Schillinger et al. 2004 
Heart failure and cardiac 
transplantation outcome GTn 592 No Holweg et al. 2005 
Cardiac allograft vasculopathy GTn 152 No Ullrich et al. 2005 
Risk of recurrent venous 
thromboembolism GTn 860 Yes Mustafa et al. 2008 
Renal disease     
Renal transplantation outcome GTn, -413A/T 1125 No Turpeinen et al. 2007 
Renal transplantation outcome GTn 1414 No Courtney et al. 2007 
Renal allograft function GTn 101 Yes Exner et al. 2004 
Renal allograft outcome GTn 771 Yes Baan et al. 2004 
Pulmonary disease     
ARDS GTn, S-TAG haplotype  1451 Yes  Sheu et al. 2009 
Chronic pulmonary emphysema GTn 201 Yes Yamada et al. 2000 
Susceptibility to pneumonia GTn 400 Yes Yasuda et al. 2006 
Lung function decline GTn 749 Yes Guenegou et al. 2006 
Other diseases     
Gastric adenocarcinoma GTn 433 Yes Lo et al. 2007 
Gastric cancer GTn 317 Yes Sawa et al. 2008 
Liver transplantation outcome GTn, -413A/T 308 GTn No            -413A/T Yes Buis et al. 2008 
Idiopathic recurrent miscarriage GTn 291 Yes Denschlag et al. 2004 
Type II diabetes  GTn, -413A/T, Haplotypes 3089 
GTn Yes                 
-413A/T No  
Haplotypes Yes 
Song et al. 2009a 
Rheumatoid arthritis GTn, -413A/T, Haplotypes 1582 
GTn Yes                 
-413A/T No 
Haplotypes Yes 
Rueda et al. 2007 
Abbreviations: ARDS = acute respiratory distress syndrome, CAD = coronary artery disease, HO-1 = heme 
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2.3 Protective role of HO-1 and its reaction products 
 
It  was  originally  assumed  that  HO  functions  only  in  the  basic  metabolism  of  heme,  and  HO  
reaction products were considered as waste products with potential toxic effects. Indeed, high 
levels of inhaled CO are known to impair O2 transport and cause tissue hypoxia, high levels of 
bilirubin  can  cause  neonatal  jaundice  and  neurologic  damage,  and  iron  is  a  pro-oxidant.  
However,  during  the  last  decade  HO-1  has  established  its  role  as  a  cytoprotective  enzyme  in  
various  tissues  and  conditions,  including  the  cardiovascular  system  (Otterbein  et  al.  2003a,  
Peterson et al. 2009). The cytoprotective mechanism of HO-1 is still unclear, but the beneficial 
effects  of  HO-1  are  presumably  mediated  by  the  degradation  of  pro-oxidative  heme  and  
production  of  biologically  active  HO  reaction  products.  Biliverdin  and  bilirubin  are  powerful  
antioxidants (Stocker et al. 1987). CO mediates the antiapoptotic, anti-inflammatory, 
antiproliferative and vasodilatory properties of HO-1 (Thorup et al.  1999, Brouard et al.  2000, 
Otterbein  et  al.  2000,  Peyton et  al.  2002),  and iron  induces  the  synthesis  of  ferritin,  which  is  
also  a  cytoprotective  molecule  and sequesters  free  iron  (Vile  and Tyrrell  1993).  The  beneficial  






















2.3.1 Antioxidant effect  
 
The  antioxidant  effect  of  HO-1  is  mediated  by  biliverdin  and bilirubin.  In  1987,  Stocker  et  al.  
showed that bilirubin scavenges peroxyl radicals, and the antioxidant activity of bilirubin 
increases in hypoxic conditions. Biliverdin and bilirubin also scavenge other ROS, including 
superoxide, hydroxides,  hypochlorous acid,  and singlet oxygen (Nakamura et al.  1987, Stocker 
and Peterhans 1989, Stocker 2004). In addition, biliverdin and bilirubin scavenge reactive 
nitrogen  species  such  as  peroxynitrite  (Kaur  et  al.  2003,  Mancuso  et  al.  2003).  Bilirubin  can  
protect cells from a 10 000-fold excess of hydrogen peroxide (H2O2) (Baranano et al. 2002). The 
powerful  scavenging  of  reactive  oxygen and nitrogen species  by  bilirubin  was  explained  by  an  
amplification cycle, whereby bilirubin is oxidized to biliverdin and recycled back to bilirubin by 
biliverdin  reductase  (Baranano  et  al.  2002).  However,  Maghzal  et  al.  (2009)  showed  that  the  
bilirubin-biliverdin redox amplification cycle plays only a limited role in cellular anti-oxidant 
defense. Similarly, Jansen et al. demonstrated recently (2010) that bilirubin is more efficient 
antioxidant than biliverdin, and conversion of biliverdin to bilirubin contributes to 
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cytoprotection  by  HO-1.  Bilirubin  generated  by  HO-1  protects  against  oxidative  stress  in  
vascular smooth muscle cells (VSMCs) (Clark et al. 2000a). In addition, bilirubin and biliverdin 
protect against I/R injury in kidneys and liver (Fondevila et al. 2004, Adin et al. 2005).  
 
2.3.2 Antiapoptotic effect 
 
The effect of HO-1 is antiapoptotic in most cells and conditions, and the antiapoptotic effect is 
predominantly mediated by CO. HO-1 prevented tumor necrosis factor TNF- -induced 
apoptosis  in  fibroblasts,  presumably  via  CO  (Petrache  et  al.  2000).  In  addition,  CO  inhibits  
TNF- -induced apoptosis of endothelial cells via the p38 MAPK pathway (Brouard et al. 2000). 
Brouard  et  al.  (2002)  also  showed  that  inhibition  of  TNF- -mediated apoptosis by HO-1/CO 
requires activation of transcription factor NF- B. However, different signaling pathways may be 
involved  in  the  antiapoptotic  effect  of  CO  in  different  cells  and  conditions.  In  VSMCs,  the  
antiapoptotic effect of CO was mediated partly by guanosine 3’5’-cyclic monophosphate (cGMP) 
(Liu et al. 2002a). In some circumstances, HO-1 and CO may also increase apoptosis, since CO 
increases endothelial cell apoptosis by increasing NO (Thom et al. 2000). In addition, Liu et al. 
(2002b)  showed  that  overexpression  of  HO-1  in  rat  aortic  smooth  muscle  cells  (SMCs)  
stimulates apoptosis, and the proapoptotic effect of HO-1 involves bilirubin/biliverdin. 
However, in the majority of experimental models HO-1 and CO have protected against 
apoptosis. HO-1 and CO prevented inflammation-related apoptotic liver damage in mice (Sass et 
al. 2003) and inhibited apoptosis in transplanted lungs and hearts (Song et al. 2003, Akamatsu 
et  al.  2004).  The  antiapoptotic  effect  of  HO-1  may  also  be  mediated  by  HO reaction  products  
other  than  CO.  Ferris  et  al.  (1999)  showed  that  HO-1  inhibits  apoptosis  by  augmenting  iron  
efflux  from  the  cells.  In  addition,  HO-1  overexpression  inhibits  Fas-mediated  apoptosis  in  
Jurkat  T  cells  by  an  iron-dependent  mechanism  (Choi  et  al.  2004).  The  third  HO  reaction  
product,  bilirubin,  may  protect  against  peroxynitrite-induced  apoptosis  (Foresti  et  al.  1999).  
Bilirubin also inhibited bile acid-induced apoptosis of rat hepatocytes by its antioxidative action 
(Granato et al. 2003). However, bilirubin is toxic to brains and increases apoptosis of neurons in 
vitro (Silva et al. 2002).  
 
2.3.3 Anti-inflammatory effect 
 
The  anti-inflammatory  action  of  HO-1  was  demonstrated  in  1996  by  Willis  et  al.  The  anti-
inflammatory role of HO-1 is supported by the chronic inflammation of HO-1 null mice and the 
severe inflammatory syndrome of the only person diagnosed to date with   HO-1 deficiency (Poss 
and Tonegawa 1997a, 1997b, Yachie et al. 1999, Kawashima et al. 2002). The anti-inflammatory 
effect  of  HO-1  is  predominantly  mediated  by  CO.  HO-1/CO  suppress  the  production  of  
proinflammatory cytokines, such as TNF- , IL-1 , IL-6, and monocyte chemotactic protein 1 
(MCP-1) and enhance the anti-inflammatory response by increasing the expression of the anti-
inflammatory  cytokine  IL-10  (Otterbein  et  al.  2000,  Morse  et  al.  2003).  Furthermore,  IL-10  
increases  the  expression  of  HO-1,  and  the  anti-inflammatory  effect  of  IL-10  is  dependent  on  
HO-1 (Lee and Chau 2002). These findings point to a positive feedback loop for amplifying the 
anti-inflammatory effect of CO. Likewise, in chronic murine cholitis the anti-inflammatory 
effect  of  CO  was  dependent  on  HO-1  induction  (Hegazi  et  al.  2005).  Otterbein  et  al.  (2000)  
showed that the anti-inflammatory effect of CO is mediated by the MAPK pathway, but does not 
involve cGMP or NO. In addition, HO-1 decreases production of proinflammatory granulocyte 
macrophage  colony-stimulating  factor  (GM-CSF)  via  the  NF- B pathway (Sarady et al. 2002). 
The anti-inflammatory effect of HO-1 may partly result from the down-regulation of adhesion 
molecules, such as E- and P-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular 
cell adhesion molecule 1 (VCAM-1) (Hayashi et al. 1999, Rucker et al. 2001, Soares et al. 2004, 
Song et al. 2009b). Down-regulation of adhesion molecules decreases infiltration of leukocytes 
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in the injured tissue and thereby attenuates inflammation. In addition, the inhibition of platelet 
aggregation  and  subsequent  thrombosis  may  contribute  to  the  anti-inflammatory  effect  of      
HO-1/CO (Brune and Ullrich 1987). 
 
2.3.4 Antiproliferative effect 
 
HO-1 inhibits proliferation of several cell types, such as SMCs, T cells, and fibroblasts (Peyton et 
al.  2002,  Song  et  al.  2002,  Song  et  al.  2004,  Zhou  et  al.  2005,  Liu  et  al.  2006).  The  
antiproliferative effect of HO-1 is predominantly mediated by CO, as shown in VSMCs by Morita 
et  al.  (1995,  1997).  Although  CO  inhibits  proliferation  of  several  cell  types,  the  signaling  
pathways involved in the antiproliferative effect of CO differ considerably in a cell type-specific 
manner. In VSMCs the antiproliferative effect of CO involves production of cGMP, activation of 
the p38 MAPK pathway, expression of the cell cycle inhibitor p21Cip1,  and inhibition of the cell  
cycle-specific transcription factor E2F-1 (Morita et al.  1997, Otterbein et al.  2003b).  In airway 
SMCs the antiproliferative effect of CO is mediated by down-regulation of the ERK MAPK 
pathway (Song et al.  2002),  and in T cells the antiproliferative effect of CO involves increased 
expression of p21Cip1 and  decreased  caspase-8  activity  and  is  independent  of  the  cGMP  and  
MAPK pathways (Song et al. 2004). Biliverdin and bilirubin may also regulate cell proliferation, 
since  Ollinger  et  al.  (2005)  showed  that  bilirubin  decreases  SMC  proliferation  by  inhibiting  
cyclins  A,  D1,  and  E,  and  cyclin-dependent  kinase  2  (cdk2)  via  the  p38  MAPK  pathway,  and  
decreases neointimal formation after balloon injury.  In addition, it  should be noted that HO-1 
and CO increase proliferation of some cell types, such as endothelial cells and regulatory T cells 
(Li  Volti  et  al.  2002,  Brusko  et  al.  2005,  Lee  et  al.  2007).  These  findings  highlight  the  
importance of HO-1 and CO, e.g. in vascular remodeling. 
 
2.3.5 Vasoactive effects 
 
HO-1 regulates vascular tone by a CO-dependent mechanism. Similar to NO, CO activates 
soluble guanylate cyclase (sGC) and increases cGMP levels, leading to vasodilation (Morita et al. 
1995,  Sammut  et  al.  1998,  Duckers  et  al.  2001).  The  vasodilatory  effect  of  CO was  reported  in  
1978 by  Sylvester  and McGowan,  and in  1988 Lin  and McGrath  showed in  rat  aortas  that  the  
effect of CO was not endothelium-dependent. Furchgott and Jothianandan (1991) compared the 
vasoactive effects of NO and CO in isolated rabbit aorta and found that similar to NO, CO caused 
vasodilation  via  production  of  cGMP,  although  CO  was  1000-fold  less  potent  than  NO  as  a  
vasorelaxant. To confirm the hypothesis that cGMP mediates CO-induced vasorelaxation, 
Hussain et al. (1997) showed in rabbit aortic rings that CO-dependent vasodilation is abolished 
by the specific sGC inhibitor 1H-[1,2,4]oxadiazolo[4,3- ]quinoxalin-1-one (ODQ). CO may also 
cause vasorelaxation via mechanisms other than by increasing cGMP levels, since CO activates 
calcium-dependent potassium (KCa) channels (Wang et al. 1997, Jaggar et al. 2002). Wang et al. 
(1997) showed that the vasodilatory effect of CO was mediated partially via cGMP and partially 
via  large-conductance  KCa channels.  SMC-derived  CO  may  also  have  paracrine  effects  on  
endothelial cells and regulate vascular tone by modulating the expression of endothelin 1 (ET-1) 
and platelet-derived growth factor  (PDGF- ) in endothelial cells (Morita et al. 1995). In some 
circumstances, the vasoregulatory effect of CO may also involve regulation of NO, since Foresti 
et  al.  (2004)  showed  that  the  vasodilatory  effect  of  CO-releasing  molecule  3  (CORM-3)  was  
dependent on endothelium-derived NO. In some models, CO may also have a vasoconstrictive 
effect.  Johnson  et  al.  (2002,  2003)  showed  that  CO  may  have  a  competing  vasoconstrictive  
effect by inhibiting the formation of NO in endothelium. Furthermore, high concentrations of 
CO  inhibit  NO  production  and  endothelial  NO  synthase  (eNOS)  activity  in  isolated  renal  
resistance vessels (Thorup et al.  1999).  Imai et al.  (2001) showed that HO-1 overexpression in 
VSMCs inhibits formation of NO, which leads to elevated blood pressure.    
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2.3.6 Anticoagulative effect 
 
HO-1 inhibits platelet activation and aggregation via a CO-dependent mechanism. Inhibition of 
platelet  aggregation  by  CO  was  reported  in  1982  by  Mansouri  and  Perry.   Brune  and  Ullrich  
showed  a  few  years  later  (1987)  that  CO  prevents  platelet  aggregation  by  activating  sGC  and  
increasing cGMP levels. In contrast, Chlopicki et al. showed recently (2006) that CO released by 
CORM-3 inhibited platelet aggragation by a mechanism independent of sGC. The suppression of 
vascular thrombosis has been shown in several studies. HO-1 induction by hemin delayed 
microvascular thrombus formation in mice in vivo, and bilirubin prevented thrombus formation 
as  efficiently  as  hemin  treatment,  suggesting  equally  important  antithrombotic  roles  for  
bilirubin  and  CO  (Lindenblatt  et  al.  2004).  Recently,  Johns  et  al.  (2009)  showed  that  HO-1  
induction by cobalt protoporphyrin IX (CoPPIX) inhibited thrombus formation in cremaster 
arterioles. Furthermore, True et al. (2007) showed that HO-1 null mice have accelerated 
thrombosis, due to increased endothelial cell apoptosis, platelet activation, and elevated tissue 
factor and von Willebrand factor (vWF) levels. They also demonstrated that both inhaled CO 
and biliverdin administration rescued the prothrombotic phenotype of HO-1 null mice (True et 
al.  2007).  In  addition,  CO  down-regulates  the  expression  of  prothrombotic  plasminogen  
activator inhibitor type 1 (PAI-1) in macrophages and enhances fibrinolysis (Fujita et al. 2001). 
Likewise,  Chen  et  al.  (2006)  showed  that  HO-1  overexpression  and  CO  inhalation  decreased  
PAI-1 levels and induced early thrombolysis after vascular injury in hypercholesterolemic mice. 
Moreover,  Matsumoto  et  al.  (2006)  showed  that  both  CO  and  bilirubin  down-regulate  PAI-1  
expression when administered to HO-1-deficient cells.  
 
2.3.7 Proangiogenic effect 
 
A  growing  body  of  evidence  shows  that  HO-1  plays  an  important  role  in  angiogenesis.  
Angiogenesis is defined as formation of new capillaries from pre-existing capillaries by 
increased migration and proliferation of endothelial cells (sprouting). The increased 
proliferation of endothelial cells in response to HO-1 overexpression was demonstrated in 1998 
by Deramaudt et al.  Later studies showed that the proangiogenic effect of HO-1 in endothelial  
cells is mediated by CO (Jozkowicz et al. 2003, Li Volti et al. 2005). CO also inhibits endothelial 
cell apoptosis (Soares et al. 2002). The proangiogenic mechanism of HO-1 involves induction of 
angiogenic growth factors and cytokines. Overexpression of HO-1 increases vascular endothelial 
growth factor (VEGF) expression in endothelial cells and VSMCs (Dulak et al. 2002, Jozkowicz 
et al. 2003). HO-1 also promotes neovascularization in rat and mouse hindlimb ischemia models 
by inducing VEGF and stromal cell-derived factor 1 (SDF-1) (Suzuki et al.  2003, Tongers et al.  
2008). In addition, several factors, including prostaglandin J and H2O2, induce VEGF synthesis 
via  an  HO-1-mediated  mechanism  (Jozkowicz  et  al.  2002,  Cisowski  et  al.  2005).  Conversely,  
HO-1  and  CO  may  also  be  involved  in  the  downstream  response  of  cells  to  VEGF  and  SDF-1  
stimulation, since VEGF and SDF-1 induce HO-1 expression (Bussolati  et  al.  2004, Deshane et 
al.  2007).  Furthermore,  inhibition  of  HO-1  attenuates  VEGF-induced  endothelial  cell  
proliferation and tube formation (Bussolati et al. 2004). However, the effect of HO-1 on 
angiogenesis  may  differ,  depending  on  conditions.  Bussolati  et  al.  (2004)  showed  that  HO-1  
inhibits inflammation-induced angiogenesis by preventing leukocyte infiltration, but enhances 
VEGF-induced noninflammatory angiogenesis. Nevertheless, these findings suggest a positive 
feedback loop between HO-1 and VEGF in promoting angiogenesis. Interestingly, Bellner et al. 
showed recently (2009) that deletion of the constitutive isoform HO-2 caused endothelial cell 
activation and promoted massive inflammation-driven angiogenesis, and this effect was 
reversed by addition of biliverdin to the HO-2 (-/-) endothelial  cells.  This supports the above-
mentioned hypothesis that the HO system suppresses inflammation-induced angiogenesis 
(Bellner et al. 2009). 
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HO-1  and  CO  may  potentially  regulate  angiogenesis  via  other  mechanisms  as  well.  HIF-1  is  a  
transcription  factor  that  regulates  the  expression  of  several  angiogenic  factors  and  induces  
angiogenesis  in  response  to  hypoxia  (Kelly  et  al.  2003).  HIF-1  is  known  to  up-regulate  HO-1  
expression, whereas CO up-regulates and stabilizes HIF-1  (Chin et al. 2007, Faleo et al. 2008). 
These findings suggest another positive feedback loop that could enhance the angiogenic effect 
of HO-1 and CO. HO-1 may also regulate the proangiogenic cytokine IL-8 (Pae et al. 2005). In 
addition to the up-regulation of proangiogenic factors, HO-1 overexpression down-regulates 
antiangiogenic factors,  such as VEGF receptor 1 (VEGF-R1) and soluble endoglin (Cudmore et 
al.  2007).  Interestingly,  Taha  et  al.  showed  recently  (2010)  that  HO-1 GTn microsatellite 
polymorphism modulates the function of endothelial cells. GTn polymorphism affected HO-1 
expression and cells carrying the S allele survived better under oxidative stress, produced lower 
levels of proinflammatory mediators, and proliferated more efficiently in response to VEGF, 
although HO-1 polymorphisms did not influence migration and sprouting of capillaries (Taha et 
al. 2010). Thus, HO-1 polymorphisms may modulate the angiogenic potential of endothelial 
cells in different diseases. 
 
2.3.8 Loss of protection in HO-1 deficiency 
 
The only known case of human HO-1 deficiency and studies on HO-1 knockout mice highlight 
the  crucial  cytoprotective  role  of  HO-1.  The  HO-1  knockout  mice  exhibited  anemia  and  
disturbed iron metabolism characterized by low serum iron levels and increased accumulation 
of  iron  in  tissues,  especially  in  kidneys  and  liver  (Poss  and  Tonegawa  1997b).  The  HO-1  
knockout mice also had progressive chronic inflammation, splenomegaly, lymphadenopathy, 
leukocytosis, vascular injury, glomerulonephritis, and premature mortality (Poss and Tonegawa 
1997b). Furthermore, fibroblasts derived from HO-1 null mice are more susceptible to 
cytotoxicity  induced  by  different  pro-oxidant  stimuli  (Poss  and  Tonegawa  1997a).  In  various  
disease  models,  HO-1  deficiency  predisposes  to  right  MI  after  chronic  hypoxia  and to  arterial  
thrombosis after vascular injury (Yet et al. 1999, True et al. 2007). HO-1 deficiency also worsens 
myocardial I/R injury, especially in concert with diabetes (Liu et al. 2005).  
 
Similar findings have been reported in human HO-1 deficiency (Yachie et al.  1999, Ohta et al.  
2000,  Kawashima  et  al.  2002).  The  symptoms  and  findings  in  the  HO-1-deficient  patient  are  
listed  in  Table  3.  The  main  findings  in  the  HO-1-deficient  boy  were  severe  systemic  vascular  
endothelial cell injury, severe hemolytic anemia with paradoxically high serum haptoglobin and 
low bilirubin levels, and reticuloendothelial dysfunction (Yachie et al. 1999). The patient also 
had tissue iron and amyloid deposition, progressive renal tubular injury, and abnormal 
coagulation/fibrinolysis (Yachie et al. 1999, Ohta et al. 2000, Kawashima et al. 2002). In 
comparison  to  the  HO-1  null  mice,  the  HO-1-deficient  boy  was  more  severely  affected  by  
oxidative stress, and the cells of the patient were extremely sensitive to hemin-induced cell 
injury  (Poss  and Tonegawa 1997b,  Yachie  et  al.  1999).  The  high  serum levels  of  pro-oxidative  
heme likely contributed to the severe vascular endothelial cell injury. The severe injuries may 
also  have  partially  resulted  from exposure  of  the  patient  to  infectious  agents  and other  stress  
factors,  starting  soon after  birth  (Ohta  et  al.  2000).  In  contrast  to  the  HO-1  null  mice  having  
splenomegaly, the HO-1 deficient patient had no spleen. The absence of spleen likely 
contributed  to  the  endothelial  cell  injury  and  tubulus  injury,  due  to  absence  of  the  splenic  
filtering  function  (Ohta  et  al.  2000).  The  patient  died  early  (at  the  age  of  6  years)  of  an  
intracranial hemorrhage and progressed disease (Kawashima et al. 2002). This case of human 
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Table 3. Symptoms and clinical findings in the heme oxygenase-1-deficient patient. 
 
Symptom/Finding Symptom/Finding 
Recurrent fever Leukocytosis 
Erythematous rash Thrombocytosis 
Growth retardation Abnormal coagulation/fibrinolysis, DIC 
Hepatomegaly Vascular endothelial injury  
Asplenia         High thrombomodulin and von Willebrand factor 
Cervical lymphadenopathy Reticuloendothelial dysfunction 
Intravascular hemolytic anemia Hematuria and proteinuria 
High serum haptoglobin Renal tubular injury 
High lactate dehydrogenase         High urinary N-acetyl- -D-glucosaminidase 
Low bilirubin         High urinary B2-microglobulin  
High ferritin  Mesangioproliferative glomerulonephritis 
Coombs test negative Iron deposition in liver and kidneys 
High serum heme Amyloid deposits in liver and adrenal glands 
Undetectable hemopexin Hyperlipidemia 
High aspartate aminotransferase Atherosclerotic changes 




2.4 HO-1 and its reaction products in cardiovascular diseases 
 
Increasing numbers of studies show that HO-1 and its reaction products protect the heart and 
vasculature  in  pathological  conditions.  Increased  expression  of  HO-1  has  been  found  in  the  
heart and vasculature in vivo and in cardiomyocytes, endothelial cells, and VSMCs in vitro in 
response  to  various  stimuli,  such  as  hyperthermia,  I/R,  hypoxia,  cytokines,  hemin,  NO  and  
angiotensin II (Raju and Maines 1994, Maulik et al. 1996, Motterlini et al. 1996, Durante et al. 
1997, Lee et al. 1997, Pellacani et al. 1998, Terry et al. 1998, Clark et al. 2000b, Hangaishi et al. 
2000,  Ishizaka  et  al.  2000,  Motterlini  et  al.  2000a).  Overexpression  or  pharmacological  
induction  of  HO-1,  or  administration  of  HO  reaction  products,  provides  protection  e.g.  in  MI  
and heart failure, atherosclerosis and vascular injury, and hypertension in experimental rat, 
mouse, and swine models. The beneficial effects of HO-1 in various disease models are 
summarized in Fig. 4. 
 
2.4.1 HO-1 in myocardial infarction and heart failure 
 
HO-1  and  its  reaction  products  have  both  short-term  and  long-term  protective  effects  on  
myocardial I/R injury and MI. The crucial stress-responsive role of HO-1 was demonstrated by 
increased  right  ventricular  dilatation,  right  ventricular  infarction,  and mural  thrombi  of  HO-1  
null mice after chronic hypoxia (Yet et al. 1999). Conversely, cardiac-specific overexpression of 
HO-1 improves postischemic cardiac function, decreases infarct size, and reduces cardiac 
apoptosis,  inflammatory cell  infiltration, and oxidative damage in I/R mouse hearts (Yet et al.  
2001, Vulapalli et al. 2002).  Likewise, cardiac gene transfer of HO-1 8 weeks before I/R 
decreased infarct size, inflammation, and expression of proapoptotic and proinflammatory 
proteins in rat hearts (Melo et al. 2002). In addition, HO-1 induction by hemin decreased infarct 
size and improved postischemic cardiac function in I/R rat hearts, and the protective effect was 
mediated by bilirubin (Clark et al. 2000b). Bilirubin also protects against reoxygenation damage 
in rat cardiomyocytes in vitro (Foresti et al. 2001).  
 






























Figure 4. Beneficial effects of HO-1 in the heart and vasculature in different disease models. 
Abbreviations: EC = endothelial cell, HO-1 = heme oxygenase-1, I/R = ischemia/reperfusion, ROS = 
reactive oxygen species, SMC = smooth muscle cell, VF = ventricular fibrillation. 
 
 
CO  exerts  protective  effects  in  the  setting  of  cardiac  I/R  as  well.  Bak  et  al.  (2005)  showed  in  
isolated  I/R  rat  hearts  that  CO  exposure  via  perfusion  buffer  decreases  infarct  size,  improves  
postischemic cardiac function, and decreases the incidence of I/R-induced ventricular 
fibrillation (VF). The same group demonstrated that pretreatment of rat hearts with the CO 
donor CORM-3 similarly protected the heart during I/R, and the protective effect involved the 
regulation of cardiac Na+, K+, and Ca2+ levels (Varadi et al. 2007). Guo et al. (2004) showed that 
administration of CORM-3 at the time of reperfusion decreased infarct size in mouse hearts in 
vivo after  30  min  of  focal  ischemia  and  24  h  of  reperfusion.  In  addition,  administration  of  
CORM-3 24–72 h before I/R induced delayed protection against MI similar to the late phase of 
ischemic  preconditioning  (Stein  et  al.  2005).  Furthermore,  rapid  release  of  CO  by  CORM-3  
exerts a positive inotropic effect on isolated perfused rat hearts, and this effect involved cGMP 
and Na+/H+ exchange (Musameh et al. 2006). However, slow release of CO by CORM-A1 did not 
affect myocardial contractility, but caused vasodilatation (Musameh et al. 2006). Based on these 
studies,  brief  exposure  to  CO  protects  the  heart  against  I/R  injury.  However,  Meyer  et  al.  
showed recently  (2010)  that  prolonged exposure  to  30–100 parts  per  million  (ppm) of  CO by  
inhaled  air  worsens  myocardial  I/R  injury,  increases  the  severity  of  postischemic  ventricular  
arrhythmias, impairs postischemic cardiac function, and increases infarct size in rats.  
 
The cytoprotective and prongiogenic effects of HO-1 point to a potential role for HO-1 in cardiac 
cell therapy and cardiac regeneration after MI. Transplantation of mesenchymal stem cells 
(MSCs) in the infarcted rat hearts increased HO-1 expression in the transplanted MSCs and in 
the cardiomyocytes of the recipient heart, decreased infarct size, and improved cardiac function 
REVIEW OF THE LITERATURE 
 
24  
(Zhang et al. 2005). HO-1 also improved survival of MSCs in the infarcted rat and mouse hearts 
during  the  first  week  after  MI  (Tang  et  al.  2005,  Zeng  et  al.  2008a).  Accordingly,  Jiang  et  al.  
showed recently (2010) that HO-1 overexpression increased the survival of transplanted MSCs 
in  the  infarcted  swine  hearts  at  week  1  post-MI.  However,  the  MSCs  were  mostly  engulfed  by  
cardiac  macrophages,  and  no  MSCs  were  detected  at  3  months  post-MI  (Jiang  et  al.  2010).     
HO-1-transfected MSCs decreased infarct size, improved left ventricular function, and increased 
microvascular  density  in  postinfarction  rat  and  swine  hearts  (Zeng  et  al.  2008a,  Jiang  et  al.  
2010, Tsubokawa et al. 2010). Although HO-1 increased survival of MSCs in the infarcted hearts 
to some extent, the beneficial effect of HO-1-modified MSCs was more likely mediated by 
paracrine factors secreted by these cells. Zeng et al. (2008b) showed that HO-1 increases 
production of growth factors and cytokines, including hepatocyte growth factor (HGF), basic 
fibroblast growth factor (bFGF) and VEGF, in MSCs in vitro, and injection of cell culture 
supernatants  of  HO-1  transfected  MSCs  in  the  infarcted  rat  hearts  improved cardiac  function,  
decreased infarct size and increased microvessel density. Furthermore, Lin et al. (2008) showed 
that  cardiac  HO-1  gene  transfer  promotes  neovascularization  in  the  ischemic  mouse  hearts  by  
up-regulating  the  angiogenic  factors  VEGF  and  SDF-1  and  recruitment  of  c-kit+  and  CD34+  
circulating stem/progenitor cells.  
 
HO-1 gene therapy is a potential therapeutic strategy for protecting the heart against ischemic 
injury  and promoting  the  healing  of  infarcted  hearts.  Pachori  et  al.  (2004)  showed that  HO-1  
gene delivery by a hypoxia-regulated viral  vector 5 weeks prior to I/R injury improved cardiac 
function, reduced infarct size, and decreased expression of proinflammatory cytokines in the 
infarcted rat hearts. Likewise, HO-1 gene delivery by a hypoxia-regulated plasmid system 
improved the recovery of cardiac function and protected against ischemic injury in infarcted 
mouse hearts (Tang et al. 2005). It has been speculated that prolonged HO-1 overexpression 
may have adverse toxic effects. The hypoxia-regulated gene delivery system alleviates the 
possible  toxic  effects  of  high  HO-1  levels,  because  it  is  active  only  in  ischemic  conditions.  The  
pre-emptive HO-1 gene delivery also improved cardiac function, reduced myocardial injury, and 
prevented adverse left ventricular remodeling 12 days after repeated episodes of I/R or 1.5 and 3 
months  after  a  single  episode  of  I/R  in  rat  hearts  (Liu  et  al.  2006,  Pachori  et  al.  2006).  
Furthermore, the pre-emptive HO-1 gene delivery provided long-term protection by increasing 
survival  of  rats,  improving  cardiac  function,  and reducing  post-MI  left  ventricular  remodeling  
and heart failure 1 year after MI (Liu et al. 2007).  
 
HO-1 also protects against pathologic left ventricular remodeling. Recently, Wang et al. (2010) 
demonstrated that cardiac-specific HO-1 overexpression in mice has several beneficial effects in 
failing  hearts.  HO-1  improved  post-MI  survival,  ameliorated  left  ventricular  dilatation  and  
dysfunction, decreased apoptosis, hypertrophy, interstitial fibrosis, and oxidative stress, and 
increased  neovascularization  (Wang  et  al.  2010).  They  also  showed  that  the  beneficial  effects  
were mediated at least partially by CO (Wang et al. 2010). Likewise, HO-1 gene therapy 
decreased apoptosis, interstitial fibrosis, and accumulation of myofibroblasts in the infarcted rat 
hearts  (Liu  et  al.  2006,  2007,  Pachori  et  al.  2006).  In  addition,  HO-1  induction  by  hemin  
attenuated left ventricular hypertrophy and fibrosis in adult spontaneously hypertensive rats 
(Ndisang and Jadhav 2009), and HO-1 induction by CoPPIX inhibited angiotensin II-induced 
cardiac hypertrophy in rats (Hu et al. 2004). Furthermore, HO-1 contributed to improved 
ventricular function and decreased hypertrophy and interstitial  fibrosis in mice lacking Bach1, 
the transcriptional repressor of HO-1 (Mito et al. 2008). 
 
HO-1  is  induced  by  numerous  factors  and  mediates  the  beneficial  effects  of  many  of  these  
factors. Resveratrol promotes neovascularization in infarcted rat hearts, in part via HO-1 (Kaga 
et  al.  2005).  Likewise,  Samuel  et  al.  showed  recently  (2010)  that  the  proangiogenic  effect  of  
thioredoxin-1  is  mediated  by  HO-1  in  infarcted  rat  hearts.  HO-1  also  contributes  to  the  
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cardioprotective effects of inducible NO synthase (iNOS), erythropoietin, and Hif-1 (Ockaili et 
al. 2005, Burger et al. 2009, Li et al. 2009).    
 
Studies  investigating  HO-1  in  cardiac  patients  are  relatively  few.  Corradi  et  al.  (2008)  showed 
increased  expression  of  HO-1  in  left  atrial  myocardium  of  patients  with  chronic  atrial  
fibrillation. HO-1 expression was higher in the left atrial areas with greater structural 
remodeling (Corradi et al. 2008). Myocardial HO-1 expression appears to increase in various 
cardiac diseases in response to stress. Grabellus et al. (2002) showed increased expression of 
HO-1 in the myocardium of patients with end-stage heart failure, whereas left ventricular 
mechanical  support  by  a  left  ventricular  assist  device  significantly  decreased  myocardial  HO-1  
expression. Furthermore, HO-1 expression was markedly increased in the myocardial tissue of a 
patient with increased production of ROS due to mitochondrial cardiomyopathy (Ishikawa et al. 
2005). HO-1 expression has also been studied in peripheral blood monocytes and lymphocytes 
of  patients  with  coronary  heart  disease  (Chen  et  al.  2005,  2009,  Ishikawa  et  al.  2005).  HO-1  
levels were increased in patients with coronary heart disease, and the levels correlated with the 
severity of disease, with the highest levels in patients with acute MI (Chen et al. 2005, 2009).  
 
The  increase  in  HO-1  is  likely  a  protective  response  in  patients,  since  higher  serum  bilirubin  
levels associated with decreased risk for coronary artery disease (Hopkins et al. 1996). Serum 
total bilirubin levels are also inversely correlated with the prevalence of metabolic syndrome 
among children and adolescents (Lin et al. 2009). The protective effect of higher serum bilirubin 
levels against ischemic heart disease was also described in patients with Gilbert syndrome, a 
genetic disorder characterized by above-normal levels of circulating unconjugated bilirubin 
(Vitek  et  al.  2002).  Conversely,  low  serum  bilirubin  concentrations  were  associated  with  
coronary artery calcification (Tanaka et al. 2009).  
 
In addition, HO-1 polymorphisms in humans may modulate the susceptibility to coronary artery 
disease. It has been suggested that the short GTn repeat length protects against coronary artery 
disease (Chen et al. 2002, Kaneda et al. 2002, Dick et al. 2005, Brydun et al. 2007, Chen et al. 
2008).  However,  in  some  studies,  especially  in  the  large  study  of  over  3000  patients  by  
Lublinghoff  et  al.  (2009),  the  association  between  HO-1 polymorphisms and coronary artery 
disease was not found (Endler et al. 2004, Holweg et al. 2005, Lublinghoff et al. 2009).   
 
2.4.2 HO-1 in atherosclerosis and vascular injury 
 
The  increased  production  of  ROS  and  vascular  inflammation  lead  to  the  development  of  
atherosclerosis. Increasing evidence shows that HO-1 protects against atherosclerotic vascular 
disease. HO-1 is induced by several proatherogenic factors, including oxidized low-density 
lipoprotein (LDL), increased blood pressure, and smoking (Wang et al. 1998, Ndisang and Wang 
2003, Fukano et al. 2006). In addition, HO-1 is found in atherosclerotic lesions in both humans 
and animals, and it is detected at high levels in macrophages/foam cells of the lesions 
throughout  development  of  the  lesions  (Wang et  al.  1998,  Ishikawa et  al.  2001b).  In  the  early  
stage  of  lesion  formation,  HO-1  is  also  expressed  in  endothelial  cells,  whereas  in  advanced  
lesions  HO-1  is  found  in  SMCs  (Wang  et  al.  1998,  Ishikawa  et  al.  2001b).  HO-1  induction  by  
hemin  reduces  lesion  size  in  LDL-receptor  knockout  mice,  whereas  inhibition  of  HO-1  by  
SnPPIX increases atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits 
(Ishikawa  et  al.  2001a,  2001b).  Furthermore,  Yet  et  al.  (2003)  showed  that  mice  deficient  in  
both  HO-1  and apolipoprotein  E  (ApoE)  develop  larger  and more  advanced  lesions  than mice  
deficient in ApoE only. HO-1 also reverses atherosclerotic plaque progression from vulnerable 
plaque to a more stable phenotype by reducing the size of the necrotic core and intraplaque lipid 
accumulation and increasing the thickness of the fibrous cap and accumulation of VSMCs in the 
intima in apoE-null mice (Cheng et al. 2009). 




HO-1 modulates the development of atherosclerosis by multiple mechanisms. HO-1 induction by 
hemin  reduces  monocyte  chemotaxis  in  response  to  oxidized  LDL  (Ishikawa  et  al.  1997).  In  
addition, Orozco et al. (2007) showed that HO-1 expression in macrophages is important for the 
antiatherogenic  effect  of  HO-1.  They  showed  that  both  reduced  or  absent  HO-1  expression  in  
macrophages increased generation of ROS, production of inflammatory cytokines, and 
formation of foam cells when treated with oxidized LDL in vitro (Orozco  et  al.  2007).  The  
absence of HO-1 also resulted in greater macrophage content in atherosclerotic lesions in vivo 
(Orozco et al. 2007). Increased iron deposition is present in atherosclerotic lesions and is 
associated with the progression of atherosclerosis in ApoE-deficient mice (Lee et al. 1999). HO-1 
may protect against excess vascular iron deposition, since HO-1-deficient mice have increased 
tissue iron accumulation (Poss and Tonegawa 1997b).  Conversely,  HO-1 prevents cell  death by 
enhancing cellular iron efflux in mouse fibroblasts (Ferris et  al.  1999).  In addition, Juan et al.  
(2001) showed that HO-1 gene transfer indeed decreases iron deposition in the atherosclerotic 
lesions of ApoE-deficient mice.     
 
The protective role of bilirubin against atherosclerosis and coronary artery disease was observed 
in  1994.  Wu  et  al.  (1994)  showed  that  bilirubin  efficiently  prevents  oxidation  of  LDL,  and  
Schwertner  et  al.  (1994)  reported  that  low  serum  bilirubin  concentration  is  associated  with  
increased risk of coronary artery disease. The inverse correlation between serum bilirubin levels 
and the  risk  for  coronary  artery  disease  was  confirmed later  in  several  studies  (Hopkins  et  al.  
1996, Vitek et al.  2002).  Bilirubin and biliverdin are efficient scavengers of oxidants,  and they 
may protect the vasculature by their antioxidant action (Stocker and Peterhans 1989). Bilirubin 
protects  VSMCs  against  oxidative  stress  and  inhibits  lipid  peroxidation  in  LDL-receptor  
knockout mice, as demonstrated by decreased plasma lipid hydroperoxide (LPO) levels (Clark et 
al. 2000a, Ishikawa et al. 2001b). Kawamura et al. (2005) showed that HO-1-derived bilirubin 
suppresses production of proinflammatory mediators and attenuates endothelial dysfunction. In 
addition, bilirubin decreases monocyte transmigration in response to oxidized LDL (Ishikawa et 
al. 1997). Bilirubin and biliverdin also reduce proliferation of SMCs in vitro and decrease 
balloon injury-induced neointima formation in hyperbilirubinemic Gunn rats (Ollinger et al. 
2005). 
 
CO potentially contributes to the antiatherogenic effect of HO-1 by several mechanisms, of 
which the anti-inflammatory and antiproliferative effects are likely the most important. 
Otterbein  et  al.  (2003b)  showed  that  CO  suppresses  arteriosclerotic  lesions  associated  with  
chronic graft rejection by inhibiting leukocyte infiltration, SMC proliferation, and expression of 
proinflammatory cytokines in the transplanted aortic segments. They also showed that CO 
reduced neointimal hyperplasia and completely prevented vascular stenosis after balloon 
angioplasty (Otterbein et al. 2003b). Recently, Hyvelin et al. (2010) showed that HO-1 induction 
by hemin reduced in-stent stenosis in rats and rabbits and a similar effect was observed in rats 
after  treatment  with  CO  donor  CORM-2.  The  anticoagulative,  antiapoptotic,  and  vasodilatory  
effects of CO may also contribute to the protection against atherosclerosis and vascular injury.  
CO inhibits human platelet aggregation in vitro and platelet-dependent thrombosis in mice 
(Brune and Ullrich 1987, Peng et al. 2004). In addition, CO suppresses rejection of mouse-to-rat 
cardiac transplants by inhibiting platelet aggregation, thrombosis, and endothelial cell apoptosis 
(Sato et al. 2001).  
 
2.4.3 HO-1 in hypertension 
 
Numerous  studies  have  shown that  HO-1  has  antihypertensive  effects  via  its  reaction  product  
CO. HO-1 is up-regulated in aortic tissue of spontaneously hypertensive rats, and in response to 
angiotensin II in many cells and organs, including VSMCs, endothelial cells, heart and kidneys 
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(Ishizaka  and  Griendling  1997,  Aizawa  et  al.  2000,  Ishizaka  et  al.  2000,  Mazza  et  al.  2003,  
Cheng et al. 2004). Administration of heme, heme derivatives, or CO reduces blood pressure of 
hypertensive  rats  (Levere  et  al.  1990,  Johnson  et  al.  1996,  Ndisang  et  al.  2002).  Accordingly,  
HO-1 gene transfer reduces blood pressure in spontaneously hypertensive rats and prevents 
angiotensin  II-induced  increase  in  blood  pressure  (Sabaawy  et  al.  2001,  Yang  et  al.  2004).  
Botros  et  al.  (2005)  showed  that  HO-1  induction  by  CoPPIX  decreases  blood  pressure  in  a  
renovascular hypertension model, whereas HO-1 inhibition by tin mesoporphyrin (SnMP) 
elevates blood pressure. Furthermore, Wiesel et al. (2001) showed in the same renovascular 
hypertension model that absence of HO-1 leads to more severe renovascular hypertension and 
cardiac hypertrophy. Interestingly, Wang et al. (2006) showed in spontaneously hypertensive 
rats  that  administration  of  hemin  for  3  weeks  by  osmotic  minipumps  caused  increased  HO-1  
expression  and  activity  and  normalized  systolic  blood  pressure,  and  these  changes  were  
maintained for 9 months after hemin treatment. In contrast to these antihypertensive effects, 
HO-1 and CO promote endothelial  dysfunction and contribute to salt-induced hypertension in 
Dahl salt-sensitive rats and deoxycorticosterone acetate (DOCA) salt-sensitive rats (Johnson et 
al. 2003, 2004, Teran et al. 2005). However, despite the skeletal muscle endothelial dysfunction 
in Dahl rats, HO-1 and CO protected the heart by promoting coronary vasodilatation in the same 
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3 AIMS OF THE STUDY 
 
The aim of the present study was to investigate the role of HO-1 in protection and repair of the 
heart, examine the potential mechanisms mediating the cardioprotective and prohealing effects 
of HO-1 in the experimental rat models, and to evaluate the expression and significance of HO-1 
in critically ill patients.  
 
 
The specific aims were: 
 
1. To investigate the expression and function of HO-1 in postinfarction rat hearts and determine 
which cells express HO-1 in the heart. (I–III) 
 
2. To determine the long-term and short-term cardioprotective effects of HO-1 induction in 
infarcted rat hearts and in isolated I/R rat hearts. (Studies II-IV) 
 
3. To determine the roles of HO-1 induction and CO donor pretreatment in postinfarction 
cardiac regeneration. (II) 
 
4. To  determine  the  roles  of  HO-1  induction  and  CO  donor  pretreatment  in  cellular  and  
extracellular remodeling in the infarcted rat hearts. (III) 
 
5. To determine the association of HO-1 polymorphisms and HO-1 plasma concentrations with 
disease  severity  (clinical  scores),  degree  of  organ  dysfunction  and  mortality  in  critically  ill  
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A  total  of  334  adult  male  Wistar  rats  were  used  in  the  experimental  studies  (I–IV).   Table  4  
shows the summary of rat numbers and groups (I–IV).  
 
 
4.2 Experimental myocardial infarction 
 
4.2.1 Experimental protocol 1: HO-1 expression in postinfarction hearts (I) 
 
MI was produced by permanent occlusion of the left anterior descending (LAD) coronary artery. 
A total of 98 adult male Wistar rats (weight 350–500 g) were used in the experiment. The rats 
were anesthetized, using medetomidine (0.5 mg/kg subcutaneously (s.c.), Domitor ; Orion, 
Turku, Finland) and ketamine (70–80 mg/kg intraperitoneally (i.p.), Ketalar ; Parke Davis, 
Barcelona, Spain), connected to a rodent respirator through a tracheotomy, and ventilated with 
oxygen-supplemented air. A thermal plate was used to maintain stable body temperature during 
the operation. The heart was exteriorized through a left thoracotomy, the pericardium was 
opened, and the proximal LAD was ligated. After the coronary ligation, the heart was returned 
to its normal position, the thorax was closed, and the rats were given atipamezole hydrochloride 
(0.75 mg/kg s.c., Antisedan ; Orion) to partially antagonize the anesthesia, physiological saline 
(10  ml  s.c.)  for  hydration,  and buprenorphin  (0.02  mg/kg  s.c.,  Temgesic , Reckitt & Colman, 
Hull, UK) twice for postoperative analgesia. The number of MI rats was 58. The sham operated 
control rats underwent the same procedure, except for the ligation of the coronary artery (n = 
40). The rats were killed with CO2 1 day, 1 week, and 4 weeks after LAD ligation. The number of 
rats  in  each  group  is  shown  in  Table  4.  The  heart  was  excised  and  cut  into  2-mm  transverse  
slices  that  were  immediately  frozen  in  liquid  nitrogen  and  stored  at  –70  C or fixed in 4% 
neutral buffered formalin for 24 h and embedded in paraffin. 
 
4.2.2 Experimental protocol 2: Effects of pre-emptive HO-1 induction and CO donor 
pretreatment on recovery of myocardial infarction (II, III) 
 
LAD  ligation  or  the  sham  operation  was  performed  in  a  total  of  180  adult  male  Wistar  rats  
(weight  280–380  g).  To  achieve  maximal  HO-1  expression  and  CO  levels  at  the  time  of  LAD  
ligation, the rats were pretreated with a single dose of the HO-1 inducer CoPPIX (5 mg/kg i.p.; 
Frontier Scientific, Logan, UT, USA) 24 h prior to LAD ligation (n = 60) or a single dose of CO 
donor  methylene  chloride  (MC,  500  mg/kg  perorally  (p.o.);  Sigma,  St.  Louis,  MO,  USA)  3  h  
prior to LAD ligation (n = 60), whereas control rats (n = 60) received no pretreatment. The rats 
were  anesthetized,  using  medetomidine  (0.5  mg/kg  s.c.)  and  ketamine  (60  mg/kg  s.c.),  and  
mechanically ventilated as described above. The heart was exposed through a lateral 
thoracotomy  and  the  coronary  artery  was  ligated  about  3  mm  from  its  origin.  The  successful  
ligation was confirmed by visual inspection of the pale color in the occluded distal myocardium. 
Postoperatively, the rats were hydrated as described above and given buprenorphin (0.05 mg/kg 
s.c.)  twice  daily  for  3  days  for  analgesia.  In  all,  16  rats  died  in  the  course  of  the  experiment  
(mortality rate 9%). The remaining rats were anesthetized with sodium pentobarbital (60 mg/kg 
i.p., Mebunat Vet ;  Orion)  1  day,  3  days,  1  week,  or  4  weeks  after  coronary  ligation.  Blood  
samples were drawn from the jugular vein and the blood carboxyhemoglobin (COHb) was 
measured by CO oximetry, using the ABL800 FLEX Analyzer (Radiometer, Copenhagen, 
Denmark). The heart was excised and weighed, and the myocardial samples were processed as 
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described above. The number of rats in each group is shown in Table 4. The induction of HO-1 
was confirmed by increased HO-1 mRNA and protein levels (study II, Fig. 1 and study III, Table 
1).  The  success  of  CO  donor  pretreatment  was  confirmed  by  the  higher  COHb  levels  at  day  1  
(study II, Fig. 1). 
 
Table 4. Summary of the rats (total n = 334) used in studies I-IV. 
Study Model 
Total n of rats 
used in the 
experiment 
Groups Final n per group 
I  Experimental MI 98 1 day MI 16 
   1 day sham 13 
   1 week MI 24 
   1 week sham 15 
   4 weeks MI 18 
   4 weeks sham 12 
II and III Experimental MI 180 1 day HO-1-induction MI 7 
   1 day CO MI 8 
   1 day control MI 8 
   1 day HO-1 induction sham 5 
   1 day CO sham 5 
   1 day control sham 5 
   3 days HO-1-induction MI 8 
   3 days CO MI 7 
   3 days control MI 8 
   3 days HO-1 induction sham 5 
   3 days CO sham 5 
   3 days control sham 5 
   1 week HO-1-induction MI 7 
   1 week CO MI 7 
   1 week control MI 7 
   1 week HO-1 induction sham 5 
   1 week CO sham 5 
   1 week control sham 5 
   4 weeks HO-1-induction MI 9 
   4 weeks CO MI 10 
   4 weeks control MI 8 
   4 weeks HO-1 induction sham 5 
   4 weeks CO sham 5 
   4 weeks control sham 5 
IV Isolated rat hearts 56 HO-1 induced I/R (Group 1a) 8 
 (I/R-model)  HO-1 induced control (Group 1b) 8 
   ZnPPIX I/R (Group 2a) 8 
   ZnPPIX control (Group 2b) 8 
   Non-pretreated I/R (Group 3a) 8 
   Non-pretreated control (Group 3b) 8 
   Baseline control 8 
Abbreviations: CO = carbon monoxide, HO-1 = heme oxygenase-1, I/R = ischemia/reperfusion, MI = 
myocardial infarction, ZnPPIX = zinc protoporphyrin IX. Studies II and III: the rats that died during the 
experiment (n = 16) and the hearts with no histological signs of MI (n = 10) are not included in the final 
number of rats/hearts per group. 




4.3 Isolated rat heart preparation (IV) 
 
A  total  of  56  adult  male  Wistar  rats  weighing  250–300  g  were  divided  into  six  experimental  
groups  and  one  baseline  control  group  (n  =  8  in  each  group).  Groups  1a  and  1b  received  no  
pretreatment. Groups 2a and 2b were given the HO-1 inducer hemin (50 mol/kg i.p.; Sigma) 
24  h  before  excision  of  the  hearts  and groups  3a  and 3b  were  given  the  HO enzyme inhibitor  
ZnPPIX (50 mol/kg i.p.; Aldrich Chemical Co., Milwaukee, WI, USA) 1 h before excision of the 
hearts. The rats were anesthetized with diethyl ether and given heparin (500 U/kg) 
intravenously (i.v.) as an anticoagulant. The hearts were rapidly excised, mounted in a perfusion 
system,  (Fig.  5B)  and  perfused  in  the  Langendorff  or  working  mode  (Fig.  5A)  with  modified  
normothermic Krebs-Henseleit buffer (118.4 mM NaCl, 4.1 mM KCl, 2.5 mM CaCl2,  25  mM  
NaHCO3, 1.17 mM KH2PO4, 1.46 mM MgCl2 and 11.1 mM glucose, pH 7.4 at 37 ºC)(Ferdinandy 
et al.  1993, Csonka et al.  1999).  The perfusion buffer was saturated with 95% O2 and 5% CO2. 
The hearts were equilibrated in the working mode for 15 min, followed by 30 min of global no-
flow ischemia and 120 min of reperfusion (groups 1a, 2a, and 3a). Time-matched nonischemic 
control  hearts  were  aerobically  perfused  for  a  total  of  165  min  (groups  1b,  2b,  and  3b).  A  
ventricular pressure curve was obtained, using a small polyethylene catheter that was placed in 
the  left  ventricle  through  the  left  atrial  cannula  and  connected  to  a  pressure  transducer  
(Ferdinandy  et  al.  1993,  Csonka  et  al.  1999).  Five  min  before  ischemia  and  at  the  15th min of 
reperfusion, the heart rate (HR), aortic flow (AF), coronary flow (CF), left ventricular developed 
pressure (LVDP), positive and negative first derivetives of left ventricular pressure (+dp/dt and 
-dp/dt) and left ventricular end-diastolic pressure (LVEDP) were monitored (Ferdinandy et al. 
1993, Csonka et al. 1999). After recording the postischemic hemodynamic parameters, the 
perfusion  was  switched  to  the  Langendorff  mode.  An epicardial  electrocardiogram (ECG)  was  
monitored throughout the experiments by two silver electrodes attached directly to the heart to 
determine  the  incidence  of  arrhythmias.  Normal  sinus  rhythm  was  characterized  by  normal  
sinus  complexes  occurring  in  a  regular  rhythm  on  the  ECG,  whereas  an  irregular  undulating  
baseline  on  the  ECG  was  considered  to  represent  VF  (Fig.  5C).  The  cardiac  functional  
parameters and ECG were also recorded from time-matched nonischemic control hearts. At the 
end of each experiment, the ventricles were cut into 2-3-mm slices and frozen in liquid nitrogen 
for  subsequent  analyses.  In  addition,  one  group of  animals  was  killed  at  baseline  (0-min  time 
point) and myocardial samples collected to serve as nonperfused baseline controls for mRNA, 
protein,  and cGMP measurements.  The  experimental  design  is  shown in  study  IV,  Fig.  1.  The  
effects of hemin and ZnPPIX pretreatments on HO-1 mRNA and protein expression are shown 




Figure 5. Isolated rat heart perfusion system. A) Simplified diagram of the perfusion system. In the 
Langendorff mode tap a is open (taps b and c are closed). In the working heart mode tap a is closed and 
taps b and c are open. B) The heart cannulated via the aorta and the left atrium. C) Representative rat 
ECGs of normal sinus rhythm and ventricular fibrillation. Abbreviations: ECG = electrocardiogram. 
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4.4 Real-time quantitative RT-PCR (I–IV) 
 
Total  RNA  was  isolated  from  rat  heart  tissues,  using  Trizol  reagent  (Invitrogen/Gibco  BRL,  
Grand Island, NY, USA) and reverse-transcribed to cDNA, using Moloney Murine Leukemia 
Virus (M-MLV) reverse transcriptase (Invitrogen/Gibco BRL). The cardiac gene expression was 
studied by real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), 
using either the GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, 
CA, USA) or the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). The PCR 
reactions  were  performed  in  duplicate  or  triplicate  in  a  25- l final volume using either SYBR 
Green or TaqMan chemistry. The primer and probe sequences are shown in Table 5. The 
TaqMan Gene Expression Assay primer and probe mix was used for controlling gene 18S 
(Applied Biosystems, part # Hs999999_s1). A dilution series of purified PCR products was used 
to generate standard curves and the data were analyzed using the absolute standard curve 
method (described in the Applied Biosystems User Bulletin #2, 1997; www3.appliedbiosystems. 
com/cms/groups/mcb_support/documents/generaldocuments/cms_040980.pdf). Either 18S 
or  glyceraldehyde  3-phosphate  dehydrogenase  (GAPDH)  was  used  as  a  control  gene  for  
normalizing the mRNA copy numbers. The control gene was selected for each study so that the 
expression of the control gene did not differ significantly among the experimental groups. 
 
  
Table 5. Primers and probes used in gene expression analyses. 
mRNA Sequence Used in 
ANP   
Forward primer 5’-AGCGGACTAGGCTGCAACAG-3’ III 
Reverse primer 5’-TGGCAATGCGACCAAGCT-3’  
BNP   
Forward primer 5’- TCGAAATTCCAAGATGGCACAT-3’ - 
Reverse primer 5’- GTCACAGCCCAAGCGACTGA-3’  
Coll1a1   
Forward primer 5’-AGCGTGCTGTAGGTGAATCGA-3’ III 
Reverse primer 5’-TGCAAGAACAGCGTAGCCTACAT-3’  
Coll3a1   
Forward primer 5’-TTGGGATGCAACTACCTTGGT-3’ III 
Reverse primer 5’-CCCGAGTCGCAGACACATATT-3’  
CTGF   
Forward primer 5’-GTGTGTGATGAGCCCAAGGA-3’ III 
Reverse primer 5’-GCAGTTGGCTCGCATCATAG-3’  
Probe 6-FAM-CCAAATGTGTCTTCCAG-MGB  
Fibronectin   
Forward primer 5’-GGCAACAAATGATCTTTGAGGAA-3’ III 
Reverse primer 5’-TCTACATTCGGCAGGTATGGTCTT-3’  
HO-1   
Forward primer 5’-CACAAAGACCAGAGTCCCTCACAG-3’ I, II, III, IV 
Reverse primer 5’-AAATTCCCACTGCCACGGT-3’  
HO-2   
Forward primer 5'-CCATGGCTGTGCTGAGGAA-3' I, IV 
Reverse primer 5'-GGTCACTTGGGATAGGATGCA-3'  
TGF- 1   
Forward primer 5’-GAAGTCACCCGCGTGCTAAT-3’ III 
Reverse primer 5’-GCTTCCCGAATGTCTGACGTA-3’  
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4.5 Histology and infarct size (II, III) 
 
Several 5- m transverse paraffin sections from the midventricular level of rat hearts were used 
for all histological analyses. The presence of MI was determined from tissue sections stained 
with Weigert van Gieson. Hearts with no histological signs of infarction (eosinophilia, 
karyolysis, and leukocyte infiltration indicative of acute infarction or collagen scars compatible 
with old infarction) were not included in the study (n = 10). Infarct size was determined 
planimetrically as the ratio of infarcted tissue or scar to the length of the entire endocardial 
circumference of the left ventricle (Pfeffer et al. 1979). Toluidine blue staining was used to 
identify mast cells. Interstitial and perivascular fibrosis were analyzed from tissue sections 
stained with collagen-specific picrosirius red. Interstitial fibrosis was measured, using ImageJ 
software.  In  all,  6–10  randomly  selected  microscopic  fields  (100x  or  200x  magnification)  
photographed from the noninfarcted remote myocardium were analyzed. The extent of 
interstitial fibrosis was expressed as the percentage of fibrosis of the total left ventricular area. 
Perivascular fibrosis was also measured by using ImageJ software. A total of 6–15 vessels per 
heart were measured and the extent of perivascular fibrosis was expressed as the ratio of fibrotic 
area surrounding the vessel to the total vessel wall area. Apoptosis of the cardiomyocytes was 
determined, using terminal transferase-mediated DNA nick-end labeling (TUNEL) (Saraste et 
al. 1997). To quantitatively assess the number of TUNEL+ cardiomyocytes, the proportions of 
the infarct area, border area, and remote myocardium of the total area of the ventricular 
sections were determined and the number of cardiomyocytes per mm2 of  border  area  and  
remote  myocardium  was  counted.  Viable  myocardium  extending  0.5–1  mm  from  the  infarct  
area  was  considered  to  represent  the  infarct  border  area.  The  number  of  apoptotic  
cardiomyocytes  was  expressed  as  the  percentage  of  TUNEL+  cardiomyocytes  in  the  total  
number of cardiomyocytes. 
 
 
4.6 Immunohistochemical analyses (I–IV) 
 
Series  of  5- m transverse paraffin sections or 7- m transverse cryosections from the 
midventricular level of rat hearts were used for imunohistochemical analyses. 
Immunofluorescent staining was performed to examine HO-1 expression and localization in the 
infarcted  rat  hearts,  the  effects  of  HO-1  and  CO  on  cardiac  regeneration  and  ventricular  
remodeling in infarcted rat hearts, and the effect of HO-1 induction or inhibition on connexin 43 
(Cx43) expression and localization in I/R rat hearts. The primary antibodies are listed in Table 
6.  The  secondary  antibodies  were:  Alexa  Fluor  488-conjugated  goat  antimouse  or  donkey  
antigoat IgG (Molecular Probes, Eugene, OR, USA), Alexa Fluor 546-conjugated goat antirabbit 
IgG (Molecular Probes), and tetramethyl rhodamine isothiocyanate (TRITC)-conjugated swine 
antirabbit IgG (Dako Cytomation, Glostrup, Denmark). We used double stranded DNA-binding 
4´6-diamino-2-phenylindole (DAPI, Molecular Probes) as a nuclear counterstain. The 
immunolabeled sections were examined, using Leica TCS 4D confocal system connected to a 
Leica RXA microscope (Leica Lasertechnik, Heidelberg, Germany), Leica DM 4500B fluorescent 
microscope (Leica Microsystems, Wetzlar GmbH, Wetzlar, Germany), or a Zeiss LSM 510 Meta 
confocal microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany).  
 
Cardiac regeneration was assessed by counting the number of c-kit+ stem/progenitor cells, 
vWF+ capillaries and -smooth  muscle  actin  ( -SMA+) vessels in the infarcted hearts. The 
following  markers  were  used  to  evaluate  proliferation  and  differentiation  of  c-kit+  cells:  Ki67  
(proliferation marker), Nkx2.5 (early cardiomyocyte transcription factor), GATA6 (SMC 
transcription factor), Ets-1 (endothelial cell transcription factor), and CD34 (hematopoietic stem 
cell marker). The vascular and capillary densities were analyzed from 6 to 15 randomly selected 
microscopic fields (200x or 400x magnification) photographed from each of the infarct, border, 
and remote areas. 
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Table 6. Primary antibodies used in immunohistochemistry and western blotting. 
 
Protein Antibody Manufacturer Application Used in 
Actin rabbit polyclonal Sigma W II, III, IV 
-SMA  mouse monoclonal Dako Cytomation IHC II, III 
CD34 goat polyclonal R&D Systems IHC II 
c-kit rabbit polyclonal Dako Cytomation IHC II 
Cx43 rabbit polyclonal Zymed IHC, W IV 
Cx43 mouse monoclonal Zymed IHC, W IV 
Ets-1 mouse monoclonal NeoMarkers IHC II 
GATA6 mouse monoclonal R&D Systems IHC II 
HIF-1  mouse monoclonal Sigma W II 
HO-1 rabbit polyclonal Stressgen IHC, W I, IV 
H3P  rabbit polyclonal Cell Signaling Technology  IHC III 
Ki67  rabbit monoclonal NeoMarkers IHC II, III 
Ki67 mouse monoclonal Dako Cytomation  IHC II 
MHC  mouse monoclonal Upstate IHC II, III 
Nkx2.5 mouse monoclonal R&D Systems IHC II 
PCNA mouse monoclonal Cell Signaling Technology  IHC III 
Procol I goat polyclonal Santa Cruz W III 
Spectrin mouse monoclonal Chemicon W II 
cTnI  rabbit polyclonal Santa Cruz  IHC III 
VEGF-A rabbit polyclonal Millipore W II 
VEGF-B mouse monoclonal R&D Systems IHC, W II 
Vimentin mouse monoclonal NeoMarkers IHC, W IV 
vWF  rabbit polyclonal Chemicon  IHC II 
 
Abbreviations: -SMA = -smooth muscle actin, Cx43 = connexin 43, HIF-1  = hypoxia inducible factor-
1 , HO-1 = heme oxygenase-1, H3P = phosphorylated histone H3, IHC = Immunohistochemistry, MHC = 
cardiac myosin heavy chain, PCNA = proliferating cell nuclear antigen, Procol I = procollagen type I, cTnI = 




Proliferation of cells in the infarct area,  border area,  and remote myocardium was assessed by 
counting  the  proportion  of  Ki67+  nuclei  in  comparison  to  the  total  count  of  nuclei  per  mm2. 
Proliferation  of  cardiomyocytes  was  determined  by  counting  the  number  of  Ki67  and  cardiac  
myosin double-positive cells throughout the infarct border area and remote myocardium, and 
expressed as the percentage of Ki67+ cardiomyocytes out of the total number of cardiomyocytes. 
The total number of cardiomyocytes in the infarct border area and remote myocardium were 
determined, as described above for cardiomyocyte apoptosis. Proliferation of fibroblasts was 
assessed by counting the number of Ki67 and vimentin double-positive fibroblastlike cells per 
mm2. The total number of vimentin+ cells per mm2 having the characteristic morphology of 
fibroblasts  was  counted  from  six  randomly  selected  microscopic  fields  (200x  or  400x  
magnification) photographed from each of the infarct, border, and remote areas. Proliferation of 
fibroblasts  was  expressed  as  the  percentage  of  Ki67+  fibroblasts  out  of  the  total  number  of  
fibroblasts.  
 
Repair  of  cardiomyocyte  DNA  was  analyzed,  using  a  marker  for  DNA  synthesis  and  repair:  
proliferating  cell  nuclear  antigen  (PCNA)  (Savio  et  al.  1998).  Repair  of  cardiomyocytes  was  
assessed by counting the number of PCNA and cardiac troponin I double-positive cells 
throughout the infarct border area and remote myocardium, and expressed as the percentage of 
PCNA+ cardiomyocytes out of the total number of cardiomyocytes. The  total  number  of  
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cardiomyocytes  in  the  infarct  border  area  and  remote  myocardium  were  determined,  as  
described above for cardiomyocyte apoptosis.  
 
Cardiomyocyte size was analyzed by measuring the cross-sectional area of 100 cardiomyocytes 
per heart, using ImageJ software. The cardiomyocytes cut in the short axis with a visible nucleus 




4.7 Western blotting and ELISA (I–IV) 
 
Protein levels in the rat heart tissue were studied, using Western blotting and enzyme-linked 
immunosorbent  assay  (ELISA).  Homogenization  of  heart  tissue  and  Western  blotting  are  
described  in  detail  in  the  original  publications  (I–IV).  The  primary  antibodies  used  in  the  
Western blotting are listed in Table 6. Detection was performed, using the SuperSignal West 
Pico Chemiluminescent System (Pierce, Rockford, IL, USA) or Opti-4CN Detection kit (BioRad 
Laboratories, Hercules, CA, USA). Signal intensities were quantified, using Gel Doc Image 
Analyzer (BioRad). 
 
Cardiac HO-1 protein was measured from homogenized heart tissues, using a StressXpress Rat 
HO-1 ELISA kit (Assay Designs/Stressgen (now Enzo Life Sciences), Victoria, BC, Canada) and a 
Multiskan EX Microplate Photometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). HO-1 
protein levels were measured from sham-operated hearts and from the infarct,  infarct border,  
and remote areas of infarcted hearts, and reported as ng of HO-1 protein per mg of total protein. 
Total protein in the heart tissue homogenates was measured, using the BCA protein assay kit 
(Pierce). A Quantikine mouse SDF-1  Elisa kit (R&D Systems, Minneapolis, MN, USA) was used 
to measure SDF-1 protein levels in the heart tissue homogenates. The SDF-1 protein levels 
were measured from the infarct areas of infarcted hearts and sham-operated hearts. 
Absorbances  were  measured  at  450  nm,  using  Multiskan  EX  Microplate  Photometer,  and  the  




4.8 Measurement of cyclic GMP (IV) 
 
The cGMP was extracted from frozen heart tissue, using the trichloroacetic acid (TCA) method 
(IV) and measured, using a competitive immunoassay (cGMP enzyme immunoassay kit, Sigma).  
 
 
4.9 Statistical analyses: experimental studies (I–IV) 
 
The  results  of  continuous  variables  are  shown  as  mean   standard  error  of  the  mean  (SEM).  
Statistical analyses were performed using SPSS software (versions 9.0, 13.0, or 16.0; SPSS Inc., 
Chicago, IL, USA). Differences between the two groups were analyzed by Student’s t-test. 
Multiple groups were compared, using either parametric one-way analysis of variance (ANOVA) 
followed by  a  Bonferroni  or  Tukey  test,  or  nonparametric  Kruskall-Wallis  test  followed by  the  
Mann-Whitney U-test. Differences between categorical variables (the incidence of VF) were 
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4.10 Clinical study (V) 
 
4.10.1 Patients and study design 
 
This  is  a  prospective  cohort  study  of  unselected  critically  ill  patients  admitted  to  one  medical  
and  two  medical-surgical  intensive  care  units  (ICUs)  in  Helsinki  University  Central  Hospital  
between  January  2004  and  July  2005.  A  total  of  244  patients  were  enrolled  after  obtaining  
written informed consent from patients or their authorized representatives; 13 patients were 
excluded  due  to  inadequate  blood  samples.  The  final  study  population  was  231  patients.  The  
baseline  characteristics  of  the  final  study  population  and  grouping  of  the  study  population  
according  to  the  International  Classification  of  Diseases  10th  edition  (ICD-10)  are  shown  in  
Tables 7 and 8. In addition, plasma samples of 58 healthy control subjects (28 women and 30 
men), a subpopulation of the Nordic reference interval project, were used to determine the 
reference range for plasma HO-1 (Rustad et al. 2004).  
 
The  HO-1  concentrations  were  measured  in  serial  plasma  samples  and  HO-1 polymorphisms 
determined. The association of HO-1 plasma concentrations and HO-1 polymorphisms with ICU 
and  hospital  mortality,  degree  of  organ  dysfunction,  illness  severity,  bilirubin,  and  C-reactive  




Table 7. Baseline characteristics of the study patients (n = 231). 
 
 Survivors (n= 186) Nonsurvivors (n=45) p value 
Age 57 (47-66) 64 (52-73) 0.009 
Gender (male) 115 (62%) 38 (84%) 0.005 
Length of ICU stay (days) 3.7 (1.9-7.6) 3.8 (2.2-8.8) 0.43 
Chronic disease  28 (15%) 13 (29%) 0.04 
First day SOFA score 7.5 (5-10) 11 (7-13) <0.001 
Maximum SOFA score 8 (6-10) 11 (9-13) <0.001 
Multiple organ dysfunction 116 (62%) 38 (84%) 0.006 
APACHE II score 22 (16-28) 28 (23-34.5) <0.001 
SAPS II score 42 (29-52) 57 (46-69) <0.001 
The data are given in median (interquartile range) in continuous variables and in count (percents) in 
categorical variables. Abbreviations: APACHE II = acute physiology and chronic health evaluation II score, 




4.10.2 Blood samples and data collection 
 
Three blood samples were collected in 10-ml ethylenediaminetetraacetic acid (EDTA) tubes. The 
first blood sample was drawn as soon as possible after ICU admission (day 1 sample, n = 160), 
the second on the following morning (day 2 sample, n = 162), and the third 48 h after the second 
sample (day 3–4 sample, n = 187). Plasma was separated as soon as possible by centrifugation at 
1600g  (+4  ºC)  for  10  min  and  stored  at  -80  ºC.  The  bilirubin  and  CRP  values  were  obtained  
from  the  laboratory  database,  since  they  were  measured  daily  as  a  routine  follow-up  of  the  
patients. The patient data were collected and stored in the Finnish Intensive Care Quality 
Consortium’s database (Intensium, Kuopio, Finland). The data included demographic factors, 
diagnosis by ICD-10, ICU and hospital mortality, and illness severity scores calculated within 
the first 24 h in the ICU: Simplified Acute Physiology Score (SAPS) II (Le Gall et al. 1993) and 
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Acute  Physiology  and  Chronic  Health  Evaluation  (APACHE)  II  score  (Knaus  et  al.  1985),  the  
degree of organ dysfunction calculated daily in the ICU: Sequential  Organ Failure Assessment 
(SOFA) score (includes separately the status of cardiovascular, respiratory, hepatic, and renal 




Table 8. Grouping of the study population (n=231) according to ICD-10 diagnosis. 
 
Diagnosis n 
Heart arrest, ventricular fibrillation 37 
Respiratory tract infection, pneumonia 30 
Sepsis 25 
Heart infarct  22 
Pancreatitis 16 
Gastrointestinal bleeding 10 
Heart failure  12 
Intoxication  9 
Meningitis, other bacterial infection 8  
Cerebrovascular disorders  8 
Convulsions  6 
Acute renal failure 4 
Liver failure 4 
Diabetes, ketoacidosis 4 
Other bacterial infection 4 
Pulmonary embolism 3 
Other 12 
Operative   16 
 
Abbreviations: ICD-10 = International Classification of Diseases 10th edition. 
 
 
The  variables  included  in  the  SAPS  II  score  are:  age  (years),  HR  per  min,  systolic  arterial  
pressure (mmHg), temperature (ºC), partial pressure of oxygen in arterial blood (PaO2; mmHg 
or kPa)/fraction of inspired oxygen (FiO2) if mechanically ventilated or with continuous positive 
airway pressure, serum HCO3, white blood cell count (E9/l), urine output (l/24 h), serum urea 
(mmol/l)  or  serum  urea  nitrogen,  serum  bilirubin  ( mol/l), serum sodium (mmol/l), serum 
potassium (mmol/l), Glasgow Coma Scale, type of admission (medical, scheduled, or 
unscheduled surgery), and underlying chronic disease (metastatic cancer, hematologic 
malignancy,  or  acquired  immune  deficiency  syndrome)  (Le  Gall  et  al.  1993).  The  APACHE  II  
score includes 12 physiological variables, age, and underlying severe chronic disease (Knaus et 
al. 1985). The physiological variables include HR per min, mean arterial pressure (mmHg), 
temperature (ºC), respiratory rate per min, oxygenation (FiO2,  mmHg),  arterial  pH (or  serum 
HCO3),  hematocrit  (%),  white  blood  cell  count  (E9/l),  creatinine  (mg/100  ml),  serum  sodium  
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Table 9. SOFA score. 
 
   SOFA score   
Organ system 0  1  2  3  4  
Cardiovascular * MAP > 70 mmHg 
MAP < 70 
mmHg 
DA  5 or 
dobutamine 
DA > 5 or 
Epi  0.1 or 
NA  0.1 
DA > 15 or 
Epi > 0.1 or 
NA > 0.1 
      
Respiratory  
PaO2/FiO2 (mmHg)  400 < 400 < 300 
< 200 (with 
mechanical 
ventilation) 
< 100 (with 
mechanical 
ventilation) 
      
Hepatic 
Bilirubin ( mol/l) < 20 20-32 33-101 102-204 > 204 
      
Renal 
Creatinine ( mol/l) <110 110-170 171-299 
300-440 or 
urine output 
< 500 ml/day 
>440 or 
urine output  
< 200 ml/day 
      
Central nervous system 
Glasgow Coma Scale 15 13-14 10-12 6-9 <6 
      
Coagulation 
Platelet count (E9/l)  150 < 150 < 100 < 50 < 20 
 
* Doses of adrenergic agents are given in g/kg/min. Abbreviations: DA = dopamine, Epi = epinephrine, 
MAP = mean arterial pressure, NA = norepinephrine, SOFA = sequential organ failure assessment score. 
 
 
4.10.3 HO-1 genotyping 
 
Genomic  DNA  was  extracted  from  whole  blood,  using  Puregene  DNA  Isolation  Kit  (Gentra  
Systems,  Minneapolis,  MN,  USA)  and  stored  at  -20  ºC.  Genotyping  of  the  GTn repeat length 
polymorphism in the HO-1 promoter was performed by DNA fragment analysis. The 5’-flanking 
region of the HO-1 gene containing the GTn repeats was amplified by PCR, using a fluorescently 
labeled forward primer and unlabeled reverse primer (primer sequences are shown in Table 10). 
The PCR reactions were performed in a 25- l  final volume containing 25 ng of genomic DNA, 
300 nM of primers, 1 x AmpliTaq Gold PCR buffer (Applied Biosystems), 3 mM MgCl2, 0.2 mM 
of each nucleoside triphosphate (NTP) (Applied Biosystems), and 0.625 units of AmpliTaq Gold 
DNA polymerase (Applied Biosystems). The PCR cycling conditions were 10 min at +95 ºC and 
40 cycles of 30 s at +95 ºC and 1 min 15 s at +54 ºC. The sizes of the labeled PCR products were 
determined, using an automated capillary sequencer (ABI3730xl DNA Analyzer, Applied 
Biosystems). A GeneScan-500 LIZ (Applied Biosystems) was used as a size marker. The number 
of GTn repeats was calculated, using GeneMaker 1.4 software (SoftGenetics, State College, PA, 
USA).  The  GTn repeat length genotype was obtained from 230 patients, because the DNA 
fragment analysis failed in one patient.   
  
Genotyping of two SNPs, -413A/T (rs2071746) and +99G/C (rs2071747), was performed by 
allelic discrimination, using the 5’ nuclease TaqMan assay. The primers and probes for -413A/T 
are  shown  in  Table  10  (Ono  et  al.  2004).  The  TaqMan  SNP  Genotyping  assay  was  used  for  
+99G/C (Applied Biosystems). The PCR reactions for the +99G/C SNP were performed in a 10-
l final volume containing 10 ng of genomic DNA, 1 x TaqMan master mix (Applied Biosystems), 
and 1 x TaqMan SNP genotyping assay mix. The PCR reactions for -413A/T were performed in a 
25- l  final  volume  containing  25  ng  of  genomic  DNA,  1  x  TaqMan  master  mix,  300  nM  of  
forward and reverse primers, and 200 nM of both probes. The PCR reactions were performed, 
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using ABI Prism 7000 Sequence Detection System (Applied Biosystems) according to the Allelic 
Discrimination protocol. The PCR cycling conditions were 10 min at +95 ºC and 40 cycles of 20 
s at +95 ºC and 1 min at +60 ºC. Negative controls with no template DNA were included in each 
PCR run. The genotypes were determined, using SDS 1.2 software (Applied Biosystems). 
Genotype assignment was performed manually and included examination of the amplification 
plot and raw fluorescence data. When necessary, samples were retested to confirm the genotype. 




Table 10. Primers and probes used in HO-1 genotyping. 
 
 Sequence 
GTn repeat length polymorphism  
GTn forward primer 5’-FAM-AGAGCCTGCAGCTTC TCAGA-3’ 
GTn reverse primer 5’-ACAAAGTCTGGCCATAGGAC-3’ 
  
-413A/T SNP (rs2071746)  
-413A/T forward primer 5’-TGACATTTTAGGGAGCTGGAGACA-3’ 
-413A/T reverse primer 5’-AGGCGTCCCAGAAGGTTCCA-3’ 
-413A/T probe for A allele 5’-FAM-CCCACCAGGCTATTGCTCTGAGCA-Tamra-3’ 
-413A/T probe for T allele 5’VIC-CCCACCAGGCTTTTGCTCTGAGC-Tamra-3’ 
 
Abbreviations: HO-1 = heme oxygenase-1, SNP = single-nucleotide polymorphism.  
 
 
4.10.4 HO-1 plasma concentration 
 
Plasma HO-1 levels were measured in serial samples, using the StressXpress human HO-1 
ELISA  kit  (Stressgen).  The  plasma  samples  were  diluted  1:5  in  sample  diluent  and  assayed  
according to manufacturers’ instructions. The HO-1 sandwich ELISA assay is specific for HO-1 
and  does  not  cross-react  with  other  HO  isoforms.  The  intra-  and  interassay  coefficients  of  
variation reported by the manufacturer are both < 10%. 
 
4.10.5 Statistical analyses: clinical study  
 
The data of the human study are shown as the median and interquartile range (IQR) for 
continuous variables or as absolute values and percentages. Differences between variables were 
considered  significant  at  a  P  value  of  <  0.05.  Statistical  analyses  were  performed,  using  SPSS 
software  (versions  12.0  or  16.0).  The  GraphROC  for  Windows  software  was  used  in  receiver-
operating characteristic (ROC) analysis (Kairisto and Poola 1995). 
 
Differences in the continuous variables were compared with the nonparametric Mann-Whitney 
U-test or Kruskall-Wallis test. Comparison of the categorical variables was performed, using the 
chi-square  test  or  Fisher’s  exact  test  if  the  number  of  cases  in  a  sample  were  lower  than five.  
Bivariate correlations were determined, using the nonparametric Spearman’s correlation. Linear 
regression analysis was used to determine the variables having independent effects on day 1 HO-
1 concentrations and multivariate forward logistic regression analysis was performed to identify 
the  variables  having  independent  predictive  value  for  ICU  and  hospital  mortalities.  Log-
transformed values were used for variables with nonnormal distribution in linear regression and 
logistic  regression  analyses.   ROC  curves  were  constructed  to  determine  the  discriminative  
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power of HO-1 plasma concentrations regarding ICU and hospital mortalities. The area under 
the  curve  (AUC)  was  calculated  with  95%  confidence  interval  (CI).  The  best  predictive  cutoff  
values maximizing the sum of sensitivity and specificity were defined, and sensitivity, specificity, 
and positive likelihood ratios with 95% CIs were calculated. 
 
Hardy-Weinberg equilibrium was calculated with Pearson’s correlation and Fisher’s exact tests. 
Pairwise linkage disequilibrium (LD) measures were determined and haplotypes were 
constructed by the solid spine of the LD algorithm, using Haploview 4.0 software (Barrett et al. 
2005).  In  addition  to  the  marker-by-marker  analysis,  we  evaluated  the  associations  by  
haplotype-based  analysis,  which  is  considered  more  capable  of  detecting  associations  (Akey  et  
al.  2001,  Zhang  et  al.  2002).   The  Genetic  Power  Calculator  was  used  for  power  calculations  
(Purcell  et  al.  2003).  With  a  relative  risk  of  2.5  for  the  heterozygotes  and  3  for  minor  allele  
homozygotes regarding hospital mortality, our sample had 83% power to detect association with 
the +99G/C polymorphism. 
 
 
4.11 Ethical aspects 
 
The local Ethical Committees for Animal Experiments approved the experimental studies. All 
the animal experiments conformed with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health, Bethesda, MD, USA (NIH Publication No. 85-
23, revised 1996). The Ethics Committee of Medicine, the Ethics Committee of Surgery, and the 
























5.1 HO-1 expression is induced in infarcted rat hearts in vivo (I–III)  
 
Previous  studies  have  shown  that  HO-1  is  induced  in  response  to  I/R,  but  less  is  known  of  
expression  of  HO-1  during  the  recovery  phase  of  MI.  Therefore,  cardiac  HO-1  expression  was  
thoroughly investigated in post-MI rat hearts. The expression of HO-1 was increased in the post-
MI hearts, both at the mRNA and protein levels, as indicated by real-time RT-PCR, HO-1 ELISA, 
and immunohistochemical analysis. HO-1 expression was particularly increased in the infarct 
area and in the infarct border area, as shown in Table 11. The expression of HO-1 mRNA peaked 
at day 1 in the infarct border area and at day 3 in the infarct area. HO-1 mRNA levels remained 
high  in  the  infarct  and infarct  border  area  at  week  1  and decreased  back  to  levels  comparable  
with sham-operated hearts by week 4. The results were similar in both MI experiments (I vs. II 
and III). HO-1 protein expression peaked in the infarct area at day 3 and remained high at week 
1.  The  HO-1  protein  levels  decreased  slowly  thereafter,  but  unlike  the  HO-1  mRNA,  the  HO-1  
protein  levels  still  remained  5-fold  higher  in  the  infarct  area  and  2-fold  higher  in  the  infarct  
border area than in the sham-operated hearts at week 4. In addition, a transient increase in both 




Table 11. HO-1 expression in infarcted rat hearts. 
 
 
HO-1 mRNA copies 
(x104) per ng total RNA 
Study I 
HO-1 mRNA copies 
(x104) per ng total RNA 
Studies II and III 
HO-1 protein 
ng per mg total protein  
Studies II and III 
1 day    
Border area 19.0±3.2 *** ††† 12.5±1.7 ** †† 1.8±0.26 * † 
Remote area 6.6±0.7 2.1±0.2 0.8±0.09 
Sham  4.9±0.6 2.0±0.2 0.7±0.08 
3 days    
Infarct area  36.8±4.0 ** ††† ‡‡‡ 7.5±0.69 *** ††† ‡‡‡ 
Border area  7.2±1.3 * 1.8±0.19 ** ††† 
Remote area  2.8±0.4 0.6±0.06 
Sham   2.4±0.4 0.4±0.05 
1 week    
Infarct area  14.2±2.1 ** ††† ‡‡‡ 6.8±1.01 *** ††† ‡‡‡ 
Border area 9.0±1.3 *** ††† 5.8±0.7 ** †† 1.3±0.15 ** † 
Remote area 2.8±0.3 * 3.0±0.3 ** 0.8±0.12 * 
Sham  1.8±0.3 1.4±0.1 0.4±0.04 
4 weeks    
Infarct area  1.7±0.1 2.0±0.16 ** †† ‡‡ 
Border area 2.4±0.3 2.1±0.2  0.8±0.07 ** † 
Remote area 2.5±0.2 1.9±0.1 0.5±0.04 
Sham  2.3±0.3 1.2±0.1 0.4±0.03 
 
Values are mean ± SEM. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. sham-operated hearts at the same 
time point. † P < 0.05, †† P < 0.01 and ††† P < 0.001 vs. remote area at the same time point. ‡‡ P < 0.01 






HO-1  protein  was  localized  in  the  coronary  artery  walls  throughout  the  myocardium,  both  in  
infarcted and sham-operated hearts (Fig. 5 A, B), and in the small arterioles of the infarct border 
area  (Fig.  5  C).  HO-1+  coronary  arteries  were  found  at  all  time  points  from  day  1  to  week  4,  
whereas  HO-1+  small  arterioles  were  observed  only  at  week  1.  HO-1  expression  was  also  
increased in the cardiomyocytes of the infarct border area during the first week after infarction 
(Fig.  5  C–E).  HO-1  showed  a  distinct  transverse  and  a  less  pronounced  longitudinal  striated  
pattern  of  staining  in  cardiomyocytes  compatible  with  the  localization  of  HO-1  protein  in  the  
sarcoplasmic  reticulum  (SR)  (Fig.  5  E,  F  and  Study  I,  Fig.  4).  In  addition,  HO-1  protein  was  
found at  the  intercalated  discs  of  the  cardiomyocytes  (Fig.  5  D and Study  I,  Fig.  4).  Increased  
expression of HO-1 was also found in the infarct area, specifically in fibroblastlike cells (Fig. 5 G) 
and  in  monocytes/macrophages  (Fig.  5  H,  unpublished  result).  The  time  course  of  HO-1  
expression  in  different  cardiac  cell  types  or  structures  is  shown  in  Table  12.  In  the  remote  
myocardium or in the sham-operated hearts, HO-1 was found only in the coronary artery walls, 





Figure 5. Localization of heme oxygenase-1 (HO-1) protein in the infarcted rat hearts. A) Representative 
image of HO-1 protein in the coronary artery wall. A higher magnification in panel B) shows the strongest 
HO-1 immunoreactivity in the endothelium of the coronary artery. C) HO-1+ arteriole (arrow) and 
cardiomyocytes in the infarct border area. D) HO-1+ cardiomyocytes in the infarct border area with the 
strongest HO-1 immunoreactivity in intercalated discs (arrowheads). E) HO-1+ cardiomyocyte in the infarct 
border area, showing both transverse and longitudinal striated patterns of staining. A higher magnification 
in panel F) shows the intracellular distribution of HO-1 in the cardiomyocyte. G) HO-1+ fibroblastlike cells 
in the infarct area at week 1 post-MI. H) Highly increased HO-1 expression in infiltrating monocytes/ 
macrophages in the infarct area at day 3 post-MI. * Infarct area. Scale bar = 50 m. 
 
 
Table 12. Time course of heme oxygenase-1 expression in cardiac cells and structures after infarction. 
 
 Day 1 Day 3 Week 1 Week 4 Sham 
Coronary arteries X X X X X 
Arterioles   X   
Cardiomyocytes X X X   
Fibroblastlike cells  X X X  
Monocytes/macrophages  X X   





5.2 HO-1 and CO protect the heart (II–IV) 
 
5.2.1 Infarct size (II, III) 
 
MI was produced in rats by LAD ligation. The effects of pretreatments on infarct size after LAD 
ligation were assessed by planimetry. As expected, we found no statistically significant 
differences between HO-1-induced, CO donor-pretreated, and control MI groups in infarct size, 
but there was a trend for smaller infarcts to occur in the HO-1-induced group at weeks 1 and 4 
after infarction (HO-1 29.4 ± 3.7% vs. control MI 41.6 ± 4.0%, P = 0.07 and HO-1 26.2 ± 4.0% 
vs. control MI 35.8 ± 7.4%, P = 0.24, respectively) (Table 13). 
 
5.2.2 HO-1 and CO inhibit cardiomyocyte apoptosis (III) 
 
The  effects  of  HO-1  induction  and  CO  donor  pretreatment  on  cardiomyocyte  apoptosis  were  
analyzed in post-MI hearts,  since HO-1 is known to inhibit  apoptosis predominantly via CO in 
different  organs  and  cells.  In  the  present  study,  the  percentage  of  TUNEL+  apoptotic  
cardiomyocytes  in  sham-operated  hearts  was  low (0.016  ±  0.0034%)  and no  differences  were  
found  between  groups.  In  the  infarcted  hearts,  cardiomyocyte  apoptosis  peaked  in  the  infarct  
border area at day 1 and deecreased slowly thereafter (Table 13). In the remote myocardium, 
cardiomyocyte  apoptosis  peaked  at  day  1  and  week  4  (Table  13).  HO-1  induction  significantly  
reduced cardiomyocyte apoptosis in the infarct border area at day 3, week 1, and week 4 and in 
the  remote  myocardium  at  weeks  1  and  4  after  infarction  (Table  13).  Pretreatment  with  CO  
resulted in similar reductions of cardiomyocyte apoptosis in the infarct border area at day 3 and 
week 1 and in the remote myocardium at week 1 after MI (Table 13). 
 
5.2.3 HO-1 and CO modulate cardiomyocyte DNA repair (III) 
 
Immunohistochemical staining of PCNA was performed to evaluate whether HO-1 and CO 
modulate  the  repair  of  cardiomyocyte  DNA  in  post-MI  rat  hearts.  PCNA  is  a  marker  of  both  
DNA synthesis and repair and so is expressed in proliferating cells and in cells undergoing DNA 
repair. In the sham-operated hearts, the percentage of PCNA+ cardiomyocytes was low (0.0077 
±  0.0024%)  and  no  differences  were  found  between  groups.  In  the  infarcted  hearts,  HO-1  
induction significantly increased the percentage of PCNA+ cardiomyocytes in the infarct border 
area  at  day  1  (3-fold,  P  =  0.030)  and  day  3  (2.3-fold,  P  =  0.009)  compared  with  control  MI  
hearts,  whereas   at  weeks  1  and 4  a  trend for  reduced  number  of  PCNA+ cardiomyocytes  was  
found (HO-1 0.43 ± 0.11% vs. control MI 0.78 ± 0.13%, P = 0.072, and HO-1 0.69 ± 0.18% vs. 
control  MI  1.37  ±  0.37%,  P  =  0.074,  respectively)  (Table  13).  Unlike  HO-1,  CO  donor  
pretreatment affected only the number of PCNA+ cardiomyocytes in the infarct border at week 4 
(Table 13). In the remote myocardium, the percentage of PCNA+ cardiomyocytes was stable in 
both  HO-1-induced  and  CO  donor-pretreated  hearts  throughout  the  study  (HO-1  0.023  ±  
0.005% and CO 0.028 ± 0.009%) and in control hearts from day 1 to week 1 (0.025 ± 0.008%). 
In contrast, the percentage of PCNA+ cardiomyocytes in the remote myocardium was about 3-
fold higher in control MI hearts than in HO-1-induced and CO donor-pretreated hearts at week 









Table 13. Effects of HO-1 induction and CO donor pretreatment on infarct size and percentage of 
apoptotic and PCNA+ cardiomyocytes.  
 





1 day HO-1 40.8±9.7   
Border area  2.60±0.79  4.78±0.67 * 
Remote area  0.089±0.014 0.024±0.005 
1 day CO 36.1±5.5   
Border area  2.64±0.59  1.64±0.40  
Remote area  0.091±0.024 0.042±0.013 
1 day control 38.4±8.3   
Border area  2.91±0.95  1.53±0.20  
Remote area  0.087±0.028 0.031±0.010 
3 days HO-1 36.5±5.5   
Border area  0.59±0.037 ** 4.91±0.59 **  
Remote area  0.080±0.007 0.035±0.008 
3 days CO  29.4±3.4   
Border area  0.56±0.062 *  2.90±0.53  
Remote area  0.079±0.009 0.016±0.005 
3 days control 36.0±5.6   
Border area  0.91±0.094  2.10±0.29  
Remote area  0.092±0.008 0.022±0.009 
1 week HO-1 29.4±3.7   
Border area  0.16±0.011 ** 0.43±0.085 
‡ 
Remote area  0.024±0.005 
† 0.020±0.005 
1 week CO 35.0±5.9   
Border area  0.18±0.022 * 1.09±0.15  
Remote area  0.025±0.004 
† 0.028±0.010 
1 week control 41.6±4.0   
Border area  0.31±0.054  0.78±0.13  
Remote area  0.054±0.011 0.021±0.004 
4 weeks HO-1 26.2±4.0   
Border area  0.18±0.029 ** 0.69±0.15  
Remote area  0.056±0.006
†  0.014±0.003 †† 
4 weeks CO 37.0±6.2   
Border area  0.28±0.035  2.16±0.28 * 
# #  
Remote area  0.070±0.012 0.026±0.007 
† 
4 weeks control 35.8±7.4   
Border area  0.31±0.031  1.37±0.31  
Remote area  0.093±0.010 0.071±0.010 
 
Values are mean ± SEM. * P < 0.05 and ** P < 0.01 vs. border area of control MI hearts at the same time 
point. † P < 0.05 vs. remote area of control MI hearts at the same time point. ‡ P < 0.05 vs. border area of 
CO pretreated hearts at the same time point. # # P < 0.01 vs. border area of HO-1 induced hearts at the 
same time point. Unpublished results of apoptotic and PCNA+ cardiomyocytes in CO pretreated groups 
are shown in the table. Abbreviations: CO = carbon monoxide, HO-1 = heme oxygenase-1, MI = 







5.2.4 HO-1 improves postischemic cardiac function (IV) 
 
The effect of HO-1 on postischemic cardiac function was studied in isolated I/R rat hearts.   HO-
1  induction  by  hemin  significantly  enhanced  the  recovery  of  postischemic  cardiac  function  of  
isolated perfused rat hearts. HO-1 induction improved AF, CF, LVDP and -dp/dt, and decreased 
LVEDP  compared  with  the  nonpretreated  I/R  group  (Table  14  and  study  IV,  Table  1).  HO-1  
induction also significantly reduced I/R-induced VF to 12.5% compared with 100% in the 
control group (Table 14 and study IV, Table 1). The HO enzyme inhibitor ZnPPIX did not affect 
myocardial function compared with the control I/R group (study IV, Table I). 
 
 
Table 14. Effect of HO-1 induction on postischemic cardiac function 
 











1a Control I/R 9.1±2.3 11.8±0.5 316±13 1.77±0.05 15.9±0.7 100 
2a HO-1 induced I/R 27.3±1.4 *** 14.3±0.3 ** 401±16 ** 1.23±0.06 *** 19.5±0.9 ** 12.5 ** 
 
Abbreviations: HO-1 = heme oxygenase-1, I/R = ischemia/reperfusion, AF = aortic flow, LVDP = left 
ventricular developed pressure, -dp/dt = negative first derivative of LV pressure, LVEDP = left ventricular 
end-diastolic pressure, and CF = coronary flow during the reperfusion. VF = incidence of ventricular 
fibrillation during the reperfusion. Data are presented as mean  SEM or as percentages (VF). ** P < 0.01 
and *** P < 0.001 vs. control I/R group. 
  
 
Reduced  cardiac  cGMP  levels  and  abnormalities  in  the  expression,  distribution  and  
phosphorylation  of  Cx43  are  known  to  increase  susceptibility  to  arrhythmias.  Cardiac  cGMP  
levels  and  Cx43  protein  levels  were  measured  to  evaluate  the  role  of  cGMP  and  Cx43  in  
mediating  the  improved  recovery  of  postischemic  cardiac  function  and  reduced  VF  by  HO-1.  
However, no differences were found between groups in cardiac cGMP levels or in the levels of 
44–46-kDa phosphorylated  forms of  Cx43.  In  contrast,  the  levels  of  nonphosphorylated  Cx43 
(at  S368)  were  significantly  higher  in  the  HO-1-induced  I/R hearts  than in  the  nonpretreated  
I/R group and ZnPPIX-pretreated I/R group (Table 15 and study IV, Fig.  5B).  In addition, the 
cardiac  total  Cx43  content  (phosphorylated  plus  nonphosphorylated  Cx43)  was  significantly  
higher in the HO-1-induced I/R group than in the nonpretreated I/R group and ZnPPIX-
pretreated  I/R  group  (Table  15  and  study  IV,  Fig.  5C),  and  comparable  to  the  HO-1-induced,  
aerobically perfused, time-matched control group (IV, Fig. 5C). The significantly increased 
nonphosphorylated Cx43 in HO-1-induced I/R hearts was localized, both in the intercalated 
discs and lateral plasma membrane, whereas in aerobically perfused hearts Cx43 was mainly in 
its phosphorylated form and localized principally in the intercalated discs.  
 
 
Table 15. Effect of HO-1 induction on cardiac cGMP and Cx43 levels 
 





Total        
Cx43 
1a Control I/R 1.38±0.24 1.70±0.44 1.49±0.17 1.52±0.19 
2a HO-1-induced I/R 1.43±0.28 2.33±0.40  2.41±0.21 ** †† 2.44±0.20 * † 
3a ZnPPIX I/R 1.42±0.20 1.59±0.21 1.37±0.12 1.42±0.12 
 
Values are mean ± SEM. Cx43 results are reported as fold change vs. baseline. * P < 0.05 and ** P < 0.01 
vs. control I/R group. † P < 0.05 and †† P  <  0.01 vs. ZnPP I/R group. Abbreviations: HO-1 = heme 
oxygenase-1, cGMP = guanosine 3’5’-cyclic monophosphate, Cx43 = connexin 43, I/R = ischemia/ 





5.3 HO-1 and CO promote neovascularization and myocardial regeneration in 
infarcted rat hearts (II) 
 
5.3.1 Differential effects of HO-1 and CO on capillary and vascular density 
 
Immunostaining of vWF and -SMA was performed to assess the effects of HO-1 induction and 
CO donor pretreatment on capillary and vascular densities at weeks 1 and 4 after infarction. The 
numbers of vWF+ capillaries and -SMA+ vessels in infarcted and sham-operated hearts are 
shown in Table 16.  The number of capillaries in the infarct area was increased in all  groups at 
week  4  compared  with  week  1  (Table  16  and  study  II,  Fig.  5B).  Furthermore,  HO-1  induction  
significantly  increased  the  capillary  density  in  the  infarct  area  at  week  4  compared  with  the  
control hearts, and a trend for increased capillary density by HO-1 induction was already found 
at week 1 (Table 16 and study II, Fig. 5B). In contrast, CO pretreatment did not affect capillary 
density  compared  with  the  control  MI  hearts.  In  addition,  capillary  density  did  not  differ  
between groups in the infarct border area, remote myocardium, or sham-operated hearts (Table 
16). 
 
Table 16. Effects of HO-1 and CO on capillary and vascular densities in infarcted rat hearts.  
 







Infarct area week 1     
HO-1 58±6 † 252±43 6.1±0.5 * †† 3.2±0.3 * †† 
CO 38±4 254±38 3.2±0.6 1.9±0.2 
Control 43±4 259±46 4.5±0.2 2.4±0.5 
Infarct area week 4     
HO-1 161±29 ** †  ‡‡ 446±26 * ‡ 13.3±0.7 ** ‡‡ 6.5±0.4 * ‡‡ 
CO 90±24 ‡ 395±24 * ‡ 12.7±0.9 * ‡‡‡ 7.1±0.6 ** ‡‡‡ 
Control 70±10 ‡ 306±25 ‡ 9.7±0.5 ‡‡ 4.8±0.4 ‡‡ 
Border area week 1     
HO-1 1324±95 354±54   
CO 1016±69 282±52   
Control 1144±63 301±58   
Border area week 4     
HO-1 976±52 182±26   
CO 918±96 182±30   
Control 930±45 185±26   
Remote area week 1      
HO-1 1876±60 105±10   
CO 1650±37 104±14   
Control 1767±70 116±14   
Remote area week 4     
HO-1 1533±85 148±7   
CO 1457±127 130±7   
Control 1404±53 145±12   
Sham week 4     
HO-1 1799±169 146±23   
CO 1523±257 152±18   
Control 1729±146 152±31   
Values are mean ± SEM and results are reported as vessel count per mm2. * P < 0.05 and ** P < 0.01 vs. 
control group at the same time point. † P < 0.05 and †† P < 0.01 vs. CO-pretreated group at the same time 
point. ‡ P < 0.05, ‡‡ P < 0.01 and ‡‡‡ P < 0.001 vs. week 1. Unpublished results of capillary and vascular 
densities in the infarct border and remote areas and in sham-operated hearts are included in the table. 




Both HO-1 induction and CO donor pretreatment significantly increased the vascular density in 
the infarct area at week 4 compared with the control MI hearts and with the vascular densities at 
week 1 (Table 16 and study II, Fig. 5A). In addition to the total number of -SMA+ vessels, the 
numbers of intermediate (25–65 m diameter) and large (> 65- m diameter) arteries were also 
counted from the infarct areas. HO-1 induction increased the number of intermediate and large 
arteries in the infarct area compared with the control MI hearts already at week 1 and further 
increase  was  seen  at  week  4  (Table  16  and  study  II,  Fig.  5C).  Unlike  HO-1  induction,  CO  
pretreatment increased intermediate and large arteries only at week 4, but the fold increase at 
week 4 compared with week 1 was greatest in CO-pretreated hearts: increase in intermediate 
arteries was 4-fold and increase in large arteries 3.7-fold (Table 16 and study II, Fig. 5C). In HO-
1-induced and control MI hearts, the increase in intermediate and large arteries from week 1 to 
week  4  was  about  2-fold.  Similar  to  capillary  density,  vascular  density  did  not  differ  between  
groups in the infarct border area, remote myocardium, or sham-operated hearts. 
 
 
5.3.2 CO activates c-kit+ stem/progenitor cells and promotes differentiation of c-kit+ 
cells into vascular smooth muscle cells and cardiomyocytes  
 
Immunohistochemical analysis of c-kit was performed to assess whether HO-1 and CO promote 
activation of cardiac stem cells in the infarcted rat hearts.  In comparison to control MI hearts,  
CO donor pretreatment significantly increased the number of c-kit+ stem/progenitor cells in the 
infarct  area  at  weeks  1  and  4  after  infarction  (2.6-fold,  P  =  0.038  and  89-fold,  P  =  0.000,  
respectively), whereas only occasional c-kit+ cells were found at days 1 and 3 and no c-kit+ cells 
were found in sham-operated hearts (study II, Fig. 2). Immunohistochemical staining was used 
to further characterize these CO-induced c-kit+ cells, in which 3% of the cells were proliferating 
cells (c-kit+/Ki67+), 10% of the c-kit+ cells expressed the early cardiac/cardiomyocyte 
transcription factor Nkx2.5 (c-kit+/Nkx2.5+), 41% expressed the smooth muscle transcription 
factor GATA6 (c-kit+/GATA6+), and 1% were positive for the endothelial  lineage marker Ets-1 
(c-kit+/Ets-1+) (study II, Fig. 3). Immunostaining was also used to evaluate the origin of the c-
kit+ cells and we found that these c-kit+ cells were negative for the hematopoietic stem cell 
marker CD34 (study II, Fig. 2). The c-kit+ cells are also negative for Sca-1 and nestin (data not 
shown), whereas some c-kit+ cells were positive for T-box18 (Tbx18), a marker for epicardium-
derived stem/progenitor cells (EDPCs) (Fig. 6) (Lakkisto et al., unpublished results). Unlike CO 
donor pretreatment, HO-1 induction increased the number of c-kit+ cells only at week 4 after 
infarction  (11-fold,  P  =  0.001)  (study  II,  Fig.  2).  A  few  occasional  c-kit+  cells  were  found  at  







Figure 6. Stem/progenitor cells in the infarct area. A-B) Representative images of c-kitpos/Tbx18pos 
stem/progenitor cells and c-kitpos/Tbx18neg stem/progenitor cells in the infarct areas of carbon monoxide 





5.3.3 HO-1 and CO modulate expression of angiogenic factors 
HIF-1 , SDF-1 VEGF-A, and VEGF-B are key factors promoting neovascularization and 
cardiac regeneration. Cardiac levels of these factors were measured to evaluate their role in   
HO-1- and CO-induced neovascularization and in the activation of c-kit+ stem/progenitor cells 
by  CO.  In  comparison  to  control  MI  hearts,  CO donor  pretreatment  increased  HIF-1  protein 
levels in the infarct areas 2-fold at day 3 and week 1 (study II, Fig. 6) and VEGF-B protein levels 
1.6-fold at week 4 (study II, Fig. 8). Cardiac SDF-1  protein levels were increased in all infarcted 
hearts compared with sham-operated hearts from day 3 to week 1 after MI (study II, Fig. 7). In 
HO-1-induced and CO donor-pretreated hearts, the SDF-1  levels  remained  high  at  week  4,  
while in the control hearts the SDF-1  levels decreased to the levels of sham-operated hearts. In 
comparison to the control MI hearts SDF-1 protein levels were 2-fold higher in the infarct 
areas of the HO-1-induced and CO-pretreated hearts at week 4 (study II, Fig. 7). In contrast to 
CO,  HO-1  induction  did  not  significantly  affect  the  HIF-1  or  VEGF-B  protein  levels.  No  




5.4 HO-1 and CO modulate proliferation of cardiac cells in infarcted rat hearts in 
vivo (II, III) 
 
5.4.1 Proliferation of cells in the infarcted rat hearts (III) 
 
HO-1 regulates proliferation of several cell types in vitro. Immunohistochemical analysis of Ki67 
and  DAPI  was  performed  to  assess  the  number  of  all  proliferating  cells  in  comparison  to  the  
total cell count and the effects of HO-1 and CO on proliferation of cells in the infarcted hearts in 
vivo. In sham-operated hearts, the total cell number was 2648 ± 81 cells per mm2 and did not 
differ by pretreatment or time point. In the infarcted hearts, the total cell count was lower in the 
infarct areas of HO-1-induced hearts than in the control MI hearts at day 3 (5825 ± 169 vs. 7110 
± 282 cells per mm2,  P  =  0.007,  study  III,  Fig.  4  and Supplemental  Table  2).  HO-1  induction  
also  reduced  the  number  of  proliferating  cells  in  the  infarct  area  at  day  3  and  in  the  infarct  
border area at week 1, and a trend for reduced proliferation was found in the infarct area at week 
1 (5.8 ± 0.8% vs. 8.2 ± 0.7% Ki67+ cells, P = 0.068; Table 17 and study III, Figures 4 and 5 and 
Supplemental Table 2). In contrast to HO-1 induction, no significant changes were observed in 
proliferation of cells in CO donor-pretreated hearts, although a trend for reduced proliferation 
of cells was seen in the infarct area at week 1 (CO 6.0 ± 0.4% vs. control MI 8.2 ± 0.7% Ki67+ 
cells, P = 0.073; Table 17). 
 
5.4.2 Proliferation of cardiomyocytes in the infarcted rat hearts (II, III) 
 
HO-1  inhibits  proliferation  of  VSMCs  and  airway  SMCs,  but  the  effects  of  HO-1  and  CO  on  
proliferation of cardiomyocytes have not been studied earlier. The proliferation of 
cardiomyocytes was assessed by immunostaining of Ki67 and cardiac myosin. In sham-operated 
hearts the percentage of proliferating Ki67+ cardiomyocytes was very low (0.0024 ± 0.0005%) 
and  no  differences  were  found  between  the  groups.  In  the  infarcted  hearts,  HO-1  induction  
significantly increased the percentage of Ki67+ cardiomyocytes in the infarct border area at days 
1 and 3, while reducing the number of Ki67+ cardiomyocytes by week 1 after MI (Table 17 and 
study  III,  Fig.  2).  HO-1  also  reduced  the  number  of  Ki67+  cardiomyocytes  in  the  remote  
myocardium at day 3 and weeks 1 and 4 (Table 17 and study III, Fig. 2). The effects of CO donor 





Table 17. Proliferation of cardiac cells in infarcted rat hearts 
 




















1 day         
HO-1 8.7±2.5 2.8±0.2  1.6±0.1  0.37±0.06 ** † 0.0034±0.001  17.7±3.2  6.9±0.7  5.1±0.8 
CO 7.0±0.8 2.9±0.5 1.7±0.3  0.13±0.03  0.0044±0.001  16.2±0.7  7.2±2.3  3.8±0.9  
Control 8.7±1.8 3.2±0.2 1.6±0.2  0.12±0.02  0.0029±0.0008  12.8±3.3  6.1±0.6  2.9±0.4  
3 days         
HO-1 27.9±2.0 * †  9.7±1.3  1.1±0.3  0.46±0.05 ** † 0.0019±0.0001 *** 23.1±4.9  16.7±1.6  2.7±0.3  
CO 38.3±3.4  9.8±1.8  1.3±0.3  0.30±0.02  0.0026±0.0003 ** 31.6±2.8 # 22.4±3.1  3.0±0.6  
Control 35.4±1.5  8.5±0.9  1.1±0.1  0.24±0.04  0.0053±0.0004  27.5±2.1  15.4±1.8  2.3±0.4  
1 week         
HO-1 5.8±0.8  2.3±0.3 ** 1.0±0.2  0.04±0.010 * † 0.0045±0.0007 ** † 6.0±0.6  3.8±0.9 * 2.4±0.6  
CO 6.0±0.4  3.4±0.7  1.7±0.6  0.15±0.034  0.0092±0.0010 * 4.9±0.6  6.0±1.3  4.3±1.2  
Control 8.2±0.7  5.3±0.5  2.0±0.6  0.13±0.020  0.0151±0.0012  6.4±0.6  8.6±1.4  5.9±1.7  
4 weeks         
HO-1 2.2±0.3 † 2.7±0.3  1.8±0.2  0.080±0.012  0.0084±0.0010 ** † 2.3±0.3 † 4.1±0.5  3.8±0.5  
CO 3.4±0.3  2.7±0.3  2.4±0.3  0.153±0.013 ** # 0.0129±0.0017  3.7±0.4  4.5±0.9  4.0±0.7  
Control 2.8±0.4  2.0±0.2  2.1±0.2  0.086±0.008  0.0142±0.0009  3.8±0.8  4.5±0.6  3.9±0.5  
 
Values are mean ± SEM and the results are reported as the percentage of Ki67+ cells of the total cell count (Ki67+ cells), the total cardiomyocyte count or the total fibroblast 
count. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. control MI group at the same time point. † P < 0.05 vs. CO-pretreated group at the same time point. # P < 0.05 vs. HO-1-









proliferation of cardiomyocytes only in the infarct border area at 4 weeks post-MI (Table 17 and 
study II, Fig. 4). However, CO donor pretreatment also reduced proliferation of cardiomyocytes 
in the remote myocardium at day 3 and week 1 (Table 17).  
 
5.4.3 Proliferation of fibroblasts in the infarcted rat hearts (III) 
 
Fibroblasts have a key role in post-MI ventricular remodeling. The number and proliferation of 
fibroblasts was assessed by immunohistochemical analysis of Ki67 and vimentin to evaluate 
whether HO-1 and CO would inhibit proliferation of fibroblasts in the infarcted hearts in vivo. 
The fibroblast counts in infarcted rat hearts are shown in study III, Supplemental Table 3. HO-1 
induction reduced the number of vimentin+ fibroblastlike cells in the infarct area (3535 ± 190 
vs.  4632  ±  317  fibroblasts  per  mm2,  P  =  0.015)  while  slightly  increasing  the  number  of  
vimentin+ cells in the infarct border area at day 3 (1195 ± 58 vs. 1004 ± 32 fibroblasts per mm2, 
P  =  0.018)  (study  III,  Figures  4  and  5  and  Supplemental  Table  3).  HO-1  induction  also  
decreased proliferation of fibroblasts in the infarct border area at week 1 and a trend for 
decreased proliferation of fibroblasts was found in the infarct area at week 4 (2.3 ± 0.3% vs. 3.8 
±  0.8%  Ki67+/vimentin+  cells,  P  =  0.074;  Table  17  and  study  III,  Figures  4  and  5  and  
Supplemental Table 3). In comparison to control MI hearts, no significant changes were found 
in proliferation of fibroblasts in CO-pretreated hearts (Table 17). 
 
 
5.5 Effects of HO-1 and CO on fibrosis and expression of extracellular matrix 
components in infarcted rat hearts (III) 
 
5.5.1 Interstitial and perivascular fibrosis and cardiomyocyte cross-sectional area 
 
Post-MI adverse ventricular remodeling is characterized by increased cardiac fibrosis and 
cardiomyocyte hypertrophy. The effects of HO-1 and CO on interstitial and perivascular fibroses 
were  determined  from  the  infarcted  and  sham-operated  hearts  at  week  4  by  picrosirius  red  
staining. HO-1 induction decreased the extent of perivascular fibrosis in both infarcted hearts 
(1.29 ± 0.06 vs. 1.74 ± 0.13, P = 0.006) and sham operated hearts (1.14 ± 0.05 vs. 1.57 ± 0.08,    
P  =  0.002),  whereas  CO  donor  pretreatment  did  not  significantly  affect  perivascular  fibrosis  
(Fig. 7). There were no significant differences between the groups in interstitial fibrosis (Fig. 7) 




Figure 7. Interstitial and perivascular fibrosis. A) Ratio of perivascular fibrosis. B) The percentage of 
interstitial fibrosis. Values are mean ± SEM. ** P < 0.01 vs. control infarct or control sham group. †† P < 
0.01 vs. CO-pretreated group. Unpublished results for CO-pretreated groups are included in the figure. 






































3 days          
HO-1 237±10 † 16.7±2.0 54.4±2.8 9.5±1.1 14.1±1.6 0.65±0.17 1.28±0.28 1.36±0.10 0.84±0.27 
CO 306±20 13.2±2.8 58.0±3.5 7.2±1.4 14.2±0.7 0.80±0.13 1.46±0.37 1.27±0.13 1.33±0.18 
Control 263±27 24.8±5.8 57.9±2.9 9.8±1.8 14.4±2.1 0.90±0.33 2.44±0.75 1.41±0.23 1.08±0.20 
1 week          
HO-1 224±34 * † 9.0±1.9 †† 84.9±7.5 † 9.4±1.7  17.1±3.2 1.03±0.05 * † 0.58±0.19 †† 0.70±0.25 0.83±0.35 
CO 428±53 37.9±7.7 119.7±6.4 14.1±2.7 17.8±1.5 1.48±0.05 1.66±0.22 1.09±0.14 1.57±0.41 
Control 362±26 31.4±9.7 100.2±4.7 10.6±2.4 14.8±1.5 1.49±0.13 1.73±0.63 0.96±0.12 1.44±0.60 
4 weeks          
HO-1 49.2±9.4 13.1±1.9 21.1±2.4 5.5±0.8 3.0±0.4 1.05±0.12 0.96±0.09 0.72±0.10 * 0.58±0.11 
CO 106.5±16.3 * # 15.4±1.8 40.7±4.5 ## 9.2±1.4 * 5.1±0.4 ** # 1.44±0.07 1.18±0.09 0.92±0.06 0.82±0.13 
Control 54.8±8.8 11.8±1.8 24.3±4.7 5.1±0.7 2.3±0.5 1.40±0.28 1.34±0.22 1.42±0.17 1.05±0.22 
 
Values are mean ± SEM. The mRNA data are reported as mRNA copies (x104) per ng of total RNA. Protein data are reported as a ratio of procollagen I or vimentin per actin. * 
P < 0.05 and ** P < 0.01 vs. control MI group at the same time point. † P < 0.05 and †† P < 0.01 vs. CO-pretreated group at the same time point. # P < 0.05 and ## P < 0.01 vs. 
HO-1-induced group at the same time point. Unpublished results for CO-pretreated groups are included in the table. Abbreviations: Coll1a1 = procollagen type I alpha 1, 




5.5.2 Expression of extracellular matrix components 
 
Collagens  type  I  and  III,  and  fibronectin  are  major  components  of  extracellular  matrix.  The  
effects of HO-1 and CO on procollagen type I (Coll1a1) and type III (Coll3a1), and fibronectin 
mRNA levels were analyzed by real-time RT-PCR. HO-1 induction decreased Coll1a1 mRNA 
expression  in  the  infarct  area  at  week  1  and  a  strong  trend  for  decreased  Coll1a1  mRNA  
expression was found in the remote area at the same time point (HO-1 9.0 ± 1.9 vs. CO 37.9 ± 
7.7, P = 0.001 and control MI 31.4 ± 9.7 P = 0.053, Table 18 and study III, Fig. 7). However, HO-
1 did not significantly affect Coll3a1 or fibronectin mRNA levels (Table 18). In contrast to HO-1, 
CO donor pretreatment increased Coll1a1, Coll3a1, and fibronectin mRNA levels in the infarcted 
hearts  at  week  4.  Coll1a1  and  fibronectin  mRNAs  were  significantly  increased  by  CO  in  the  
infarct  area  and  Coll3a1  mRNA  in  the  remote  area  (Table  18).  In  addition,  a  strong  trend  for  
increased Coll3a1 expression was found in the infarct area at weeks 1 and 4 (week 1: CO 119.7 ± 
6.4 vs. control MI 100.2 ± 4.7, P = 0.053 and HO-1 84.9 ± 7.5, P = 0.010; week 4: CO 40.7 ± 4.5 
vs. control MI 24.3 ± 4.7, P = 0.054 and HO-1 21.1 ± 2.4, P = 0.008, Table 18). 
 
The effects of HO-1 and CO on procollagen type I and vimentin protein levels were measured by 
Western blotting. Vimentin protein expression was used as an indirect measure of fibroblast 
number. As in the Coll1a1 mRNA levels, HO-1 induction decreased the levels of procollagen type 
I  protein  in  the  infarct  area  at  week  1  (Table  18  and  study  III,  Fig.  7).  In  comparison  to  CO-
pretreated hearts, HO-1 also decreased procollagen type I protein in the remote area at week 1 
(Table 18).  HO-1 also decreased vimentin protein in the infarct area at week 4 and a trend for 
decreased vimentin expression was observed in the remote area at week 4 (0.58 ± 0.11 vs. 1.05 ± 
0.22, P = 0.093, Table 18 and study III, Fig. 7). Although CO pretreatment increased the mRNA 
levels of Coll1a1, Coll3a1, and fibronectin, no significant changes were found in the procollagen 
type I or vimentin protein levels by CO (Table 18). 
 
 
5.5.3 Expression of CTGF, TGF- 1, and ANP 
 
Connective tissue growth factor (CTGF) and transforming growth factor beta1 (TGF- 1) are key 
factors regulating cardiac fibrosis and ventricular remodelling while atrial natriuretic peptide 
(ANP) is a marker of heart failure. The mRNA levels of CTGF, TGF- 1 and ANP were measured 
by  real-time  RT-PCR.  HO-1  induction  decreased  the  expression  of  CTGF  mRNA  both  in  the  
infarct and remote areas at week 4 and a trend for lower CTGF levels was found in the infarct 
area at day 1 (6.9 ± 1.1 vs. 10.2 ± 0.9, P = 0.068) (Fig. 8 and study III, Fig. 8). In contrast, the 
CTGF mRNA levels were increased by HO-1 in the remote area at day 3 (Fig.  8 and study III,  
Fig. 8). The effects of CO pretreatment differed again from the effects of HO-1 induction, since 
CO significantly increased the expression of CTGF mRNA in the infarct area at week 4 (Fig. 8). 
No significant differences were found between the groups in CTGF mRNA levels in the infarct 
border area or sham-operated hearts.  
 
Both  HO-1  induction  and  CO  donor  pretreatment  increased  the  TGF- 1  mRNA  levels  in  the  
infarct area at day 3 (Fig. 8). Increased TGF- 1 mRNA levels were also found in the infarct areas 
of CO-pretreated hearts at week 4 (Fig. 8). No significant differences were found between the 
groups in TGF- 1 mRNA expression in the infarct border or remote areas or sham-operated 
hearts. 
 
HO-1 induction decreased the levels of ANP mRNA in the infarct border area at day 3 and week 
1 (2.0 ± 0.5 vs. 3.1 ± 0.3, P = 0.050) (Fig. 8 and study III, Fig. 8). Decreased ANP mRNA levels 
were  also  found  in  the  infarct  border  areas  of  CO-pretreated  hearts  at  week  1  (Fig.  8).  No  
RESULTS 
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significant  differences  were  found  between  the  groups  in  ANP  mRNA  levels  in  the  infarct  or  




Figure 8. CTGF, TGF- 1 and ANP mRNA expression in the infarcted hearts. A) CTGF mRNA levels in the 
infarct  area.  B)  CTGF mRNA levels  in  the  remote  area.  C)  TGF- 1 mRNA levels in the infarct area. D) 
ANP mRNA levels in the infarct border area. Values are mean ± SEM. * P < 0.05 and ** P < 0.01 vs. 
control MI group.  † P < 0.05 and   †† P < 0.01 vs. CO-pretreated group. Unpublished results for CO-
pretreated groups are included in the figure. Abbreviations: ANP = atrial natriuretic peptide, CO = carbon 
monoxide, CTGF = connective tissue growth factor, HO-1 = heme oxygenase-1, TGF- 1 = transforming 




5.6 Clinical study 
 
5.6.1 HO-1 polymorphisms 
 
Different polymorphisms have been identified in the human HO-1 gene. The GTn repeat length 
polymorphism  and  the  -413A/T  SNP  polymorphism  are  the  most  studied  of  HO-1 
polymorphisms. The allelic distribution of the HO-1 GTn repeat length polymorphism is shown 
in Fig. 9. The GTn repeat length ranged from 18 to 40, and the most frequent repeat lengths were 
30 (47.6%) and 23 (18.6%). Based on the trimodal allelic distribution, the GTn repeat length was 
divided  into  short  (S),  medium  (M),  and  long  (L)  alleles.  The  frequencies  of  the  S,  M  and  L  
alleles were 36%, 59%, and 5%, respectively. The HO-1 SNPs  (+99G/C  and  -413A/T)  were  in  
Hardy-Weinberg equilibrium. The frequencies of the +99G/C genotypes were: GC 10.4% 
(24/231) and GG 89.6% (207/231).  The frequencies of the -413A/T genotypes were: AA 35.5% 
(82/231),  AT  48.5%  (112/231)  and  TT  16.0%  (37/231).  The  allele  frequencies  did  not  differ  
between men and women. 
 
Strong LD was observed between the polymorphisms studied. The D’ measure of LD between 
the two SNPs (+99G/C and -413A/T) was 1.0, while the r2 value that takes allele frequencies into 
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account was 0.08. The most common repeat length allele,  GT(30),  was in complete LD (D’=1) 
with  the  -413A  and  +99G  alleles.  The  next  most  frequent  repeat  length  alleles,  GT(23)  and  
GT(24), were in complete LD with the -413T and +99G alleles. In addition, the group of L alleles 
was in perfect LD with the +99C allele (both D’ and r2=1). The different haplotypes formed by 





Figure 9. Allelic distribution of the heme oxygenase-1 (HO-1) GTn repeat length polymorphism and 
classification of the GTn repeats into S, M and L alleles. 
 
5.6.2 HO-1 plasma concentrations 
 
HO-1  plasma  concentrations  have  been  studied  only  in  a  few  previous  studies.  The  plasma  
samples of 58 healthy controls were used to establish the reference range for plasma HO-1. The 
plasma HO-1 reference range (95% CI) was 0.66–2.39 ng/ml, with a median of 1.5 ng/ml (IQR 
1.13–1.77 ng/ml). The concentrations did not differ between men and women. The HO-1 plasma 
concentrations  of  the  critically  ill  study  patients  were  significantly  higher  than  the  reference  
values (Fig. 10 and study V, Fig. 2). The median day 1 plasma HO-1 concentration of the study 
patients was 6.9 ng/ml (IQR 5.1–9.9 ng/ml),  the day 2 HO-1 6.6 ng/ml (IQR 4.9–9.3 ng/ml),  
the  day  3-4  HO-1  6.4  ng/ml  (IQR  4.9–8.1  ng/ml)  and  the  maximum  HO-1  concentration  7.3  
ng/ml (IQR 5.6–10.2 ng/ml).  The HO-1 levels were elevated in all critically ill patients 
regardless of the diagnosis (study V, Table 3). The HO-1 plasma levels were highest in patients 
with pancreatitis (9.0 ng/ml, IQR 7.7–14.5 ng/ml), sepsis (8.4 ng/ml, IQR 5.7–12.0 ng/ml), or 
respiratory tract infection (8.4 ng/ml, IQR 5.8–9.5 ng/ml). Slightly lower HO-1 plasma 
concentrations  were  measured  from  patients  with  heart  failure  (7.2  ng/ml,  IQR  5.5–10.0  
ng/ml),  heart  arrest  (6.3  ng/ml,  IQR  5.1–10.2  ng/ml),  or  acute  MI  (6.4  ng/ml,  IQR  4.6–8.5  
ng/ml).  The  HO-1  plasma  levels  were  lowest  in  patients  with  cerebrovascular  disorders  (3.7  
ng/ml,  IQR 2.3–4.1  ng/ml)  or  intoxication  (4.9  ng/ml,  IQR 4.0–10.1  ng/ml).  One  patient  was  
excluded from further analysis due to autoimmune hemolytic anemia and extremely high HO-1 






Figure 10. Heme oxygenase-1 (HO-1) plasma concentrations of controls and study patients at different 
time points. Values are shown as median (line) and interquartile range (IQR, boxes) and 5th and 95th 
percentiles (whiskers). *** P < 0.001 vs. control group. Unpublished data on maximum HO-1 levels is 
included in the figure. 
 
5.6.3 Association of HO-1 polymorphisms with HO-1 plasma concentrations, disease 
severity, and mortality 
 
HO-1 polymorphisms have been shown to modulate HO-1 expression levels and associate with 
different diseases. In the present study, HO-1 polymorphisms significantly affected the HO-1 
plasma concentrations. The -413T/GT(L)/+99C haplotype was associated with significantly 
lower  HO-1  concentrations  at  all  time points  compared  with  the  other  haplotypes  (Fig.  11  and 
study V, Fig. 3). Of the 24 patients carrying the -413T/GT(L)/+99C haplotype, 14 had the day 1 
plasma HO-1 value. The -413T allele was also associated with lower day 3-4 HO-1 plasma 
concentrations than the AA homozygotes (6.1 vs. 6.9 ng/ml, P = 0.021). 
 
Patients with the -413T/GT(L)/+99C haplotype had less frequently multiple organ dysfunction 
(MOD) (SOFA score > 6) than patients with other haplotypes on day 1 in ICU (46% vs. 70%, P = 
0.017). However, the HO-1 polymorphisms were not associated with ICU or hospital  mortality 





Figure 11. Patients with the heme oxygenase-1 (HO-1) -413T/GT(L)/+99C haplotype (n = 24) had 
significantly lower HO-1 concentrations compared to patients with other haplotypes (n = 207). Values are 
shown as median (line) and interquartile range (IQR, boxes) and 5th and 95th percentiles (whiskers).           






5.6.4 Association of HO-1 plasma concentrations with disease severity and mortality 
HO-1 is a highly inducible stress responsive enzyme, and thereby a potential marker of disease 
severity  and  predictor  of  outcome  in  critically  ill  patients.  Therefore,  the  association  of  HO-1  
plasma concentrations with disease severity and mortality was investigated in this study. The 
day 1 and day 2 HO-1 concentrations correlated significantly with the day 1 and day 2 bilirubin 
levels  (Table  19).  In  addition,  the  day  1  HO-1  concentration  correlated  significantly  with  CRP  
concentration,  the  disease  severity  scores  APACHE  II  and  SAPS  II,  the  first-day  SOFA  score  
(especially the coagulation, liver,  renal,  and pulmonary scores) and the maximum SOFA score 
(Table 19). The day 1 HO-1 concentrations in the day 1 SOFA quartiles are shown in study V, Fig. 
4. When organ failures were analyzed separately in the linear regression analysis, renal failure 
(P  =  0.02)  and  ventilation  failure  (P  =  0.02)  were  associated  independently  with  the  HO-1  
values.  Patients  with  MOD  on  the  day  1  of  intensive  care  had  significantly  higher  HO-1  
concentrations at all time points than patients with no MOD (day 1 HO-1 7.8 vs. 6.1 ng/ml, P = 
0.015; day 2 6.9 vs. 5.6 ng/ml, P = 0.003; and day 3-4 6.5 vs. 5.6 ng/ml, P = 0.004). 
 
 
Table 19. Correlation of HO-1 plasma concentrations with CRP, bilirubin and clinical scores. 
 
Variable r2 p 
Day 1 CRP 0.18 0.02 
Day 1 bilirubin 0.27 0.001 
Day 2 bilirubin 0.26 0.001 
APACHE 0.27 0.001 
SAPS II 0.17 0.038 
Day 1 SOFA 0.32 <0.001 
   Central nervous system SOFA 0.003 0.966 
   Cardiovascular SOFA 0.138 0.085 
   Coagulation SOFA 0.336 <0.001 
   Liver SOFA 0.373 <0.001 
   Renal SOFA 0.298 <0.001 
   Pulmonary SOFA 0.232 0.003 
Max SOFA 0.34 <0.001 
Abbreviations: APACHE II = acute physiology and chronic health evaluation II score, CRP = C-reactive 
protein, HO-1 = heme oxygenase-1, SAPS II = simplified acute physiology score II, SOFA = sequential 
organ failure assessment score.  
 
Age  did  not  correlate  with  HO-1  concentrations,  but  men  had  higher  day  2,  day  3-4,  and  
maximum HO-1 concentrations than women (P < 0.001, P = 0.001 and P = 0.001, respectively), 
while their disease and organ failure scores did not differ from women’s scores. In the linear 
regression analysis used to identify the variables independently associating with the day 1 HO-1 
concentration,  the  day  1  CRP  values,  gender,  carriage  of  the  T/GT(L)/C  haplotype,  SAPS  II  
score,  and  SOFA  score  were  included.  The  day  1  SOFA  score  (P  =  0.001)  and  T/GT(L)/C  
haplotype (P = 0.03) were associated independently with the day 1 HO-1 concentrations. 
 
The ICU mortality rate was 7.4% (17/231) and the hospital  mortality rate 19.5% (45/231).  The 
ICU and hospital mortalities for those 160 patients (of 231) with the day 1 plasma HO-1 were 6% 
(10/160)  and 21% (33/160).  The  patients  with  the  day  1  plasma HO-1  did  not  differ  from the  
patients without the plasma sample regarding hospital mortality, SAPS II, gender, SOFA, or the 
carriage of the T/GT(L)/C haplotype (data not shown), but they were slightly younger (median 
57 vs. 61 years, P = 0.04). The day 1 HO-1 concentration and the maximum HO-1 concentration 
during the first 4 days in the ICU were significantly higher in patients who died in the ICU than 
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in  ICU  survivors  (day  1  HO-1  11.4  vs.  6.5  ng/ml, P  <  0.001  and  maximum  HO-1  9.9  vs.  7.2  
ng/ml, P = 0.006, respectively). The maximum HO-1 concentration was also higher in hospital 
nonsurvivors than in survivors (8.4 vs. 7.1 ng/ml, P = 0.02), but the other HO-1 concentrations 
(day  1,  day  2  and  day  3-4)  did  not  differ  significantly  between  the  hospital  nonsurvivors  and  
survivors (P = 0.08–0.45).  
 
The discriminative power of plasma HO-1 regarding ICU and hospital mortalities was 
determined  by  ROC  analysis.  The  AUC  for  the  day  1  HO-1  concentration  regarding  ICU  
mortality  was  0.83  (95% CI  0.73–0.93)  (Fig.  12).  In  comparison,  the  AUC for  the  APACHE II  
regarding ICU mortality was 0.81 (95% CI 0.68–0.93), for the SAPS II 0.85 (95% CI 0.76–0.93), 
and for the day 1 SOFA 0.86 (95% CI 0.71–1.0) (Fig. 12). The best cutoff value for the day 1 HO-1 
regarding  ICU  mortality  was  7.4  ng/ml,  with  sensitivity  of  1.00  (95%  CI  0.74–1.00)  and  
specificity of 0.58 (95% CI 0.51–0.65), positive likelihood ratio of 2.4, and correct classification 
rate of 0.60. The AUC for the maximum HO-1 concentration regarding hospital  mortality was 
0.61 (95% CI 0.52–0.71), while the first-day HO-1 value produced an AUC of 0.59 (95% CI 0.47–
0.71) (Fig. 12). The AUC for the APACHE II score regarding hospital mortality was 0.76 (95% CI 
0.66–0.85), for the SAPS II score 0.79 (95% CI 0.70–0.88), and for the day 1 SOFA 0.74 (95% 







Figure 12. ROC curves for the day 1 HO-1 concentration, APACHE II score, SAPS II score and day 1 
SOFA score in predicting ICU mortality and hospital mortality. (Unpublished data.)  Abbreviations: 
APACHE II = acute physiology and chronic health evaluation II score, HO-1 = heme oxygenase-1, ROC = 
receiver operating characteristic, SAPS II = simplified acute physiology score II, SOFA = sequential organ 
failure assessment score. 
 
Multiple regression analysis was used to investigate the factors associating independently with 
both  ICU  and  hospital  mortalities.  All  variables  associated  significantly  with  mortality  were  
included:  day  1  HO-1  concentrations,  SAPS  II  score  and  SOFA  score  regarding  ICU  mortality  
and the maximum HO-1 concentration, SAPS II score without age,  age,  day 1 SOFA score,  and 
gender  regarding  hospital  mortality.  The  SAPS  II  score  without  age,  age,  male  gender,  and  
maximum HO-1 concentration were independently associated with hospital mortality                 
(P  =  0.001,  P  =  0.004,  P  =  0.04,  P  =  0.01,  respectively).  Only  the  day  1  SOFA  score  was  







This study shows the manifold, and for the most part salutary, effects of the HO-1/CO pathway 
in  the  heart  during  healing  of  MI  and  during  reperfusion  of  the  ischemic  myocardium  in  the  
animal  models  used.  In  addition,  this  study  sheds  light  on  the  role  of  HO-1  in  critically  ill  
patients, as well as in the subpopulation of patients with severe cardiac disease.  
 
 
6.1 HO-1 expression in infarcted rat hearts (I–III) 
 
The study I was carried out to obtain detailed data on HO-1 expression in infarcted hearts.  At 
the  time this  study  was  conducted,  the  increased  HO-1  expression  had  been shown in  I/R rat  
and porcine hearts and in hypoxic cardiomyocytes (Maulik et al.  1996, Borger and Essig 1998, 
Sharma et al.  1999, Hangaishi et  al.  2000, Foresti  et  al.  2001),  but few data were available on 
the long-term expression of HO-1 in failing hearts (Raju et al. 1999). This study was the first to 
demonstrate the spatiotemporal expression of HO-1 in post-MI rat hearts (I). Similar results 
were obtained recently from following studies (II, III), with some additional quantitative data on 
HO-1 protein levels.   
 
The  results  of  studies  I–III  showed  that  the  expression  of  HO-1  was  induced  in  the  infarcted  
hearts,  especially  in  the  infarct  area  and  infarct  border  area.  HO-1  expression  peaked  in  the  
infarct border area at day 1 and was localized in the cardiomyocytes. HO-1 is known as a highly 
inducible stress-responsive protein (Otterbein and Choi 2000). Therefore, this early increase of 
HO-1 in the cardiomyocytes bordering the infarct area likely represents a defense response 
against  both  ischemia  and  ROS  produced  in  the  ischemic  myocardium,  and  potentially  
promotes the survival of these cardiomyocytes. Increased HO-1 protein was detected in the 
cardiomyocytes of the infarct border area until  week 1.  At week 4,  HO-1 protein was no longer 
detected in the cardiomyocytes, although HO-1 protein levels were still elevated in the infarct 
border  area,  according  to  the  HO-1  ELISA  results.  However,  the  lower  sensitivity  of  
immunofluorescent staining likely explains this difference. 
 
HO-1  is  a  microsomal  enzyme,  as  originally  described  by  Tenhunen  et  al.  (1968,  1969)  and  
primarily localized in the smooth endoplasmic reticulum (Maines 1988), which is the main 
component  of  the  SR in  cardiomyocytes.  In  addition  to  microsomes,  localization  of  HO-1  was  
also reported in mitochondria (Converso et al. 2006a) and in nucleus (Lin et al. 2007a). In the 
present  study,  HO-1  showed a  strong  transverse  and a  weaker  longitudinal  striated  pattern  of  
staining in rat cardiomyocytes compatible with the localization of HO-1 mainly in transverse 
junctional SR and to a lesser extent in longitudinal SR. Interestingly, increased HO-1 protein 
was  also  detected  in  the  intercalated  discs  of  cardiomyocytes  bordering  the  infarct  area.  The  
function  of  intercalated  discs  is  to  connect  cells  to  each  other  and  conduct  (electrical)  signals  
between cells through gap junctions. The localization of HO-1 in the intercalated discs suggests a 
possible role for HO-1 in signal conduction and it prompted us to investigate the effect of HO-1 
induction on expression and distribution of cardiac gap junction protein Cx43 in study IV.  
 
In the infarct area HO-1 expression peaked at day 3 and was highly expressed in the infiltrating 
monocytes/macrophages (Lakkisto et al. unpublished result) and to a lesser extent in fibroblast-
like cells, whereas at week 1 HO-1 was mainly expressed in fibroblast/myofibroblasts. Likewise, 
Hangaishi  et  al.  (2000)  showed  high  levels  of  HO-1  in  monocytes/macrophages  and  in  
myofibroblasts in response to I/R in rat hearts.  The exact role of HO-1 in the infarct-invading 
monocytes/macrophages  is  not  known.  The  preferential  expression  of  HO-1  in  anti-
inflammatory human M2 macrophages was demonstrated recently (Sierra-Filardi et al. 2010). 
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HO-1 also contributes to the activation of human macrophages toward the anti-inflammatory 
M2 phenotype (Weis et al. 2009). Furthermore, HO-1-overexpressing macrophages possessed 
an anti-inflammatory phenotype in vitro and improved renal function in mouse renal I/R injury 
in vivo (Ferenbach  et  al.  2010).  Whether  HO-1  is  also  associated  with  the  anti-inflammatory  
macrophages in the infarcted heart, and the specific role of HO-1-expressing macrophages in the 
healing of MI, remains to be determined in further studies. Likewise, the function of HO-1 in the 
fibroblasts/myofibroblasts of the infarct area is still unclear, although it is known that HO-1 
inhibits apoptosis of fibroblasts and decreases proliferation of cardiac fibroblasts in vitro (Ferris 
et al. 1999, Petrache et al. 2000, Liu et al. 2006).  
 
Study I also revealed a constant expression of HO-1 in the coronary artery walls of the rat heart 
and  a  transient  expression  of  HO-1  in  the  small  arterioles  of  the  infarct  border  area.  These  
results pointed to a possible role for HO-1 in maintaining perfusion and vascular homeostasis in 
the surrounding areas of infarction. The effects of HO-1 that may potentially contribute to the 
preservation  of  perfusion  include  vasodilatation  (Morita  et  al.  1995),  inhibition  of  endothelial  
cell  apoptosis (Brouard et al.  2000), and inhibition of platelet aggregation by the HO reaction 
product CO (Brune and Ullrich 1987). In the light of current knowledge of the angiogenic effect 
of HO-1 (Dulak et al. 2008), and since a significant (although small) increase in capillary density 
was observed in the control MI hearts from week 1 to week 4 in study II, it would be tempting to 
speculate that the increased expression of HO-1 in the infarct border area vasculature could also 




6.2 Protection against postischemic dysfunction and ventricular fibrillation by 
HO-1 in ischemic/reperfused rat hearts (IV) 
 
The cytoprotective properties of HO-1 have been studied extensively in different I/R injury 
models and different organs (Katori et al. 2002a). The purpose of study IV was to investigate the 
effect  of  HO-1  induction  on  postischemic  cardiac  function  and  I/R-induced  arrhythmias.  The  
results  showed  that  HO-1  induction  by  hemin  improved  postischemic  cardiac  function  and  
reduced VF in I/R rat hearts. Similar protection against postischemic cardiac dysfunction by 
HO-1  has  been  reported  in  several  experimental  studies.  Pharmacological  HO-1  induction  by  
hemin (Clark et al. 2000b) or N-tert-butyl- -phenylnitrone improved myocardial function after 
I/R in isolated perfused rat hearts (Bak et al. 2002), and cardiac-specific overexpression of HO-
1  improved  postischemic  cardiac  function  in  isolated  transgenic  mice  hearts  (Yet  et  al.  2001,  
Vulapalli  et  al.  2002).  In  addition  to  the  acute  cardioprotection  in  I/R  hearts,  pre-emptive  
cardiac HO-1 gene transfer results in long-term improvement in cardiac function in infarcted rat 
hearts preserving left  ventricular function up to 1 year after MI (Pachori et  al.  2004, Liu et al.  
2006,  Liu  et  al.  2007).  The  role  of  HO-1  reaction  products  in  the  prevention  of  postischemic  
cardiac dysfunction was not examined in this study, but others have shown that both bilirubin 
and CO are involved in the recovery of postischemic cardiac function in isolated rat and mouse 
hearts (Clark et al. 2000b, Bak et al. 2002, Bak et al. 2003). 
 
In  study  I,  HO-1  immunoreactivity  was  detected  in  the  intercalated  discs  of  cardiomyocytes  
bordering  the  infarct  area,  suggesting  a  role  for  HO-1  in  signal  conduction  between  
cardiomyocytes. Therefore, the main interest in study IV was the antiarrhythmic effect of HO-1. 
The antiarrhythmic effect of HO-1 was also studied by Tosaki’s group and they have 
demonstrated, using isolated perfused rat and mouse hearts, that the antiarrhythmic effect of 
HO-1 is mediated by CO (Bak et al. 2002, Bak et al. 2003), and exposure of isolated hearts to CO 
via perfusion buffer dose-dependently reduces the incidence of I/R-induced VF (Bak et al. 2005, 
Varadi et  al.  2007).  CO is known to increase cGMP levels by activating sGC (Kharitonov et al.  
1995),  and  cGMP  modulates  gap  junctional  coupling  in  hamster  cardiomyocytes  (De  Mello  
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1998).  In  addition,  reduced  cGMP  levels  are  associated  with  increased  susceptibility  to  I/R-
induced VF in rat hearts (Pabla et al. 1995). Bak et al. (2005) reported increased cardiac cGMP 
levels  in  response  to  administration  of  CO  via  perfusion  buffer  and  suggested  that  the  
antiarrhythmic effect of CO is related to increased cGMP in isolated rat hearts. In contrast, the 
results  of  study  IV  showed  decreased  cardiac  cGMP  levels  in  all  I/R  rat  hearts  regardless  of  
pretreatment. This indicates that the antiarrhythmic effect of hemin preconditioning was 
independent of cGMP in this study. In addition, similar decrease of cGMP release in response to 
ischemia was shown earlier in isolated rat hearts by Agullo et al. (1999). 
 
Important mecahisms leading to arrhythmias and cardiac dysfunction are ischemia-induced 
abnormalities  in  the  cardiac  levels  of  K+, Ca2+,  and  Na+ ions. The cardiac levels of these 
electrolytes  were  not  examined in  this  study,  but  two previous  studies  showed that  HO-1  and 
CORM-3 regulate tissue K+, Ca2+, and Na+ levels, thereby protecting the heart against I/R injury 
(Bak et al. 2003, Varadi et al. 2007). Thus, the cardioprotective effect of HO-1 may partly be due 
to the regulation of ion balance via CO. This is also supported by earlier studies showing that CO 
inhibits L-type Ca2+ channels in HEK293 cells (Dallas et al. 2009) and activates KCa channels in 
VSMCs (Wang and Wu 1997).   
 
The  novel  finding  of  study  IV  was  the  modulation  of  expression,  phosphorylation,  and  
distribution of the predominant ventricular gap junction protein Cx43 by HO-1 induction. Gap 
junctions are transmembrane channels mediating intercellular communication, including 
electrical  coupling,  between neighboring  cardiomyocytes.  Abnormalities  in  gap  junctions  such  
as decreased connexin expression and alterations in gap junction distribution and 
phosphorylation increase the incidence of arrhythmias in both human cardiac diseases and 
animal models (Severs et al. 2004, 2008). The results of study IV showed in isolated rat hearts 
that under normoxic conditions Cx43 was phosphorylated and localized in the intercalated discs 
of cardiomyocytes. I/R decreased the levels and caused dephosphorylation of Cx43, as 
demonstrated earlier by Schulz et al. (2003) in swine hearts. In contrast, HO-1 induction 
prevented the I/R-related decrease in total Cx43 level, suggesting that preservation of Cx43 total 
level  may at least partly contribute to the cardioprotective and antiarrhythmic effects of HO-1.  
The importance of normal Cx43 levels was demonstrated by Lerner et al. (2000) and Schwanke 
et  al.  (2002)  showing  increased  incidence  of  I/R-induced  ventricular  arrhythmias  and  loss  of  
preconditioning in heterozygous Cx43 knockout mice, due to reduced expression of Cx43. 
 
The study IV also showed that the preservation of Cx43 total level in the I/R rat hearts by HO-1 
was for the most part due to increased levels of nonphosphorylated Cx43 at serine 368 (S368). 
In  comparison  to  other  I/R  groups,  HO-1  induction  resulted  in  greater  accumulation  of  S368  
nonphosphorylated Cx43 in both the intercalated discs and lateral plasma membranes of 
cardiomyocytes. Ischemia is known to cause dephosphorylation and lateral redistribution of 
Cx43, which are related to electrical uncoupling of cardiomyocytes and increased susceptibility 
to arrhythmias (Matsushita et al. 1999, Lampe et al. 2006, Solan and Lampe 2009). Since HO-1 
induction  decreased  the  incidence  of  VF  while  increasing  S368  nonphosphorylated  Cx43,  the  
cardioprotective  and  antiarrhythmic  effects  of  HO-1  induction  may  at  least  partly  be  
independent  of  gap  junctional  coupling.  Indeed,  Li  et  al.  (2004)  showed  using  mouse  
cardiomyocytes that although Cx43 is essential in ischemic preconditioning, protection against 
I/R  injury  does  not  involve  intercellular  communication  through  gap  junctions.  One  possible  
mechanism for  the  cardioprotection  associated  with  increased  nonphosphorylated  Cx43 could  
be  the  inhibition  of  gap  junction-mediated  spread  of  cell  injury  due  to  uncoupling  of  
cardiomyocytes  (Garcia-Dorado  et  al.  2004).  It  was  shown  in  swine  and  rabbit  hearts  that  
inhibition  of  gap  junctional  communication  with  different  blockers  decreases  infarct  size  after  
I/R  (Garcia-Dorado  et  al.  1997,  Miura  et  al.  2004).  Other  possible  mechanisms  of  
cardioprotection related to Cx43 may also exist. Cx43 localized in cardiomyocyte mitochondria 
has  been  implicated  in  ischemic  preconditioning  in  swine  hearts  (Boengler  et  al.  2005).  
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Furthermore, nonjunctional Cx43 hemichannels play a role in cellular volume regulation (Quist 
et al. 2000) and in activation of cell survival pathways (Plotkin and Bellido 2001, Plotkin et al. 
2002).  Whether  HO-1  prevents  the  spread  of  I/R  injury  by  causing  uncoupling  of  
cardiomyocytes or modulates the Cx43-associated protective mechanisms that are independent 
of gap junctional coupling remains to be determined in further studies.  
  
Multiple putative phosphorylation sites of Cx43 exist. Phosphorylation of serine residues, 
including S368, decreases the permeability of Cx43 hemichannels, i.e. decreases intercellular 
communication  (Lampe  et  al.  2000,  Bao  et  al.  2004,  Solan  and  Lampe  2009).  Under  
physiological conditions and in response to ischemic preconditioning, Cx43 is predominantly 
phosphorylated, keeping the gap junctions in a closed state, whereas ischemia causes 
dephosphorylation of Cx43 and opening of gap junctions, contributing to the spread of tissue 
injury  (Schulz  et  al.  2003).  Based  on  this,  one  would  expect  impaired  cardiac  function  and  
increased incidence of VF associating with increased S368 nonphosphorylated Cx43 in study IV. 
Since this was not the case, we speculate that increase in S368 nonphosphorylated Cx43 by HO-
1 may enhance intercellular communication and electrical coupling, thereby decreasing the 
incidence of VF. Vetterlein et al. (2006) showed in I/R rat hearts that ischemic preconditioning 
caused redistribution of Cx43 in the lateral plasma membrane of cardiomyocytes, associating 
with improved survival of cardiomyocytes during subsequent prolonged ischemia. They did not 
specify  the  phosphorylation  status  of  Cx43,  but  Hund  et  al.  (2007)  showed  that  ischemia  
increases  phosphorylation  of  Cx43  at  S368,  whereas  ischemic  preconditioning  prevents  
phosphorylation  in  isolated  perfused  mouse  hearts.  This  suggests  indirectly  that  S368  
nonphosphorylated Cx43 could be involved in the beneficial effects of ischemic preconditioning, 
and also of hemin preconditioning. However, the significance of S368 nonphosphorylated Cx43 
in the hemin-preconditioned hearts remains unclear, since contrasting results of decreased 
phosphorylation of Cx43 at S368 have also been reported in ischemic rat hearts (Axelsen et al. 
2006, Matsushita et al. 2006). Therefore, the specific role of S368 nonphosphorylated Cx43 in 
cardioprotection by HO-1 remains to be evaluated in further studies. 
 
Taken together,  the data on expression, distribution and phosphorylation of Cx43 suggest that 
HO-1  may  decrease  the  incidence  of  arrhythmias  and  improve  postischemic  cardiac  function  
partially by preserving cardiac total Cx43 levels in I/R hearts. HO-1 may also inhibit the spread 
of cell injury in I/R hearts by increasing S368 nonphosphorylated Cx43 that causes uncoupling 
and  lateralization  of  Cx43.  However,  the  cardioprotective  and  antiarrhythmic  effects  of  HO-1  
may also be independent of gap junctional coupling. 
 
In humans, the role of HO-1 in cardiac arrhythmias is unclear. Increased atrial HO-1 mRNA and 
protein levels have been shown in patients with chronic atrial fibrillation (Bukowska et al. 2008, 
Corradi  et  al.  2008).  The  induction  of  HO-1  in  these  patients  may  result  from  increased  
oxidative stress in the atrial myocardium (Bukowska et al. 2008, Corradi et al. 2008). It is also 
well known that CO poisoning causes cardiac arrhythmias, which are a major cause of death in 
patients with CO poisoning (Dolan 1985).  In contrast,  the effect of low doses of CO on cardiac 
arrhythmias is controversial. Urban air pollution containing CO is associated with cardiac 
arrhythmias (Link and Dockery 2010), whereas CO exposure of coronary artery patients causing 
3–6% COHb levels does not increase the frequency of ventricular arrhythmias (Hinderliter et al. 
1989, Dahms et al. 1993). Since HO-1 and low doses of CO efficiently inhibit cardiac arrhythmias 
in rodents, they may also have therapeutic potential in humans. HO-1 gene therapy and CORMs 
will  likely  be  the  most  useful  therapeutic  strategies  to  investigate  in  humans,  presuming  that  
they turn out to be safe for patients.    
 
It should be noted that study IV has some limitations. The most important limitation is that the 
cardiac mRNA, protein, and cGMP levels were measured and Cx43 immunohistochemical 
analysis performed at the end of the 120-min reperfusion. Therefore, the biochemical and 
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immunohistochemical results represent the conditions at that time point, but the effect of HO-1 
induction on cGMP and Cx43 levels and Cx43 localization during ischemia or early reperfusion 
cannot be evaluated, based on this study. Since the cGMP levels were similar in all I/R groups at 
the  120-min  reperfusion,  it  is  likely  that  hemin  preconditioning  had  no  significant  effect  on  
cardiac cGMP content before or during the ischemia. Instead, phosphorylation of Cx43 may 
change rapidly (Crow et al. 1990, Boengler et al. 2006). Therefore, both phosphorylation status 
and localization  of  Cx43 during  ischemia  and early  reperfusion  may  have  been different  from 
those  at  120  min  of  reperfusion.  In  addition,  the  infarct  size  was  not  measured  in  this  study,  




6.3 The myriad effects of HO-1 and CO on the recovery from rat myocardial 
infarction (II, III) 
 
The results of studies II and III showed that HO-1 and CO promoted the healing of infarcted rat 
hearts  by  multiple  mechanisms.  The  study  II  was  the  first  to  show  that  CO  activated  c-kit+  
stem/progenitor cells and promoted vasculogenesis and myocardial regeneration by regulating 
the expression of the angiogenic factors HIF-1 , SDF-1  and  VEGF-B.  It  also  revealed  
differential  mechanisms  of  action  for  HO-1  and  CO  in  cardiac  regeneration,  since  HO-1  
appeared to promote angiogenesis.  The study III demonstrated for the first  time the effects of 
HO-1 induction on proliferation and repair of cardiomyocytes in the infarcted hearts and, 
furthermore, the effects of HO-1 on proliferation of cardiac fibroblasts and cardiac fibrosis in 
vivo. In addition, the role of CO in cellular and extracellular remodeling is clarified here.  
 
6.3.1 Neovascularization and myocardial regeneration (II) 
 
An intriguing mechanism for the healing of MI has emerged during the last decade, since it has 
become evident that the heart is  a regenerating organ. The adult mammalian heart contains a 
population of resident c-kit+ CSCs with the potential for regenerating infarcted myocardium 
when activated with growth factors or delivered into the infarcted hearts (Beltrami et al. 2003, 
Dawn  et  al.  2005,  Linke  et  al.  2005,  Tillmanns  et  al.  2008).  In  addition,  paracrine  factors  
secreted from stem/progenitor cells and from the ischemic myocardium contribute significantly 
to  cardiac  regeneration  (Gnecchi  et  al.  2008,  Smart  and  Riley  2008).  Estimates  of  the  
cardiomyocyte renewal rate in humans vary from 0.45–1% per year to 22% per year (Bergmann 
et al. 2009, Kajstura et al. 2010). 
 
Although the cytoprotective and proangiogenic roles of HO-1 are well  established (Dulak et al.  
2008),  few  studies  have  investigated  the  role  of  HO-1  in  cardiac  cell  therapy  or  cardiac  
regeneration.  HO-1  transfection  improves  survival  of  transplanted  MSCs  in  ischemic  mouse  
hearts  (Tang  et  al.  2005,  Zeng  et  al.  2008a).  HO-1-overexpressing  MSCs  protected  against  
cardiomyocyte apoptosis and cardiac dysfunction, increased capillary density, and decreased 
infarct  size  in  infarcted  rat  hearts  (Zeng  et  al.  2008a,  Tsubokawa  et  al.  2010).  Similar  effects  
were shown in infarcted rat hearts injected with cell culture supernatant of HO-1-transfected 
MSCs, suggesting that the paracrine factors secreted by HO-1-modified MSCs mediate the 
beneficial effects of these cells in the heart (Zeng et al. 2008b). In addition to our results (II), 
there  is  only  one  other  study  by  Lin  et  al.  (2008)  investigating  the  effect  of  HO-1  on  cardiac  
regeneration. They showed that HO-1 gene transfer promotes neovascularization in ischemic 
mouse  hearts  by  markedly  increasing  recruitment  of  circulating  c-kit+  and  CD34+  
stem/progenitor cells and increasing the levels of VEGF and SDF-1 (Lin et al. 2008). We showed 
that pharmacological HO-1 induction caused only small increases of c-kit+ cells in the infarcted 
rat hearts despite increased SDF-1  levels, suggesting that HO-1 rather induced angiogenesis in 
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this study (II). The difference between these results may be due to the different species used, or 
to different methods for increasing HO-1 expression. 
 
The interesting novel finding in study II was the strong activation of c-kit+ stem/progenitor cells 
and formation of new arteries in the infarcted rat hearts by CO. CO increases circulating 
endothelial  progenitor  cells  and enhances  endothelial  repair  after  vascular  injury  in  mice  and 
rabbits (Lin et al.  2009, Wu et al.  2009, Wegiel  et  al.  2010).  The CO-induced c-kit+ cells were 
negative for the hematopoietic stem cell marker CD34 (II), and in later studies negative for Sca-
1 which is another marker of bone marrow-derived progenitor cells (Lakkisto et al., unpublished 
result). These results indicate that the CO-activated c-kit+ cells were more likely of local origin, 
not derived from bone marrow. Resident CSCs have the potential to differentiate into all cardiac 
cell types: cardiomyocytes, endothelial cells, and VSMCs and form new capillaries and arteries 
(Beltrami  et  al.  2003,  Linke  et  al.  2005,  Tillmanns  et  al.  2008).  In  study  II,  CO  promoted  a  
substantial differentiation of c-kit+ cells into VSMCs and to a lesser extent into cardiomyocytes, 
whereas few endothelial cell-differentiating cells were found. In concert, CO increased vascular 
density, especially the number of intermediate and large arteries, but failed to increase capillary 
density.  Furthermore,  increased  proliferation  of  cardiomyocytes  was  observed  in  the  infarct  
border area coincident with the increase in c-kit+ cells, potentially representing the proliferation 
of  newly  formed cardiomyocytes  derived  from c-kit+  cells.  These  results  suggest  that  CO may 
also activate EDPCs. EDPCs are crucial to the development of coronary vessels and the cardiac 
fibrous skeleton during embryogenesis (Winter and Gittenberger-de Groot 2007) and 
differentiate into SMCs, but not into endothelial cells in vitro (Wada et al. 2003, van Tuyn et al. 
2007). In support of the EDPC hypothesis, adult c-kit+ human and mouse EDPCs also give rise 
to cardiomyocytes (Limana et al. 2007) and Tbx18+ mouse EDPCs to cardiomyocytes and 
coronary SMCs, but not endothelial cells (Cai et al. 2008). In further studies, some c-kit+ cells 
were positive for Tbx18 suggesting that the c-kit+ cells in study II may have originated from the 
epicardium (Lakkisto et al. unpublished result). 
 
The  inability  of  CO  to  increase  capillary  density  in  the  infarcted  hearts  is  in  contrast  with  
previous in vitro studies showing that CO mediates the proangiogenic properties of HO-1 
(Jozkowicz et al. 2003, Li Volti et al. 2005). This may be due to different conditions in the heart 
in vivo compared  with  in vitro endothelial  cell  cultures.  CO  may  also  have  a  function  in  the  
heart that is different from that of the vasculature, since CO accelerates endothelial cell 
proliferation in vitro and endothelial  repair after carotid artery injury in vivo (Lin et al. 2009, 
Wegiel et al. 2010). It is also noteworthy that the effects of CO or HO-1 on proliferation of 
endothelial cells in hypoxic/ischemic conditions are unknown. Thus CO may function differently 
in ischemic conditions compared with physiological conditions. 
 
6.3.2 Expression of angiogenic factors 
 
No c-kit+ cells were found in sham-operated rat hearts, suggesting that the hypoxia-induced 
factors secreted from the infarct area were involved in the activation of c-kit+ cells by CO. The 
results of study II showed that CO increased HIF-1 , SDF-1  and VEGF-B levels in the infarct 
area, whereas VEGF-A levels did not differ significantly between groups. HIF-1 is a transcription 
factor  that  initiates  the  cellular  response  to  hypoxia  (Weidemann  and  Johnson  2008).  HIF-1  
directly  induces  the  expression  of  several  angiogenic  factors,  including  VEGF  and  SDF-1,  and  
induces angiogenesis (Forsythe et al. 1996, Kelly et al. 2003, Ceradini et al. 2004, Weidemann 
and Johnson 2008). CO increases HIF-1  levels in macrophages in vitro and in transplanted rat 
kidneys in vivo, and protects against I/R injury in lungs and kidneys via an HIF-1-dependent 
mechanism  (Chin  et  al.  2007,  Faleo  et  al.  2008).  CO  may  activate  HIF-1  by causing more 
severe  ischemia  in  the  infarcted  myocardium.  However,  Chin  et  al.  (2007)  showed  in  
macrophages and in lung I/R injury that CO activates and stabilizes HIF-1  by causing a 
DISCUSSION 
64 
transient increase in ROS arising from mitochondria. Interestingly, HO-1 may contribute to the 
HIF-1-mediated response to CO, since HIF-1 is known to regulate the expression of HO-1 
(Ockaili et al. 2005). Furthermore, the cardioprotective effects of the HIF-1  subunit were 
dependent on HO-1 activity in mouse hearts (Czibik et al. 2009). 
 
Study  II  is  the  first  to  show  that  CO  increases  the  levels  of  VEGF-B  in  infarcted  rat  hearts.  
VEGF-B is a member of the VEGF family that promotes angiogenesis and arteriogenesis 
selectively in ischemic hearts (Li et al. 2008, Lähteenvuo et al. 2009). VEGF-B is also implicated 
in  formation  of  coronary  arteries  during  embryogenesis  (Tomanek  et  al.  2002,  2006)  and  it  
promotes  survival  of  cells,  including  cardiomyocytes  and  blood  vessels,  and  regulates  energy  
metabolism  by  regulating  fatty  acid  uptake  in  different  animal  models  (Zhang  et  al.  2009,  
Hagberg et al.  2010, Pepe et al.  2010).  However,  the significance of increased VEGF-B in CO-
induced vasculogenesis remains to be determined in further studies. 
 
VEGF-A was not significantly involved in either HO-1- or CO-induced neovascularization in this 
study. The majority of previous studies have demonstrated increased VEGF-A levels in response 
to  HO-1  induction,  but  contrasting  results  have  also  been  reported.  HO-1  induction  increases  
VEGF-A production in endothelial cells and VSMCs by a CO-dependent mechanism (Dulak et al. 
2002, Jozkowicz et al. 2003). HO-1 transfection increases VEGF-A levels in MSCs (Tsubokawa 
et al. 2010). In addition, cardiac HO-1 gene transfer increased VEGF-A levels in ischemic mouse 
hearts and systemic HO-1 gene delivery in mouse serum (Lin et al. 2008, 2009). Several factors 
also increase VEGF-A via an HO-1-dependent mechanism (Kim et al. 2006, Samuel et al. 2010, 
Shibuya et al.  2010).  In contrast,  Lin et al.  (2009) showed that CO does not increase VEGF-A 
levels in mouse serum. In addition, short exposure of keratinocytes to the HO-1 inducer heme 
increases VEGF-A expression, while longer exposure may decrease VEGF-A expression (Jazwa 
et al.  2006).  Iron released in the HO reaction may also inhibit  VEGF-A synthesis (Dulak et al.  
2002).  The  lack  of  significant  VEGF-A response  in  study  II  may  have  been due  to  a  different  
HO-1 inducer and different methods for CO delivery compared with previous studies or to the 
different time points studied. 
  
In study II, both HO-1 induction and CO pretreatment caused a sustained increase in SDF-1 in 
the infarcted myocardium. SDF-1  is a chemokine playing an important role in the mobilization 
and homing of stem/progenitor cells into the infarcted heart (Abbott et al. 2004, Elmadbouh et 
al. 2007, Zhao et al. 2009), in the survival of hypoxic/reoxygenated cells (Hu et al. 2007), and in 
neovascularization and myogenesis of the infarcted hearts (Elmadbouh et al.  2007, Zhao et al.  
2009). SDF-1  levels increase naturally in response to myocardial  ischemia, but decrease by 7 
days  post-MI  in  rats  (Askari  et  al.  2003).  The  decline  in  SDF-1  appears  to  occur  at  a  critical  
time, because Fransioli et al. (2008) showed that c-kit+ stem cells naturally appear in the infarct 
area 1–2 weeks after MI in mice. The decline in SDF-1  by week 1 may thus partly explain the 
inefficient cardiac repair after MI. Indeed, sustained elevation of SDF-1  by delivery of SDF-
1 overexpressing fibroblasts or by cardiac SDF-1  gene transfer increases stem cell 
accumulation  in  the  ischemic  heart  and  improves  cardiac  function  in  mouse  and  rat  hearts  
(Askari  et  al.  2003,  Abbott  et  al.  2004).  Deshane  et  al.  (2007)  showed  that  SDF-1  promotes  
angiogenesis in endothelial cells and aortic rings in vitro and  in  Matrigel  plugs  in vivo via  an  
HO-1-dependent  mechanism.  In  contrast,  Lin  et  al.  (2008,  2009)  showed  that  cardiac  HO-1  
gene transfer promoted neovascularization in infarcted mouse hearts via SDF-1- and VEGF-
dependent mechanisms, and systemic HO-1 gene delivery and low-dose CO exposure increased 
SDF-1 levels in mouse serum. The data shown by Lin et al. (2008, 2009) are consistent with the 
sustained increase of SDF-1  by  HO-1  induction  and  CO  pretreatment  in  study  II.  The  up-
regulation of SDF-1  by  HO-1  and  CO  may  provide  new  therapeutic  approaches  to  enhance  




6.3.3 Proliferation and survival of cardiomyocytes 
 
 
The proliferation of cardiomyocytes is one piece of a puzzle in myocardial regeneration. The 
heart contains a population of small proliferative cardiomyocytes, and the proliferation of 
cardiomyocytes is  increased in response to MI in both human hearts and experimental animal 
models  (Beltrami  et  al.  2001,  Yuasa  et  al.  2004,  Chen  et  al.  2007). However, this increase as 
such is not sufficient for repair of infarcted hearts. Enhancement of cardiomyocyte proliferation 
by  cell  cycle  regulators  or  growth  factors  is  needed  to  decrease  infarct  size  and  to  improve  
myocardial function after MI (Engel et al. 2006, Woo et al. 2006).  
 
HO-1  regulates  the  cell  cycle  in  a  cell  type-specific  manner  and  the  effect  of  HO-1  on  cell  
proliferation is mediated by CO (Peyton et al. 2002, Song et al. 2002, Wegiel et al. 2008, Wegiel 
et al. 2010). Previous in vitro studies have shown that HO-1 increases proliferation of 
endothelial cells, whereas it decreases proliferation of several other cell types: vascular and 
airway  SMCs,  cardiac  and  lung  fibroblasts,  and  pancreatic  stellate  cells  (Li  Volti  et  al.  2002,  
Peyton et al. 2002, Song et al. 2002, Zhou et al. 2005, Liu et al. 2006, Schwer et al. 2010). Due 
to the role of HO-1 in regulation of the cell cycle in several other cell types, we investigated 
whether HO-1 promotes healing of infarcted hearts by regulating the proliferation of 
cardiomyocytes.  The  study  III  is  the  first  to  show  the  temporal  and  spatial  effects  of  HO-1  
induction on proliferation of cardiomyocytes in postinfarction rat hearts. The role of CO in the 
proliferation of cardiomyocytes is also shown here. Taken together, the results suggest that    
HO-1 and CO may potentially regulate the cardiomyocyte cell cycle in infarcted hearts. However, 
the overall effect of HO-1 and CO on proliferation of cardiomyocytes appears to be dependent on 
the milieu of cardiomyocytes at a given time and location in the postischemic heart.  
 
The  results  showed  that  HO-1  induction  increased  the  number  of  Ki67+  proliferating  
cardiomyocytes in the infarct border area during the first few days after MI, whereas this effect 
was  not  seen  in  the  CO  donor-pretreated  group.  This  suggests  that  HO-1  may  increase  
proliferation of cardiomyocytes in the infarct border area by protecting the cardiomyocytes and 
maintaining cellular homeostasis in the ischemic myocardium via the antioxidative activity of 
another HO reaction product, bilirubin. Bilirubin decreases infarct size and improves cardiac 
function after I/R in rats (Clark et al. 2000b). In contrast to HO-1 induction, CO increased the 
number  of  proliferating  cardiomyocytes  in  the  infarct  border  area  concomitantly  with  the  
increase  in  c-kit+  stem/progenitor  cells  at  week  4.  However,  this  effect  was  only  seen  in  CO-
pretreated hearts, suggesting that it represented proliferation of newly formed cardiomyocytes 
derived from c-kit+ cells rather than specific regulation of the cardiomyocyte cell cycle by CO.  
 
In contrast to the infarct border area, HO-1 inhibited proliferation of cardiomyocytes under the 
supposedly  normal  conditions  in  the  remote  myocardium  (study  III)  and  a  similar  effect  was  
seen in CO donor-pretreated hearts. This suggests indirectly that HO-1 may inhibit progression 
of the cardiomyocyte cell cycle under physiological conditions via CO. Previous in vitro studies 
showing  that  HO-1  inhibits  proliferation  of  other  muscle  cell  types,  VSMCs,  and airway  SMCs 
support  this  hypothesis  (Peyton  et  al.  2002,  Song  et  al.  2002).  However,  further  studies  in  
cardiomyocytes in vitro are needed to confirm the inhibitory effect of the HO-1/CO pathway on 
cardiomyocyte proliferation under physiological conditions and evaluate the effects of HO-1 and 
its reaction products on cardiomyocyte proliferation under hypoxic conditions. Nevertheless, 
these opposing spatiotemporal effects of HO-1 and CO on cardiomyocyte proliferation are likely 
to result in the enhanced recovery from MI. 
 
Limiting the expansion of the infarct by protecting the cardiomyocytes is equally important in 
the  recovery  from  MI  as  myocardial  regeneration.  The  results  of  study  III  demonstrated  that  
HO-1 improves survival of cardiomyocytes, as indicated by increased repair of cardiomyocyte 
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DNA and decreased apoptosis of cardiomyocytes. The cardioprotection is partially mediated by 
CO.  
 
HO-1 increased the repair of cardiomyocyte DNA in the infarct border area during the first few 
days  after  MI,  as  indicated  by  the  increased  number  of  PCNA+  cardiomyocytes.  CO  did  not  
affect the number of PCNA+ cardiomyocytes during these first days after MI, pointing again to 
the role of bilirubin in maintaining cellular homeostasis in the early phase of infarct healing. In 
contrast,  CO increased  the  number  of  PCNA+ cardiomyocytes  in  the  infarct  border  at  week  4.  
Whether this increase in cardiomyocyte repair is associated with CO-induced cardiac 
regeneration or pathological changes in the CO-pretreated hearts remains to be determined.  
 
In chronic heart diseases, the increase in PCNA+ cardiomyocytes may also serve as a marker of 
stress  and  the  development  of  heart  failure.  Increased  repair  of  cardiomyocyte  DNA  was  
demonstrated in patients with dilated cardiomyopathy and severe heart failure while 
implantation  of  a  left  ventricular  assist  device  reduced  PCNA  expression  (Francis  et  al.  1999,  
Bartunek  et  al.  2002).  In  infarcted  rat  hearts,  both  HO-1  induction  and  CO  pretreatment  
attenuated the increase in PCNA+ cardiomyocytes at week 4 in the remote myocardium, 
suggesting  that  HO-1  may  protect  against  adverse  ventricular  remodeling  and development  of  
heart failure in the late phase of infarct healing via CO, if increased PCNA expression is 
considered as a marker of heart failure.  
 
The  antiapoptotic  action  of  HO-1  is  well  characterized  in  different  cells  and tissues,  including  
cardiomyocytes. HO-1 gene transfer inhibits angiotensin II-mediated apoptosis in rat 
cardiomyocytes in vitro (Foo et al. 2006). Cardioselective overexpression of HO-1 inhibited 
cardiomyocyte apoptosis in I/R mouse hearts and in the failing mouse hearts (Vulapalli et al. 
2002,  Wang  et  al.  2010).  In  addition,  HO-1  induction  by  CoPPIX  protects  transplanted  rat  
hearts from I/R injury and decreases cardiomyocyte apoptosis (Katori et al. 2002b). Consistent 
with previous studies, HO-1 decreased cardiomyocyte apoptosis in study III. A similar reduction 
of  cardiomyocyte  apoptosis  was  found  in  the  CO  donor-pretreated  hearts,  indicating  that  the  
antiapoptotic effect of HO-1 is mediated by CO, as shown previously in several studies (Sato et 
al. 2001, Uemura et al. 2005, Piantadosi et al. 2008, Wang et al. 2010).  
 
6.3.4 Cardiac fibrosis and extracellular matrix components (III) 
 
Cardiac  fibroblasts  are  the  most  numerous  cell  type  in  the  rat  heart,  contributing  to  cardiac  
structure  and  function  (Camelliti  et  al.  2005,  Banerjee  et  al.  2007,  Porter  and  Turner  2009).  
Fibroblasts are equally important cells in the healing of infarcted heart as cardiomyocytes, due 
to  their  key  role  in  post-MI  ventricular  remodeling  (Porter  and Turner  2009).  Fibroblasts  are  
activated in response to acute MI: they migrate into the infarct area, proliferate, and participate 
in  the  repair  of  injury  by  forming  a  fibrous  scar  (Sun  and  Weber  2000,  Porter  and  Turner  
2009).  However,  improper  activation  of  fibroblasts  and increased  fibrosis  in  the  noninfarcted  
myocardium together with apoptosis and hypertrophy of cardiomyocytes lead to the 
development of heart failure (Sun and Weber 2000, Porter and Turner 2009).  
 
The  results  of  study  III  suggested  that  HO-1  induction  may  attenuate  the  fibrotic  response  to  
MI, since a lower total number of cells and lower numbers of vimentin+ fibroblastlike cells were 
found in the infarct area,  along with decreased proliferations of cells in the infarct area and in 
the infarct border area. Attenuated proliferation of fibroblasts was also suggested by lower levels 
of vimentin protein (an indirect measure of fibroblast number) at week 4.  In contrast to HO-1 
induction,  the  unpublished  results  of  CO-pretreated  hearts  showed that  CO did  not  affect  the  
number or proliferation of all cells or fibroblasts alone. Consistent with these results, Liu et al. 
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(2006) showed earlier that HO-1 gene transfer inhibits proliferation of rat cardiac fibroblasts in 
vitro and decreases the infiltration of myofibroblasts in the infarct area in vivo. 
 
Taken together the results of cardiac fibrosis and expression of the extracellular matrix 
components  HO-1  and  CO  appear  to  modulate  the  biochemical  function  of  fibroblasts  by  
divergent mechanisms. HO-1 induction decreased the levels of Coll1a1 mRNA and procollagen 
type I protein at week 1, and the extent of perivascular fibrosis at week 4. HO-1 inhibits fibrosis 
in  kidneys,  liver,  and  lungs  (Tsuburai  et  al.  2002,  Gaedeke  et  al.  2005,  Tsui  et  al.  2005).  
However, HO-1 had no effect on the extent of interstitial fibrosis or on the expression of Coll3a1 
or  fibronectin  mRNAs  that  are  usually  increased  in  interstitial  fibrosis.  In  addition,  no  
differences were found in cardiomyocyte cross-sectional area (III). In contrast, HO-1 induction 
by  hemin  attenuated  left  ventricular  hypertrophy  and  fibrosis  in  adult  spontaneously  
hypertensive  rats,  and  HO-1  gene  transfer  decreased  interstitial  collagen  at  1.5  and  3  months  
after  I/R  injury  in  rat  hearts  (Liu  et  al.  2007,  Ndisang  and  Jadhav  2009).  These  contrasting  
results  are  likely  due  to  the  different  models  and  time  points  studied.  It  is  likely  that  week  4  
post-MI is too early to detect differences in interstitial fibrosis or in cardiomyocyte hypertrophy. 
In addition, increased interstitial fibrosis is more characteristic of hypertension.  
 
In  contrast  to  HO-1  induction,  CO  had  no  significant  decreasing  effect  on  the  extent  of  
perivascular or interstitial fibrosis or on the levels of procollagen I and vimentin proteins. 
Instead, CO activated the gene expression of fibronectin, Coll1a1, and Coll3a1 at week 4. These 
results suggest that CO does not mediate the antifibrotic effect of HO-1 in the heart.  This is  in 
contrast with previous studies showing that CO suppresses bleomycin-induced fibrosis in lungs 
and inhibits development of renal fibrosis in obstructive nephropathy (Zhou et al. 2005, Wang 
et al.  2008).  However,  the CO may have varying effects on different organs, since Andre et al.  
(2010)  showed  that  chronic  CO  exposure  by  CO-enriched  air  increased  interstitial  and  
perivasular fibrosis in healthy rat hearts. It would also be tempting to speculate that the 
increased gene expression of major extracellular matrix proteins at week 4 could be associated 
with  CO-activated  stem/progenitor  cells.  As  discussed  above,  the  CO-activated  c-kit+  cells  are  
likely of epicardial origin. EDPCs play a crucial role in formation of the fibrous skeleton of the 
heart (Winter and Gittenberger-de Groot 2007), and it is currently believed that the majority of 
cardiac  fibroblasts  originate  from  EDPCs  (Snider  et  al.  2009).  Further  studies  are  needed  to  
address the effect of CO on cardiac fibroblasts and fibrosis, because increased cardiac fibrosis as 
a side effect would clearly lower the possible therapeutic value of CO.  
 
The expression of TGF- and CTGF was measured to evaluate whether the effects of HO-1 and 
CO  on  cardiac  fibrosis  are  mediated  by  regulating  the  expression  of  these  factors.  TGF-  
promotes cardiomyocyte hypertrophy and increases fibrosis in the late phases of infarct healing 
(Bujak and Frangogiannis 2007). However, it plays an important anti-inflammatory role in the 
early phase of infarct healing (Bujak and Frangogiannis 2007). TGF- also contributes to 
limiting the expansion of inflammation into the noninfarcted myocardium (Frangogiannis et al. 
2005). CTGF is one of the downstream mediators of the profibrotic effect of TGF-   
 
The results of study III showed that HO-1 induction increased the gene expression of TGF- 1 in 
the infarct area and CTGF in the remote area at day 3. In addition, CO-pretreated hearts showed 
similar increases in TGF- 1  expression  at  day  3.  These  results  point  to  the  anti-inflammatory  
roles of HO-1 and CO and suggest that in the early phase of infarct healing the beneficial effects 
of  HO-1  may  be  mediated  in  part  by  CO  and  the  anti-inflammatory  cytokine  TGF- 1. 
Furthermore, the simultaneous transient increase in CTGF expression may be associated with 
the progression of infarct healing from the inflammatory phase to the proliferative phase 
characterized by suppression of the inflammatory response and formation of the fibrous scar. 
TGF-  and IL10 mediate the anti-inflammatory action of HO-1 against ovalbumin-induced 
airway  inflammation  in  mice  (Xia  et  al.  2007).  In  addition,  CO  protects  macrophages  against  
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anoxia/reoxygenation-induced apoptosis by increasing TGF-  via Hif-1  (Chin et al.  2007).  In 
contrast, HO-1 induction by heme arginate decreased cardiac TGF-  levels and fibrosis in 
DOCA-salt hypertension (Jadhav and Ndisang 2009). HO-1 did not affect TGF- 1 expression at 
the late phase of infarct healing, but it significantly decreased the expression of CTGF at week 4 
in the infarct area and in the remote area (III).  This suggests that in the late phases of infarct 
healing,  HO-1  may  protect  against  fibrosis  by  down-regulating  CTGF.  Unlike  HO-1  induction,  
CO increased  both  TGF- 1  and CTGF mRNA in  the  infarct  area  at  week  4.  This  suggests  that  
TGF- 1 and CTGF may mediate the increased expression of fibronectin, Coll1a1, and Coll3a1 
mRNAs by CO.  
 
6.3.5 Infarct size (II, III) 
 
Despite  the  several  beneficial  effects  of  both  HO-1  and  CO  in  post-MI  hearts,  no  significant  
effect on infarct size was found. A trend for smaller infarcts was found in HO-1-induced hearts, 
suggesting that HO-1 may have prevented the expansion of ischemic injury by promoting 
angiogenesis in the infarct area and survival and proliferation of cardiomyocytes in the infarct 
border  area.  Recently,  Wang et  al.  (2010)  showed that  the  infarct  size  was  similar  in  cardiac-
restricted    HO-1-transgenic  mice  compared  with  nontransgenic  mice  and  also  in  CORM-3-
pretreated mice compared with control mice, although both HO-1 overexpression and CORM-3 
treatment alleviated ventricular remodeling and improved cardiac function 4 weeks after LAD 
ligation. Therefore,  it  appears that the salutary effects of HO-1 and CO do not always result  in 
decreased  infarct  size  in  the  permanent  LAD  ligation  model.  In  addition,  week  4  may  be  too  
early to detect improvement in infarct size, especially in CO-pretreated hearts. It is possible that 
the regeneration process has recently been initiated in CO pretreated hearts at week 4, because 
vascular density was increased and the greatest accumulation of c-kit+ cells was found at that 
time  point.  In  addition,  CO  promoted  mainly  formation  of  new  arteries,  while  more  efficient  
formation of new cardiomyocytes may be needed to decrease infarct size. 
 
6.3.6 Limitations of the myocardial infarction studies (II, III) 
 
The  MI  studies  have  some  limitations.  One  of  the  major  limitations  is  the  use  of  CoPPIX  to  
induce HO-1 and methylene chloride as a CO donor. Metalloporphyrins, including CoPPIX, may 
have nonspecific effects unrelated to HO-1 induction or inhibition. Likewise, in comparison to 
new CORMs, methylene chloride may also have nonspecific effects. Another major limitation is 
the  lack  of  echocardiography  measurements.  As  discussed  above,  HO-1  and  CO  may  improve  
cardiac  function  and  prevent  adverse  ventricular  remodeling  without  affecting  infarct  size.  A  
third possible limitation is the use of HO-1 induction and CO donors as pretreatments, whereas 
treatments administered post-MI may be more clinically relevant.  
 
 
6.3.7 Therapeutic potential of HO-1 and CO in myocardial infarction 
 
Taken together,  results of studies II and III show that HO-1 and CO have numerous beneficial  
effects  in  infarcted  rat  hearts.  They  promote  neovascularization  and cardiac  regeneration,  and 
modulate  cellular  and  extracellular  remodeling  after  MI.  In  humans,  HO-1  expression  is  
increased  in  failing  hearts  (Grabellus  et  al.  2002)  and  in  the  atrial  myocardium  of  atrial  
fibrillation patients (Corradi et al. 2008), indicating that HO-1 is induced in response to stress 
in the human heart, similar to the situation in rat hearts. Furthermore, low-dose CO inhalation 
had  anti-inflammatory  effects  and improved responsiveness  to  metacholine  in  a  pilot  study  of  
patients with chronic obstructive pulmonary disease (COPD) (Bathoorn et al. 2007). Therefore, 
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therapeutic induction of HO-1 or administration of HO reaction products could potentially 
enhance recovery and repair of the post-MI human hearts as well. However, additional studies, 
e.g.  in the swine MI model,  are warranted to confirm the beneficial  effects of HO-1 and CO in 




6.4 Role of HO-1 in critically ill patients – focus on patients with cardiac disease  
 
HO-1  is  highly  induced  by  various  stresses,  especially  oxidative  stress,  which  is  a  common  
feature in the critically ill, regardless of the underlying disease. In addition, HO-1 
polymorphisms affect the transcriptional activity of the HO-1 gene  and  are  accociated  with  
different clinical conditions, e.g. outcome of organ transplantation and restenosis after 
peripheral angioplasty and coronary stenting (Hirai et al. 2003, Exner et al. 2004, Schillinger et 
al.  2004, Buis et al.  2008).  The study V was conducted to investigate the role of HO-1 plasma 
levels and HO-1 polymorphisms in critically ill  patients and evaluate whether measuring HO-1 
levels would be of use in the care of these patients. In addition, the role of HO-1 in the subgroup 
of cardiac patients is further discussed here.  
 
The HO-1 GTn repeat length polymorphism was evaluated together with the HO-1 -413A/T and 
+99G/C SNPs for the first time (V). The frequencies of the HO-1 GTn repeat length alleles and 
the HO-1 -413A/T and +99G/C alleles were consistent with the frequencies in previous studies 
with Caucasian patient populations (Gulesserian et al. 2005, Turpeinen et al. 2007, Lublinghoff 
et  al.  2009).  In study V, the +99C allele was in perfect LD with the long GT allele.  Similar LD 
between the GTn and the +99G/C polymorphism was reported earlier in one study (Gulesserian 
et al. 2005). The transcriptional activity of the HO-1 gene decreases with increasing numbers of 
GTn repeats (Hirai et al. 2003, Brydun et al. 2007, Song et al. 2009a). However, the functional 
importance of the +99G/C polymorphism remains to be determined in further studies. LD 
between the GTn microsatellite polymorphism and -413A/T SNP was also reported in several 
studies  (Buis  et  al.  2008,  Sheu  et  al.  2009,  Song  et  al.  2009a),  and  greater  functional  
importance  of  the  -413A/T polymorphism over  the  GTn repeat length polymorphism has been 
suggested in a few studies (Ono et al. 2004, Buis et al. 2008). The results of this study suggested 
greater  significance  of  the  GTn repeat length polymorphism  (V).  It  must  be  noted  that  in  
previous studies, the GTn repeat length has been divided into two or three categories, with the 
lowest L allele length varying from 26 to 33 repeats.  This inconsistency in the classification of 
GTn repeat  lengths  may  have  substantially  affected  interpretation  of  the  results  and  of  the  
functional importance of this polymorphism.  
 
The results of study V showed that the -413T/GT(L)/+99C haplotype independently affected the 
day 1 plasma HO-1 concentrations. The HO-1 plasma levels were significantly lower in patients 
with  the  -413T/GT(L)/+99C  haplotype,  which  is  in  line  with  previous  studies  showing  lower  
transcriptional activity of the HO-1 gene  with  increasing  numbers  of  GTn repeats  (Hirai  et  al.  
2003, Brydun et al. 2007, Song et al. 2009a). The short GTn associated with better outcome in 
many diseases  (Kaneda  et  al.  2002,  Chen et  al.  2004,  Mustafa  et  al.  2008).  Therefore,  it  was  
surprising that the -413T/GT(L)/+99C haplotype was associated with lower appearance of MOD 
in study V. However, Sheu et al. (2009) also showed that the long GT allele protected against the 
acute respiratory distress syndrome and Melley et al. (2007) suggested an optimal range of HO-
1 induction in critically ill patients, based on COHb measurements. However, which of these is 
protective  against  MOD,  the  -413T/GT(L)/+99C  haplotype  or  the  lower  plasma  HO-1  
concentration, remains to be determined in further studies. 
 
No association was found between HO-1 polymorphisms and ICU or hospital mortalities or 
disease severity scores throughout the study population or in the subgroups, including the group 
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of 71 cardiac patients. The lower appearance of MOD and lower HO-1 plasma levels in patients 
with the -413T/GT(L)/+99C haplotype may explain this, because HO-1 plasma levels were 
higher in the ICU and hospital  nonsurvivors than in survivors,  and higher HO-1 plasma levels 
were associated with MOD and more severe disease. It is also noteworthy that in a large number 
of studies, HO-1 polymorphisms were not associated with the disease studies or the outcome 
(Tiroch et al. 2007, Turpeinen et al. 2007, Lublinghoff et al. 2009).     
 
The HO-1 plasma levels were significantly higher in all critically ill ICU patients than in healthy 
controls  (V).  Patients  with  pancreatitis  or  bacterial  infection  had  the  highest  HO-1  
concentrations. Pancreatitis is characterized by necrosis of pancreatic tissue and activation of a 
systemic inflammation response (Pandol et al. 2007). Patients with cardiac disease also had 
relatively high HO-1 plasma levels, although not as high as patients with pancreatitis or bacterial 
infection.  Nevertheless,  HO-1  appears  to  be  induced  in  cardiac  diseases,  such  as  acute  MI,  
similar to its up-regulation in experimental MI (I–III). These results also suggest that in cardiac 
diseases  HO-1  induction  may  be  more  local  than  systemic,  thereby  resulting  in  lower  HO-1  
plasma levels than in pancreatitis and severe sepsis, which are characterized by robust systemic 
inflammation. HO-1 is an intracellular protein, and increased plasma HO-1 may originate from 
injured tissues and cells or from inflammatory cells, especially monocytes and macrophages, or 
both.  Increased  HO-1  immunoreactivity  was  earlier  shown  in  failing  hearts  (Grabellus  et  al.  
2002),  as  has  increased  HO-1  mRNA  and  protein  in  the  atrial  myocardium  of  patients  with  
chronic atrial fibrillation (Corradi et al. 2008). Eide et al. (2008) showed that pregnant women 
with pre-eclampsia have increased HO-1 mRNA and protein expression in decidua basalis 
concomitant with elevated serum HO-1 levels.  Patients with silicosis also have increased HO-1 
immunoreactivity in the lungs along with increased serum HO-1 levels (Sato et al. 2006). On the 
other  hand,  HO-1  expression  is  increased  in  circulating  monocytes  in  various  acute  
inflammatory  illnesses  in  children  (Yachie  et  al.  2003),  and  in  circulating  monocytes  and  
lymphocytes of patients with coronary artery disease,  which also supports the release of HO-1 
from inflammatory cells (Chen et al. 2009).  
 
Based on the results of study V, the role of increased HO-1 levels in critically ill patients remains 
unclear. Increased expression of HO-1 is commonly considered to protect against stress and 
tissue injury (Otterbein and Choi 2000). HO-1 protects the renal tubuli from oxidative injuries 
in various renal diseases (Morimoto et al.  2001) and rat liver against I/R injury and improves 
microcirculation  (Schmidt  et  al.  2007).  HO-1  also  has  cytoprotective  effects  on  the  heart  and  
vasculature  (Idriss  et  al.  2008)  and  on  the  lungs  (Jin  and  Choi  2005).  However,  the  lower  
frequency of MOD in patients with the -413T/GT(L)/+99C haplotype and lower plasma HO-1 
levels  suggests  that  increased  HO-1  may  also  have  detrimental  effects.  Melley  et  al.  (2007)  
showed  that  both  low  minimum  and  high  maximum  blood  COHb  levels  were  associated  with  
increased ICU mortality. These results suggest that there may be a therapeutic window for HO-1 
expression. High levels of HO reaction products may indeed have adverse effects. The release of 
pro-oxidative free iron may cause adverse effects as well as increased bilirubin, and high level of 
CO impairs O2 transport  and  tissue  O2 delivery  (Horvath  et  al.  1975,  Emerit  et  al.  2001,  
Smithline et al. 2003, Immenschuh et al. 2007).  
 
HO-1 plasma levels were associated with bilirubin and CRP levels,  disease severity scores,  and 
the  degree  of  organ  dysfunction  (V).  However,  the  association  was  not  very  strong.  The  weak  
association of HO-1 levels with its reaction product bilirubin suggests that bilirubin is not a good 
marker for HO-1 activity, possibly because it is also produced by the constitutive isoform HO-2 
or because the elimination of bilirubin may be impaired. The association of HO-1 with CRP was 
evaluated, because HO-1 levels were highest in patients with infection or inflammation. The 
association between HO-1 and CRP was very weak, suggesting that CRP may represent more a 
marker  of  infection  and  inflammation,  whereas  HO-1  may  instead  represent  a  marker  of  
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oxidative stress and illness severity,  because the association of HO-1 with the APACHE II and 
SOFA scores was stronger.  
 
The  degree  of  organ  dysfunction  was  associated  independently  with  day  1  plasma  HO-1,  
especially  the  renal  and  ventilation  failure.  In  addition,  ICU  and  hospital  nonsurvivors  had  
significantly higher HO-1 plasma levels than survivors, and maximum HO-1 was associated 
independently with hospital mortality. HO-1 levels were increased in all critically ill patients, 
regardless of the diagnosis. Therefore, the higher plasma concentrations of HO-1 in more 
severely ill patients likely reflects the magnitude of stress of these patients and suggest a 
potential role for HO-1 as a general marker of disease severity. Accordingly, Chen et al. (2005) 
showed  that  HO-1  protein  expression  is  increased  in  monocytes  and  lymphocytes  of  patients  
with coronary artery disease, and the expression levels are higher in patients with acute MI than 
in patients with unstable or stable angina pectoris. In addition, Scharte et al. (2006) suggested 
that  endogenous  CO  production  by  HO-1  may  reflect  the  disease  severity.  In  study  V,  plasma  
HO-1  had  better  predictive  power  for  ICU  mortality  than  hospital  mortality,  although  the  
maximum plasma HO-1 concentration was an independent predictor of hospital mortality. In 
comparison  to  the  clinical  scores,  plasma  HO-1  had  equally  good  power  to  predict  ICU  
mortality.  However,  the  predictive  power  of  HO-1  for  hospital  mortality,  which  is  clinically  
considered more important than ICU mortality, was markedly lower than the APACHE II, SAPS 
II, and SOFA scores. These results support the role of HO-1 as a potential marker of disease 
severity  and  organ  dysfunction  and  also  demonstrate  that  HO-1  is  better  at  predicting  early  
mortality than long-term mortality. 
 
Taken together, HO-1 may be useful as a general marker of illness severity. However, in acute 
cardiac diseases measuring HO-1 plasma levels is not likely to add value to the established 
cardiac  markers,  such  as  troponins  I  and T  and N-terminal  probrain  natriuretic  peptide  (NT-
proBNP).  It  is  also  noteworthy  that  several  drugs,  such  as  aspirin,  statins,  and  proton  pump  
inhibitors, increase HO-1 expression in tissues and cells and therefore they may increase plasma 
HO-1  as  well  (Grosser  et  al.  2003,  Grosser  et  al.  2004,  Lee  et  al.  2004,  Becker  et  al.  2006).  
Future studies to evaluate the kinetics of plasma HO-1 and the usefulness of HO-1 as a marker of 




6.5 Future prospects 
 
The present study shows that HO-1 is induced by stress in both experimental animal models and 
humans. The cytoprotective properties of HO-1 are well known, and the present study highlights 
the cardioprotective role of HO-1 and its reaction products. Despite the increasing knowledge of 
HO-1 in cardiovascular diseases, further studies are needed to evaluate the possible therapeutic 
potential of HO-1 and its reaction products in cardiovascular diseases. 
 
The possible roles of HO-1 and especially CO in post-MI cardiac regeneration are intriguing and 
warrant further studies. The activation of stem/progenitor cells by CO needs to be confirmed 
using  new  CORMs  as  CO  donors.  The  origin  of  CO-induced  stem/progenitor  cells  should  be  
specified,  and  the  paracrine  mechanisms  leading  to  the  activation  and  accumulation  of  stem  
cells should be investigated. In the present study, HO-1 induction and CO donor were used as 
pretreatments. In future studies, the treatments administered after infarction would be more 
clinically  relevant.  The  long-term  effects  of  HO-1  and  CO  treatments  on  cardiac  regeneration  
shoud also be investigated. 
 
The possible roles of HO-1 and CO in cardiac regeneration and the beneficial effects of HO-1 on 
cardiac cellular and extracellular remodeling open numerous therapeutic possibilities. Gene 
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therapy and cell therapy are new promising approaches to treatment of ischemic heart diseases. 
The angiogenic potential of cardiac HO-1 gene therapy has already been shown in mice (Lin et 
al. 2008). HO-1 overexpression has also improved survival of MSCs in infarcted rat, mouse, and 
swine  hearts  and  increased  production  of  growth  factors  and  cytokines  in  MSCs  (Tang  et  al.  
2005, Zeng et al. 2008b, Jiang et al. 2010). HO-1 gene therapy could potentially limit ischemic 
injury by protecting the heart, and promote recovery and repair of postinfarction hearts. HO-1 
gene therapy could also be used in combination with cell therapy to improve the results of cell 
therapy. CO mediates many of the beneficial properties of HO-1 and could be used to improve 
the results of cell therapy, similar to HO-1. Preconditioning of stem cells with CO could improve 
survival of transplanted cells in the infarcted hearts. CO may also modulate the differentiation of 
stem cells. In addition, systemic administration of CO as inhalation or as CORMs could promote 
cardiac regeneration by also activating resident CSCs in humans.   
 
HO-1 plasma concentrations were significantly increased in all  critically ill  patients in study V. 
Being a highly inducible stress-responsive enzyme, HO-1 presumably reflects the degree of 
oxidative stress in different diseases. Therefore, HO-1 is a potential novel marker of illness 
severity, and it could also be useful in predicting the outcome in different diseases. Few studies 
have investigated HO-1 plasma concentrations,  so the significance of plasma HO-1 in different 
diseases  is  unknown.  In  addition,  the  patient  population  in  V  was  very  heterogenous.  Further  
studies in more selective patient populations are needed to evaluate the possible role of plasma 























The  present  study  investigated  the  expression  of  HO-1  in  infarcted  rat  hearts  and  the  role  of    
HO-1  in  the  protection  against  cardiac  I/R  injury  and  in  the  healing  of  postinfarction  hearts.  
HO-1 polymorphisms and HO-1 plasma levels were also examined in critically ill patients. The 
results of this study show that: 
 
 
1. HO-1  expression  is  induced  in  response  to  MI,  especially  in  the  infarct  and  infarct  border  
areas. HO-1 protein localizes in the vascular walls, the cardiomyocytes of the infarct border 
area,  and  in  the  monocytes/macrophages  and  fibroblasts  of  the  infarct  area.  These  results  
imply an important role for HO-1 in recovery of the infarcted rat hearts. 
 
2. HO-1  induction  by  hemin  improved  the  recovery  of  postischemic  cardiac  function  and  
attenuated reperfusion-induced VF possibly by a Cx43-dependent mechanism. These results 
suggest that HO-1 induction potentially protects against I/R injury. 
 
3. HO-1 and CO promote neovascularization and myocardial regeneration in the infarcted 
hearts  by  different  mechanisms.  CO  promotes  vasculogenesis  and  formation  of  new  
cardiomyocytes by activating c-kit+ stem/progenitor cells via HIF-1 , SDF-1  and VEGF-B, 
whereas HO-1 promotes angiogenesis, possibly via SDF-1 . Thus, HO-1 and CO may provide 
new therapeutic strategies to enhance cardiac regeneration after MI.  
 
4. HO-1 has beneficial effects on cellular and extracellular remodeling after MI. HO-1 protects 
the  heart  in  the  early  phase  of  infarct  healing  by  increasing  survival  and  proliferation  of  
cardiomyocytes.  In  the  late  phases  of  infarct  healing,  HO-1  promotes  survival  of  
cardiomyocytes, modulates the production of extracellular matrix components, and reduces 
perivascular fibrosis. CO mediates part of the beneficial effects of HO-1, e.g. the antiapoptotic 
effect, but it may also have some adverse effects, since it increased the expression of 
extracellular  matrix  components.  These  results  suggest  that  HO-1  may  protect  against  
pathological ventricular remodeling. 
 
5. HO-1 plasma levels are significantly increased in critically ill patients, including cardiac 
patients, and are associated with the degree of organ dysfunction and disease severity. HO-1 
plasma concentrations are higher in ICU and hospital nonsurvivors than in survivors, and 
the maximum HO-1 concentration is associated independently with hospital mortality. 
Patients  with  the  -413T/GT(L)/+99C haplotype  have  lower  HO-1  concentrations  and lower  
incidence of MOD. These results imply that HO-1 may be useful as a marker of disease 
severity, although HO-1 levels appear to be modulated by HO-1 polymorphisms. 
 
 
The present study shows that HO-1 is induced in response to stress in both experimental animal 
models  and  severely  ill  patients.  In  addition,  pre-emptive  HO-1  induction  and  CO  donor  
pretreatment promoted post-MI cardiac regeneration, and HO-1 induction modulated post-MI 
cellular and extracellular remodeling. The numerous beneficial effects of the HO-1/CO pathway 
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